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Abstract
In recent years there has been an explosion of interest in the physiological functions of
intrinsically disordered peptides (IDPs) and how they are involved in diseases, specifi-
cally amyloid diseases. A fascinating aspect of amyloid is that rigid, ordered fibrils can
be formed from highly flexible IDPs such as, Amyloid-β (Aβ) and human Islet Amyloid
Polypeptide (hIAPP). These two peptides aggregate to form amyloid in two, currently
incurable diseases: Alzheimer’s disease and Type II Diabetes Mellitus (TIIDM) respec-
tively.
The early steps of how Aβ and hIAPP transition from disordered monomers to con-
formers compatible with amyloid formation is an enigma which remains a challenge to
understand in molecular detail. The combination of IDP structural fluidity and the
complexities of amyloid formation makes structural analysis and study of this area chal-
lenging to investigate but has the potential to reveal invaluable information. The strat-
egy for such investigation presented here focuses on searching for small molecules able
to stabilise monomeric conformers of these peptides and hence to potentially disfavour
amyloid formation.
This work presents a methodological strategy to assess small molecule effects on recom-
binantly expressed and purified Aβ40 amyloid aggregation. The strategy is then imple-
mented on a carefully selected set of lead molecules; a library of 67 compounds were
selected from in silico rapid overlay of chemical structures (ROCS) analysis based on
structural similarity to either 1,2-naphthoquinone, adapalene, bexarotene, MM3003, or
UV11352. These were screened for Aβ40 amyloid perturbation effects using a Thioflavin-
T fluorescence assay and lead compounds were identified. Lead compounds which could
modulate amyloid formation were then assessed by a carefully selected toolbox of meth-
ods including Electrospray ionisation ion mobility mass spectrometry, and electron mi-
croscopy. Finally a set of complementary NMR methods are presented which enable
residue specific structural propensity (residual dipolar couplings, temperature coeffi-
cients and δCα measurements) and flexibility (transverse relaxation rates, heteronuclear
nuclear Overhauser effects) of small molecule-induced conformers to be monitored and
compared with the same proteins in the absence of bound ligand.
The framework laid out in this work has great impact potential due to is applicability
to the amyloid and IDP fields. The ability to study early species in the amyloid process
will reveal insights on important structures and potential folding routes in the amyloid
aggregation process.
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Chapter 1
Introduction
The purpose of this thesis is to create a methods approach to study structural conforma-
tions in the intrinsically disordered Amyloid-beta40 (Aβ1-40) and human Islet Amyloid
Polypeptide (hIAPP) monomers which are important in either encouraging or delay-
ing amyloid formation. The aim was to achieve this using small molecules to stabilise
various monomer conformations.
To provide context for this work, this chapter introduces key concepts required for un-
derstanding amyloid formation, intrinsically disordered peptides (IDPs) and how they
can be entwined. Some major amyloidogenic peptides are intrinsically disordered and
understanding of the disorder to amyloid transition remains imprecisely defined. The
heterogeneous conformer landscapes of intrinsically disordered peptides (IDPs) add com-
plexity to the already elaborate amyloid system. Methods which have contributed to
the challenging study of such transitions in these fields are also introduced
Firstly, amyloid will be introduced and a summary of the current understanding of how it
is formed will be presented. Additionally, the association of amyloid with disease will be
highlighted to demonstrate why amyloid formation needs to be better understood. A key
area where more research is needed is the identification of precursor states, in amyloid
formation especially for intrinsically disordered peptides since they are responsible for
approximately 30 human amyloid diseases [1].
Next intrinsically disordered peptides (IDPs) will be discussed, challenging the com-
mon misconception that structure is required for function. Contrasts between IDPs
and misfolded proteins will be highlighted. To relate specifically to the topic of this
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work, two amyloidogenic IDPs, Aβ40 and hIAPP, will be discussed focusing on current
understanding of the monomer behaviour.
Finally, a selection of methods will be discussed which have been used to investigate var-
ious stages of amyloid aggregation, and IDP conformations. This section will highlight
why a multi-method approach is required for studying such heterogeneous systems and
will note strategies which have been implemented to battle some of the major challenges
which still afflict the field today.
This chapter concludes with clarification of the thesis aims and the approaches which
will be taken to accomplish them.
1.1 The Impact of Amyloid
1.1.1 Introducing Amyloid
The aggregation of proteins into amyloid fibrils, a process known as amyloidosis, and
their subsequent deposition into extracellular plaques or intracellular inclusion bodies is
the key marker of amyloid diseases [1]. Amyloid structures can form both intracellularly
and extracellularly [7]. Intracellularly, amyloid can perturb protein and RNA transport
[8] as well as cause physiological disruption by sequestering cellular proteins impairing
their functionality [9] and perturbing chaperones [10] and homeostasis. Approximately
50 different proteins are associated with amyloid formation in human diseases [1, 11],
including Alzheimer’s disease, Type II Diabetes Mellitus, and Parkinson’s disease, thus
elucidation of how amyloid formation occurs is of paramount importance.
Owing to this there has been great advancement in methodology to study amyloid, as
reviewed by Iadanza et al., [1]. Figure 1.1 shows the journey of Amyloid understanding
from its discovery in the 16th century until recently.
Amyloid fibrils are the most thermally stable, low energy protein aggregates known
[7, 12]. It is currently thought that amyloid is a structure which is accessible to most
small, simple polypeptides showing little or no sequence homology [13–16] (although
there is contradiction and not all studies agree [17]), but cellular control and tight
protein homeostatic regulation prevent most proteins from aggregating. This section
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Figure 1.1: The progression of amyloid structure research over nearly four centuries
The timeline displays the history of key discoveries across the amyloid field showing
the path to finding atomic level structures of amyloid fibrils. Taken from [1].
summarises the current understanding and remaining key questions and challenges in
the field.
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1.1.2 The Major Architecture for Amyloid Aggregates
Amyloid can be defined as a stable non-covalent, fibrillar protein aggregate with a domi-
nating cross-β core where the β-sheets lie perpendicular to the fibril axis [1, 7, 12, 18–21]
arranged either in parallel or anti-parallel orientations. The fibrillar structures can be
observed using electron microscopy (EM), Figure 1.2(a), [7, 12] and the repetitive cross-
β structure gives rise to a distinctive X-ray diffraction pattern, Figure 1.2(b), exhibiting
9.7 A˚ (caused by the packing of β-sheets perpendicular to the fibril axis [21–25]) and
4.7 A˚ reflections (caused by the packing of adjacent β-strands along the fibril axis [21–
25]), Figure 1.2(e). A further typical characteristic of amyloid is red green biofringence
under polarised light, Figure 1.2(c and d) [7, 26, 27]. Figure 1.2(f) shows a model fibril
reconstructed from cryo-EM data.
Figure 1.2: Common indicators of amyloid.
a) A negative stain EM image of Aβ40 aggregates which shows long fibrillar species. b)
X-ray fibre diffraction pattern showing ∼ 10 A˚ and 4.7 A˚ reflections of the cross-β
fibril architecture. c) Aβ stained with congo red under bright light and d) under
polarised light pictures showing congo red-green birefringence, indicative for the
β-sheet content. Scale bars: 100 µm. e) Schematic of how the reflections observed in
the X-ray diffraction pattern map onto a fibril with parallel β-sheet packing,
perpendicular to the fibril axis (pink arrow). f) Atomic model of Aβ42 fibril based on
cryo-EM. Adapted from [28, 29].
When observed at a macroscopic scale, amyloid fibrils formed from different peptides,
regardless of whether they are natively folded (such as β2-microglobulin or insulin) or
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intrinsically disordered (such as Amyloid-β (Aβ), hIAPP, or α-synuclein) are morpho-
logically similar when visualised using techniques such as negative stain transmission
electron microscopy (TEM) or atomic force microscopy (AFM) [21, 22]. The fibrils
present as unbranched, linear structures with twisted patterning. The length of the
fibrils can vary greatly up to the micron scale [12, 21, 22, 30]. In contrast, the fibril
diameters observed are much smaller, typically 50 - 100 A˚[25, 31] which vary depend-
ing on the number of protofilaments which are twisted together. Within samples there
is variation in protofibril stoichiometry of fibril composition [32, 33] and the protofila-
ments can be observed in different arrangements; wrapped around one another, or lined
up side-by-side forming ribbons [32, 34–37].
Due to the repetitive backbone structure, a ‘dry steric zipper’ interface is formed (from
which water is excluded) as subsequent backbone groups interdiginate [38, 39] resulting
in the highly ordered, and densely packed amyloid structures. The β-strands in the
cross-β core are extended so the approximate dihedral angles around the Cα are φ =
-120 o and ψ = +120o and the hydrogen bonds between each β-strand are essentially
planar [40]. The cross-β structure dependence on backbone interactions for stability [23]
could partially explain why so many peptides are able to form amyloid [41], however,
side-chain packing on steric zipper regions is also important for some amyloid formation
[42].
Despite this similar amyloid architecture, many (but not all [43]) amyloid peptides are
unable to induce (a process termed cross-seeding) or co-assemble as amyloid with differ-
ing protein sequences, i.e. α-synuclein and β2-microglobulin cannot associate together to
form amyloid fibrils. This indicates that side-chain interactions, and therefore sequence
specificity, play a role in amyloid formation which is supported as sequence similarity
strongly influences the formation of amyloid fibrils when inducing amyloid formation
with differing peptides [42].
On close inspection of amyloid fibrils, heterogenicity in fine fibrillar structure is observed
between fibrils formed not only from different precursor proteins, but also between fibrils
formed from the same peptides. Figure 1.3 shows contrasting fibril structures created
from a single sample of Aβ40.
Studies involving a combination of cryo-EM and solid state NMR have confirmed this
and have revealed more details on the heterogeneous structures of fibrils, such as varied
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Figure 1.3: Great heterogeneity is observed in fine fibril structures.
a) Reconstructed models of 12 Aβ40 fibrils based on cryo-EM data collected from a
single sample. b) Atomic representations of 3Q and 2A fibril polymorphs of Aβ9-40
viewed down the fibril axis with colour coded residue types: Hydrophobic (green),
polar (purple), negatively-charged (red), and positively charged (blue). Backbone
nitrogen and carbonyl oxygen atoms are cyan and pink. Adapted from [32, 44–46].
twist and pitch [32], arising from side-chain packing [47]. To date, many studies have
shown the role of packing interactions of residues in forming protofilaments and their
influence on morphology when combining into mature amyloid fibrils. Interestingly, the
ability for different fibril morphologies to be created from the same amyloid peptide
may be linked to variation in disease progression [48]. In Alzheimer’s diseases, different
morphologies have been observed which appear to correlate with different stages in the
disease [48].
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1.1.3 Current Understanding of the Mechanism of Amyloid Formation
The process by which soluble, monomeric peptides are converted, essentially irreversibly,
into insoluble amyloid fibrils has been the focus of much research but remains a major
question in the amyloid field. Current understanding of amyloid formation is that it
does not occur via a simple, step-wise, linear process. Rather, the amyloid pathway is
a playground of partially-folded peptide conformations with various degrees of disorder
and folding. Monomers and oligomers sample a variety of forms, with a multitude of
kinetic and thermodynamic factors contributing to the journey from monomer to fibril
[1, 22]. Figure 1.4 presents a schematic for these processes.
Figure 1.4: The amyloid formation pathway is complex.
The transition from a disordered (red) or folded (orange) monomers to form ordered
fibrils (lilac) found in disease-associated plaques and deposits (purple) in multiple
amyloid diseases consists of many interconverting states (including oligomers (yellow
and green), nuclei (light blue), and protofibrils (light blue)), many of which remain
undefined.
Firstly the monomeric amyloid peptide must adopt a conformation which is conducive
to self-association (Figure 1.4(orange)) to form an amyloid-prone oligomer [49], (Figure
1.4(green)). For folded monomers the native fold may need to be partially or more fully
unfolded to initiate amyloid formation. In the case of β2-microglobulin (the protein
responsible for Dialysis Related Amyloidosis) the folded monomer is insufficient for fibril
formation, as is evidenced from both in vivo [50] and in vitro [51–54] studies. However,
in the presence of contributory factors such as copper ions [55, 56], collagen [57], heparin
[58], or post translational modifications (e.g. cleavage of the six N-terminal residues)
[59, 60], the structured β2-microglobulin monomer is perturbed and becomes a precursor
to amyloid [61]. A key feature of this precursor is an exposed Pro32 converts from its
native cis orientation to trans [62]. In order for an intrinsically disordered monomer
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(Figure 1.4(red)) to become amyloidogenic (Figure 1.4(orange)), the conformational
landscape (see Section 1.2.1) must be biased to promote the induction of amyloidogenic
structures. In the case of Aβ40 - an IDP - there is evidence that the extended chain must
adopt a transient α-helix which then converts to a β-sheet (Figure 1.4(red-orange fade)),
in order to participate in the amyloid formation pathway. Such structural transitions
can be aided through interactions with other cellular components, for example, there
is evidence that Aβ40 associates with lipid bilayers to prompt aggregation, additionally
interaction with metal ions can also encourage aggregation.
Amyloid-prone monomers associate together and result in a heterogeneous mixture of
transient and dynamic oligomers which may be on- or off-pathway intermediates [63],
(Figure 1.4(yellow)). This attribute of oligomers in the amyloid formation pathway
makes their study highly complex and challenging. It is unclear whether different
oligomeric species are able to inter-convert to reach an amyloid state or whether they
must disassemble and re-assemble to form on-pathway intermediates [63–66].
With increasing oligomer size a nucleus (Figure 1.4(light blue)) forms in a process termed
primary nucleation [66, 67]. A nucleus can be defined as the smallest aggregate whereby
it is more energetically favourable to grow and sequester more monomers rather than
dissociating into its constituent parts. Pre-nucleus sized oligomers are more likely to
dissociate, especially in the presence of amyloid fibrils as the fibril stability (between
the aggregate and the aqueous environment) drives the addition of monomer to fibril
[67]. The formation of the aggregation-competent nucleus is kinetically disfavoured due
to its high energy state. Nucleus formation is thus the rate-limiting phase of amyloid
initiation and occurs during the lag phase of assembly, 1.5. The amyloid mechanism is
generally accepted to be a ‘nucleated growth reaction’; essentially meaning that subse-
quent to nucleus formation, fast monomer association to the nucleus occurs [68] causing
the fibril to grow as a protofibril (Figure 1.4(dark blue)), and thus the elongation phase
of the process ensues. Evidence of the nucleated growth mechanism is observed (usu-
ally by Thioflavin T (ThT) fluorescence, see Section 1.4.1) by introducing pre-formed,
aggregation-competent fibril seeds to a monomeric pool. This results in immediate elon-
gation and amyloid fibril formation [69, 70], (Figure 1.4 and Figure 1.5(light purple)).
The primary method of elongation occurs when aggregation prone monomers bind to the
ends of the elongating fibril. Molecular dynamic simulations indicate that on association,
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Figure 1.5: A generic ThT fluorescence profile of amyloid aggregation.
A schematic to demonstrate the fluorescent output of ThT as a representation of fibril
formation (solid line) from monomeric protein and when growth is seeded (dashed line)
by the addition of seeds at the start of the reaction.
a structural rearrangement is induced resulting in full incorporation of the monomer to
the fibril end [71]. As more monomers add to the growing aggregate, the aggregate
becomes more thermodyamically stable and thus more monomers will associate to the
growing fibril [72, 73].
Subsequently, a variety of secondary pathways can occur: secondary nucleation and frag-
mentation [67, 74]. Secondary nucleation happens when monomers bind to the surface
of prexisting fibrils and a nucleus forms[75, 76]. The underlying molecular mechanism
of this is not fully understood as it is unknown whether the nucleus remains attached
to the side of the fibril or if it can dissociate to elongate independently [67]. Moreover,
it is currently unknown whether secondary nucleation can occur at any point on the
fibril surface or if a specific site is required. The current perspective of the field is in
favour of specific sites due to the inability for cross-seeding of different amyloids [67, 77].
Residue-specific investigation into this effect (e.g. using NMR) would be impactful to
aid the understanding of this phenomenom.
Fragmentation can also contribute to the rate of fibril formation. In this process, fibrils
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break and expose two new ends from which elongation can occur [78, 79]. The extent of
the significance of each of these processes varies between protein sequences. For example
fragmentation has a negligible contribution to aggregation for Aβ40, whereas for prions
it is the major method which determines disease progression [66, 80].
For each of these processes, the monomer conformation may play a key role with varying
affinities for binding to each type of species present in the amyloid pathway. There is
an need for greater understanding of how monomers interact with each of the species
involved both directly and indirectly in the amyloid aggregation pathway. When the
monomer species is intrinsically disordered, an additional layer of complexity is added
and compounds challenges to study the heterogenous system of the amyloid pathway. If
specific structural requirements of the monomer state were revealed which prevent, for
example, monomer addition to an extending fibril, greater mechanistic understanding
would be ascertained. This could ultimately lead to direction for therapeutic approaches
for some of the many amyloid-associated diseases affecting human society.
1.1.4 Amyloid Diseases have an Immense Impact Globally
Amyloid diseases are some of the most prevalent health issues facing current society.
According to the World Alzheimer Report 2018 [81], the number of people suffering
from dementia (a generic term for a subset of amyloid diseases associated with amyloid
deposition in the brain) worldwide is approximately 50 million and this figure is expected
to rise to 152 million people by 2050 [81]!
Table 1.1 lists a selection of amyloid diseases, the dominant protein involved in fibril
formation, and details any structural features in the monomer protein. Notably, over a
third of the diseases listed are related to intrinsically disordered peptides, or peptides
with intrinsically disordered regions, forming amyloid.
Table 1.1: Amyloid diseases and their associated proteins. Reproduced and adapted
from [1].
Disease Peptide Residues Native structure
Neurodegenerative diseases
Neuroferritinopathy Ferritin 175 or
183
All α
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Disease Peptide Residues Native structure
Spongiform encephalopathies Prion protein or
fragments thereof
253 Natively unfolded
(residues 1-120) and
α-helical (residues
121-230)
Parkinson disease α-Synuclein 140 Natively disordered
Dementia with Lewy bodies α-Synuclein 140 Natively disordered
Frontotemporal dementia
with Parkinsonism
Tau 352–441 Natively disordered
Amyotrophic lateral sclerosis Superoxide dis-
mutase
153 All β,
immunoglobulin-like
Huntington disease Huntingtin with
polyQ expansion
3,144 The polyQ-
containing region
is largely disordered
Spinocerebellar ataxias Ataxins with
polyQ expansion
816 All β, AXH domain
(residues 562-694);
the rest are un-
known
Spinocerebellar ataxia 17 TATA box-
binding protein
with polyQ ex-
pansion
339 α+β, TBP-like
(residues 159-339);
unknown (residues
1-158)
Spinal and bulbar muscular
atrophy
Androgen recep-
tor with polyQ
expansion
919 All α, nuclear recep-
tor ligand-binding
domain (residues
669-919); the rest
are unknown
Hereditary dentatorubral-
pallidoluysian atrophy
Atrophin 1 with
polyQ expansion
1,185 Unknown
Familial British dementia ABri 23 Natively disordered
Familial Danish dementia ADan 23 Natively disordered
Non-neuropathic systemic amyloidoses
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Disease Peptide Residues Native structure
AL amyloidosis Immunoglobulin
light chains or
fragments
∼90 All β,
immunoglobulin-like
AH amyloidosis Immunoglobulin
heavy chains or
fragments
∼220 All β,
immunoglobulin-like
AA amyloidosis Fragments of
serum amyloid
A protein
76-104 All α, unknown fold
Familial Mediterranean fever Fragments of
serum amyloid
A protein
76-104 All α, unknown fold
Senile systemic amyloidosis Wild-type
transthyretin
127 All β, prealbumin-
like
Familial amyloidotic
polyneuropathy
Mutants of
transthyretin
127 All β, prealbumin-
like
Haemodialysis-related amy-
loidosis
β2-Microglobulin 99 All β,
immunoglobulin-like
ApoAI amyloidosis N-terminal frag-
ments of ApoAI
80-93 Natively disordered
ApoAII amyloidosis N-terminal frag-
ment of ApoAII
98 Unknown
ApoAIV amyloidosis N-terminal frag-
ment of ApoAIV
∼70 Unknown
ApoCII amyloidosis ApoCII 79 α+disordered
ApoCIII amyloidosis ApoCIII 79 α+disordered
Finnish hereditary amyloido-
sis
Fragments of gel-
solin mutants
71 Natively disordered
Lysozyme amyloidosis Mutants of
lysozyme
130 α+β, lysozyme fold
Fibrinogen amyloidosis Variants of fib-
rinogen α-chain
27-81 Unknown
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Disease Peptide Residues Native structure
Icelandic hereditary cerebral
amyloid angiopathy
Mutant of cys-
tatin C
120 α+β, cystatin-like
Non-neuropathic localized diseases
Type II diabetes Islet amyloid
polypeptide (also
known as amylin)
37 Natively disordered
Aortic media amyloidosis Lactadherin C2-
like domain
50 Unfolded
LECT2 amyloidosis Leukocyte cell-
derived chemo-
taxin 2
151 Unknown
Localized cutaneous amyloi-
dosis
Gelactin 7 136 All β
Hypotrichosis simplex of the
scalp
Corneodesmosin 529
(trun-
cations
cause
amyloid)
Unknown
Calcifying epithelial odonto-
genic tumours
Odontogenic
ameloblast-
associated pro-
tein
153 Unknown
Senile seminal vesicle amyloi-
dosis
Semenogelin 1 462 Unknown
Medullary carcinoma of the
thyroid
Calcitonin 32 Natively disordered
Atrial amyloidosis Atrial natriuretic
factor
28 Natively disordered
Hereditary cerebral haemor-
rhage with amyloidosis
Mutants of
amyloid-β pep-
tide
40 or 42 Natively disordered
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Disease Peptide Residues Native structure
Pituitary prolactinoma Prolactin 199 All α, four-helical
cytokines
Injection-localized amyloido-
sis
Insulin 21 and
30
All α, insulin-like
Injection-localized amyloido-
sis
Enfuvirtide 36 Disordered
Aortic medial amyloidosis Medin 50 Unknown
Hereditary lattice corneal
dystrophy
Mainly C-
terminal frag-
ments of kerato-
epithelin
50-200 Unknown
Corneal amyloidosis associ-
ated with trichiasis
Lactoferrin 692 α+β, periplasmic-
binding protein like
II
Cataract -Crystallins Variable All β, -crystallin like
Calcifying epithelial odonto-
genic tumours
Unknown ∼46 Unknown
Pulmonary alveolar pro-
teinosis
Lung surfactant
protein C
35 Unknown
Inclusion-body myositis Amyloid-β pep-
tide
40 or 42 Natively disordered
Cutaneous lichen amyloidosis Keratins Variable Unknown
1.1.5 Amyloid Toxicity in Disease
It has been clear for the best part of four centuries (Figure 1.1) that fibrillar, amyloid
deposits are linked to pathologies in disease [1, 82]. In the last 20 years, research focus has
been adjusted towards identifying and structurally characterising proteinacious species.
The current consensus of the field is that the oligomeric intermediates on- or off- the
amyloid fibril pathway are more likely to be the main toxic species in amyloid disorders
[83, 84], rather than mature fibrils [85].
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Research focusing on oligomers formed from amyloidogenic proteins is particularly im-
portant in light of the general consensus that some of them act as toxic agents in amyloid
disorders [82, 86–92]. Oligomeric species are generally formed from assembling partially-
folded or partially-unfolded states which are highly heterogeneous. For folded proteins,
a possible explanation of the hypothesised toxicity of some oligomers, is the exposure
of chemical groups (namely from hydrophobic residues [93]) which would usually be
protected in the folded core of the peptide. In fact greater toxicity of prefibrillar and
oligomeric species relative to larger amyloid fibrils is not entirely surprising as the smaller
species have a higher surface area to volume ratio and thus have more surface groups
exposed per volume that are available to interact aberrantly with cellular components
(membranes, organelles, other proteins, nucleotides etc.) causing disruption to cellular
processes [12, 94]. Mature amyloid fibrils may, in fact, be relatively protective to cells
acting as a reservoir to sequester the toxic species in inert, stable aggregates [95–97].
Despite this, there is contrasting evidence, indicating that mature fibrils can indeed in-
fer toxicity and cellular disruption [98]. In dialysis-related amyloidosis, β2-microglobulin
aggregates to form amyloid fibrils which are deposited in joints causing stress and dis-
function [99]. However, for neurodegenerative disorders, such as Alzheimer’s disease, no
such correlation between the amount of fibrillar aggregates and disease severity has been
observed [100, 101], e.g. in post-mortem analyses of Alzheimer’s disease patient brain
samples [100]. This suggests that the cytotoxic, disease-causing species is not detectable
as an aggregate [102].
For amyloidogenic IDPs, maintaining structural disorder may be important in prevent-
ing, or at least delaying, amyloid formation. Early oligomers of the disordered peptide,
α-synuclein (involved in Parkinson’s Disease) are substantially disordered until a con-
formational change occurs in the oligomer as a whole adopts an on-pathway, β-sheet
rich structure akin to an amyloid-like core [103]. This implies that gain of structure in
oligomers may correlate with amyloid formation and the same may be true for monomer
transitions.
1.1.6 Functional Roles of Amyloid
In the last two decades it has been realised that the amyloid fold is not restricted to pro-
tein aggregation disorders but can be found as functional fibrous structures produced by
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bacteria and fungi, as well as in higher eukaryotes [2], Table 1.2. One of the most widely
accepted roles of amyloid aggregation in biology is as part of a controlled response to ad-
dress perturbed protein homeostasis [104] by allowing partially folded proteins to clump
together in an inert state, i.e. hydrogen bond donors and acceptors can align to form
hydrogen bonds, and hydrophobic regions can associate to minimise the unfavourable
interaction with aqueous environments. In E. coli and Salmonella spp, amyloid fibrils
are used in cell adhesion, as well as in biofilm formation [105]. Another bacteria, Strep-
tomyces coelicolor which live in soil, produce functional amyloids called chaplins that
bind to hydrophobic surfaces [106] and coat aerial hyphae assisting spore dispersal and
the colonisation of surrounding soil [107]. In humans, amyloid can have roles involving
interaction with secretory hormones (such as insulin) and in melanosomes where it fa-
cilitates and regulates the reactivity of melanin small molecule indolequinone precursors
[106]. Furthermore, amyloids function in the human hemostatic system, factor XII can
be activated by amyloids in vitro [108] and converts fibrinogen to fibrin fibres which are
rich in β-sheets like amyloids [109].
Table 1.2: Functional amyloid in various organisms. Reproduced and adapted from
[2].
Species Protein Function Evidence
Bacteria
E. coli,
Salmonella spp.
Curli Biofilm formation, host invasion EM, Congo red,
ThT, and CD
Streptomyces
coelicolor
Chaplins Modulation of water surface ten-
sion (i.e. development of aerial
structures)
CD, ThT and EM
Fungi
Podospora anser-
ine
HET-s Regulation of heterokaryon forma-
tion
EM, CD, FTIR,
Congo red and
NMR
Saccharomyces
cerevisiae
URE2p Regulation of nitrogen catabolism Electron diffraction,
X-ray, Congo red,
EM and ThT
S. cerevisiae Sup35p Regulation of stop-codon read-
through
EM, Congo red, CD
and X-ray
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Species Protein Function Evidence
Most fungi Hy-
drophobins
Fungal coat formation, modulation
of adhesion and surface tension
AFM, CD, FTIR,
ThT, NMR, Congo
red and X-ray
Animalia
Insects and fish Chorion
proteins
Structural and protective functions
in the eggshell
Congo red, X-ray,
EM, FTIR and CD
Nephila clavipes
Spidroins
Structural (i.e. spider silk) EM and CD
Homo sapiens Pmel17 Scaffolding and sequestration of
toxic intermediates during melanin
synthesis
X-ray, Congo red,
EM and ThT
The presence of functional amyloids throughout domains of life [2, 110–115] prompts the
questioning of the role of amyloid in the origins of life [116]. Over time some proteins
have evolved to omit sequences with high amyloidogenic potential, such as strings of
hydrophobic residues, or alternating sequences of polar and non-polar residues [41]. The
fact that amyloidogenic proteins persist in biological organisms highlights the advantages
for this structure in biology. In general, aggregation is a slow process (at physiological
protein concentration), often taking years for disease to develop to present symptoms and
thus there is little evolutionary pressure to select against aggregation-prone sequences
at important evolutionary life stages. However, for functional amyloid often elaborate
systems have evolved to control assembly such that it occurs rapidly and in the correct
cellular location, e.g. Pmel17 [106].
1.2 Intrinsically Disordered Peptides
Previously, the view on protein folding was that a folded structure was essential for
functionality. In many cases this holds true as protein function is enabled through
structure, for example, specific 3D environments in active sites for enzyme catalysis and
precise recognition features for some allosteric binding and transport [117]. However,
25 % of proteins expressed in humans are disordered, and approximately 50 % contain
disordered stretches of at least 30 amino acids [118], bringing the role of disordered
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peptides into the spotlight. The present view is that intrinsic disorder plays a role in
signalling and various other cell processes, (discussed further in section 1.2.2) [117, 119,
120].
1.2.1 Defining Intrinsic Disorder
The term ‘Intrinsically Disordered Peptide’ has been defined as a peptide which possesses
at least one region which does not have a fixed secondary or tertiary structure [118]. A
limitation of this definition is that misfolded or unfolded proteins may also be lacking
in fixed secondary or tertiary structures for part or all of their lifetime. For example,
placement of ribonuclease A (the folded protein used in the famous folding experiments
by Anfinsen et al., [121]) in 8 M urea will yield a peptide chain lacking in secondary
and tertiary structure, yielding an unfolded chain. The definition of an IDP has evolved
over time as common features of IDPs have been observed.
A common misconception is to expect IDPs to exist as purely random coils. In reality,
IDPs fleetingly sample different structural motifs and exist as a mixture of transient,
partially folded states, which have low energy barriers allowing the rapid interconversion
of conformers [122–127], Figure 1.6. Conformational preferences can be sequence specific
and can depend on the previous conformation sampled by the IDP [120, 124].
In general, IDPs are characterised by having a high content of polar or charged residues
[120] which can be viewed as ‘disorder-promoting’ residues: A, R, G, Q, S, P, E and
K [128], and a low proportion of hydrophobic, uncharged residues [120]: W, C, F, I,
Y, V, L, and N [128]. IDPs are usually geared towards exhibiting solubility in aqueous
environments, hence the amino acid composition preferences. Additionally, the high
net charges (causing electrostatic repulsion resulting from equally charged residues) and
enhanced Proline content (causing steric prevention of close proximity) help to prevent
self-association of the IDP [128]
1.2.1.1 Contrasting Disordered, Misfolded, and Unfolded Peptides
Using recent NMR methods and metadynamics simulations the energetic landscape of
IDPs has been modelled and compared with that of a folded peptide and its unfolded,
or misfolded derivatives [129].
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Figure 1.6: A schematic showing energy barriers between conformational states for folded
peptides and IDPs.
The energy level profile for a typical folded protein (left) and an IDP (right). For the
folded protein there is a clearly defined state which is most stable and therefore most
of the protein will occupy this low energy state. However, for an IDP the landscape is
much shallower with small energy barriers between many different conformers which
the peptide can sample. Adapted from
https://www.mpbenowitz.work/#/foldingproteins/.
Protein folding today is visualised as an energy landscape with multiple routes to reach
the lowest energy form of the protein [7, 130–132]. The potential folding paths, in
line with the Levinthal Paradox [133], are restricted to occur via specific kinetically
controlled folding routes to reduce the amount of potential folds a protein visits during
folding to its native state [134]. This can be achieved through the use of chaperones
(e.g. ER chaperone BiP), and restricted steric environments (e.g. the exit channel of
the ribosome). Additionally the formation of key structural motifs early in the folding
process can bias the rest of the conformational search to ensure highly efficient folding
[133, 135–137].
As a natively folded protein folds from its high energy, unfolded state to achieve its
most stable, low energy, fully folded conformation, it encounters transition state energy
barriers (peaks on the energy landscape), as well as stable intermediate conformations
(energy minima or troughs on the energy landscape). For intrinsically disordered pep-
tides, it has been postulated by Granata et al., [129] that the opposite trend is true: an
IDP is most stable in a structure-less, state, when secondary structures are transiently
sampled in the dynamic conformer equilibrium. As such, a key contrast for IDPs and
folded peptides is that intermediate peptide conformations of IDPs are reached from
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the global minimum through partial folding events, whereas for folded proteins, inter-
mediate peptide conformations are attained from the global minimum through partial
unfolding events [138–140]. IDPs are entropically stabilised whereas folded proteins are
enthalpically stabilised.
Factors which alter the environment (e.g. changes in pH or temperature, or addition of
small molecules which stabilise peptide conformations) can modulate the energy profile
of different folded, and partially folded states altering the population distribution of a
protein conformer landscape [12]. These intermediates may be on-pathway structures as
the protein moves towards its favoured conformation, or they may be kinetically stable
off-pathway forms [68, 141] in which the protein may become trapped. This is especially
true for partially folded, or misfolded forms of folded proteins which may sit in deep
energy troughs with high transition energy barriers. Accumulation of proteins in such
states can lead to high local concentrations of partially folded proteins which renders
aggregation more possible [68].
Increasing temperatures of IDP systems allows higher free energy states of IDPs to
become more populated. As temperature increases, entropy also increases pushing the
system to act more freely, however, the higher energy in the system makes higher energy
conformers of IDPs more accessible and these can be more structured (and therefore
compact) conformers of IDPs. This could be an explanation for the increased rates of
aggregation of IDPs as temperatures increase [129].
Misfolded proteins (i.e. proteins which have failed to adopt the correct secondary and
tertiary configurations of their native folded form) can have detrimental consequences
in biological systems. Unlike IDPs, misfolded proteins have not evolved to exist in
their environment and thus they are more likely to have unwanted interactions with
other cell components. For example, a misfolded, or unfolded, protein is more likely
to have hydrophobic residues exposed to an aqueous environment [138, 142, 143], this
may lead to self-association with other exposed hydrophobic residues resulting in further
misfolding. Alternatively, such residues may drive association with other unfolded or
misfolded peptides initiating an aggregation mechanism [144], or such exposed residues
may induce interactions with other cell components [138, 142, 143]. For these reasons
cells have mechanisms to deal with and remove misfolded or unfolded species.
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The primary mechanism to prevent damage incurred from incorrectly or incompletely
folded proteins is to ensure that proper folding occurs initially through the use of chap-
erones in most stages of the peptide ‘life cycle’ (ie. folding, assembly, transport, degra-
dation) [145]. Indeed, the primary response to a build up of misfolded or unfolded-
structured proteins is to increase chaperone expression levels [146] via the Heat Shock
Response [147, 148], for example, in E. coli this aids the association of misfolded pro-
teins with chaperonins such as GroEL or GroES [146]. Alternative strategies include
protein degradation through the Unfolded Protein Response, localisation into cellular
compartments, and sequestering of peptides into relatively inert aggregates. In bacte-
ria misfolded proteins are sequestered into inclusion bodies at the cell poles [149]. In
eukaryotes, aggregates can be stored in one of two distinct compartments: the juxtanu-
clear quality control compartment (JUNQ) next to the nucleus, or the Insoluble Protein
Deposit (IPOD) near the vacuole (in yeast) where the fate of trapped proteins is still
undetermined [104]. Additionally, mammalian cells can also form specialised inclusion
bodies; Russell (or Lewy) bodies to contain large amounts of ubiquitinated or phospho-
rylated proteins [150], and aggresomes which fuse to the lysosome to allow degradation
of their proteinacious content [151, 152].
Although aggregation is generally regarded as an undesirable consequence of protein
misfolding, there is speculation that if peptides aggregate to form an unreactive, stable
structure when this may be a protective mechanism employed by cells to prevent further
cell damage. Such aggregates may be amorphous or highly structured amyloid fibrils
which were described in Section 1.1.
If amorphous aggregates form, they can be destroyed in eukaryotes through being en-
gulfed by double-membraned autophagosomes which then fuse to the lysosome so their
contents can be degraded [153], or ubiquitin-labelled aggregates can be destroyed by
the 26S proteasome [153]. Alternatively, some cells can expel unwanted aggregates by
exocytosis (then aggregates can be removed from blood is via receptor mediated uptake
into cells whose protein degradation pathways are not saturated [154]), or through the
creation of asymmetrical daughter cells, one of which contains aggregate material which
then undergoes apoptosis, leaving and aggregate-free daughter cell [104]. Destruction of
amyloid fibrils is more difficult owing to the immense stability as discussed in Section
1.1.2. There are however some examples of physiological methods to degrade amyloid
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aggregates; for example, Insulin-degrading enzyme (IDE) has been shown to digest fib-
rilar insulin, glucagon, hIAPP and Aβ [155], as can neprilysin, a zinc-associated type II
metalloprotease, [156].
An arising question from this is to consider how IDPs may elude these responses. Pre-
liminary ideas suggest that recognition of exposed hydrophobic regions could be a key
indicator of misfolded proteins. Chaperones mostly interact with unfolded or partially
folded cytosolic proteins through mechanisms involving recognition of exposed hydropho-
bic areas [146] which would explain why IDPs, which are generally lacking in hydrophobic
residues, are not cleared by the heat shock response cascade. This, in turn, raises the
question of the homestatic mechanisms involved in levels of IDPs and how IDPs are
removed from cells if there is an error in their regulation? Thus far, Uversky et al.,
[120], have speculated that IDPs may escape unwanted interactions via functional mis-
folding as a regulatory mechanism. This ignites questions on how a misfolded IDP can
be distinguished from a misfolded structured peptide and ultimately begs the question
of whether a peptide can misfold if there is no ‘correct’ fold to be adopted? Indeed,
is an amyloid-prone conformer of Aβ40 misfolded, and what about a conformer which
can form amorphous aggregates? Is an amyloid-prone IDP conformer closer to a folded
protein than an IDP conformer which can only form amorphous aggregates? There are
many questions still be be answered in the IDP field which are interesting to peruse, but
are beyond the scope of this project.
1.2.2 Functional Disorder
In the last two decades, the importance of disorder in protein function has been realised.
IDPs have been found to have roles in a wide variety of cellular functions including (but
not limited to); mechanisms to sustain harsh environments [157], roles as interaction
hubs or scaffolds to bring together multiple complex components [158], tunable regula-
tory factors affecting transcription levels and as transcription factors [159], enzymatic
catalysis [160], regulation of protein synthesis [161], membrane curvature induction [162],
and multiple others reviewed in [163, 164]. Figure 1.7 provides an overview of IDP func-
tions. Indeed, time has become an important dimension in the characterisation of protein
function due to disorder-to-folded transitions [165].
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Figure 1.7: A summary of roles of IDPs.
a) Overview of structural (green), functional (purple), and regulatory (blue) roles of
intrinsic disorder in protein complexes. b) Basic entropic activity and roles based on
disorder-to-order transitions. Taken from [119].
One of the key features of IDP function is the ability to interact with a wide range of sub-
strates, a property enabled through the high levels of IDP flexibility and dynamics [118].
For this reason IDPs can act as hub proteins, bringing together a variety of substrates.
An impressive property for IDPs is how they can achieve interaction specificity despite
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their wide variety of interaction partners [117, 166–169]. Rationalisation of this can be
explained through the great sensitivity of IDPs to environmental conditions [170, 171]
due to low energy barriers between conformers (see Section 1.2.1). IDPs interact weakly
but specifically with substrates in what is termed interaction ‘fuzziness’ [172, 173]. The
specificity of the interactions arise from the entropic force generated by intrinsically
disordered segments interacting with substrates [174]. The binding energy is the sum
of the favourable enthalpic binding interaction and the unfavourable restriction in IDP
entropic flexibility upon binding. Interaction fuzziness can be beneficial, for example,
in the HSR, IDPs play a role to interact with substrates which do not have a defined
structure (owing to the misfolded nature of the proteins initiating the response). Such
IDPs function as transcription factors and chaperones to trigger the plant version of the
HSR [175].
Virtually all protein functions, whether folded or disordered, rely on interactions with
other molecules, be they other proteins, lipids, polysaccharides, or small molecules [117].
In many cases, IDPs undergo coupled folding and binding due to the stability this
interaction confers on one of the many conformations of an IDP [124]. The coupled
folding and binding of proteins allows a much greater range of interactions within the
same set of proteins, and therefore provides versatility. For example, different signalling
proteins can bind to one receptor, leading to different reactions, and a given signalling
protein can in turn bind to different receptors [124]. Due to the large solvent-accessible
surface area of IDPs, such peptides/proteins have a large surface area for interaction with
either multiple substrates which are distantly located [162] or, the extensive surface area
can be wrapped around a single substrate. For example, p21 can bind to different cyclin
dependent kinase proteins in different conformations [176], wrapping around a protein
partner in order to protect the substrate form interactions with other proteins in the
cell [177, 178].
IDPs may be the result of evolutionary mechanisms to develop finely tuned signalling and
control systems in complex organisms [179]. This is based on the increasing prevalence
of IDPs found in eukaryotic signalling pathways compared to in prokaryotes, Figure
1.8. It is possible that the complex signal regulation enabled by IDPs has provided an
evolutionary gateway to higher organisms.
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Figure 1.8: Prevalence of disorder in proteomes across different domains of life.
The fraction of IDPs or IDRs in proteomes of increasing size. Excluding viruses, as
proteomes increase in size there is a trend that more disorder is observed. Taken from
[180].
1.3 Intrinsic Disorder in Amyloid
1.3.1 Introducing Aβ40: an important IDP in Alzheimer’s Disease
Aβ is the major proteinaceus component of extracellular Alzheimer’s plaques [181–
185], with the 40 residue Aβ40 being the most abundant species present. In vivo the
Aβ40:Aβ42 molar ratio is ∼ 10:1 [186–188] and there is evidence to suggest that the
ratio between these two peptides can influence AD pathology [189, 190]. Although it
is well evidenced that Aβ42 is the most amyloidogenic form of Aβ [191], the ratio of
Aβ40:Aβ42 is a useful marker of Alzheimer’s disease [192, 193], and the two peptides
can interact to form amyloid as well as aggregating independently. Alzheimer’s disease
is responsible for two thirds of the 50 million cases of dementia worldwide [81]. As a
progressive neurodegenerative disorder, Alzheimer’s disease manifests as acute memory
loss, cognitive decline and behavioural alterations [194] and is usually (but not always)
associated with the presence of amyloid deposits, or plaques, in neural tissue [195]. As
Alzheimer’s disease is predicted to become more prevalent as the global population ages,
the already high, socio-economic costs approximately $1 trillion in the US alone [81])
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are set to increase making research on the underlying biochemical causes and features
of Alzheimer’s disease an important field [82, 90].
Aβ40 is an amphipathic peptide which has been confirmed as an IDP by solution NMR
and circular dichroism experiments (CD) [196, 197]. The amino acid sequences for the
main Aβ peptides are shown in Figure 1.10. There is a range of Aβ peptide lengths
due to the unspecificity of cleavage from its precursor protein; amyloid precursor pro-
tein (APP), Figure 1.9. APP is expressed ubiquitously in many human cell types but
is particularly abundant in the central nervous system [198, 199] reaching its highest
expression level in synapses during early postnatal development [200] (when synapses
and neuronal connections are formed [201, 202]). APP is an integral membrane protein
with over four isoforms which range from 695 to 770 amino acids residues [203–206]
and is highly glycosylated. APP is cleaved by a multitude of proteases to create many
bio-molecules which have a broad range of cellular functions, of which many are still
unclear [207]. For example, if α-secretase cleaves APP followed by λ-secretase then sol-
uble C-terminal fragments (CTFs) called APPα and APPβ can be formed which have
neuroprotective effects (see [208, 209] and references therein). Additionally there is in
vitro evidence for some cleavage products to have roles in the activation of adenylyl
cyclase/PKA-dependent pathways [210]. The diversity of roles of many of the peptides
produced from APP are mentioned in [203] and discussed more extensively in references
therein.
To create Aβ40 and other Alzheimer’s-associated isoforms, APP is cleaved on the ex-
tracellular side by β-site APP cleavage enzyme (BACE), a β-secretase, to create the
Aβ N-terminal [181, 211]. Next a complex containing γ-secretase cleaves the intramem-
brane APP via hydrolysis to generate intrinsically disordered peptides of 39-43 residues
in length Figure 1.10 (reviewed in [203, 205, 212]) which have varying structural propen-
sities [213, 214]. The specificity of the γ-secretase is thought to be controlled by genetic
variations in APP isoforms but the mechanism for this is unclear [205]. The distribution
of cleavage products is not even: Aβ40 makes up 90 % of the APP cleavage products,
whereas Aβ42 makes up 9 % [215]). The first 28 residues from the N-terminal of the
cleaved proteins are from the extracellular domain of APP, and the remaining 11-15 are
from the transmembrane domain [216]. This may become evident in structural analysis
of Aβ peptides.
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Figure 1.9: The proteolytic processing of APP.
APP can be cleaved by α-, β- and β-secretases (the cleavage sites of these proteases
are labelled in black on the full-length APP). Cleavage can lead to amyloidogenic (red
arrows) or non-amyloidogenic (blue arrows) pathways. For the amyloidogenic
pathwasy, β-secretase cleaves first releasing soluble APPβ, next γ-secretase cleaves
releasing Aβ extracellularly, and the amyloid precursor protein intracellular domain
(AICD) intracellularly. In the non-amyloidogenic pathway,α-secretase cleaves within
the Aβ sequence creating soluble APP and the membrane-tethered αAPP-C terminal
domain, which in turn is cleaved by γ-secretase releasing P3. The cell membrane is
shown in red and black.
Figure 1.10: Sequences of Aβ cleavage products.
Sequence differences at the C-teminal of Aβ caused by unspecific γ-secretase cleavage.
Aβ is not the sole peptide species associated with Alzheimer’s disease. In Alzheimer’s
patients’ brains, intracellular lesions are also often found, these are intracellular neu-
rofibrillary tangles [217] with the major proteinaceus component being another IDP,
Tau [218, 219]. Rather than study Tau alongside Aβ40, a different IDP (human Islet
Amyloid Polypeptide, (hIAPP)) which is involved in Type II Diabetes Mellitus (TIIDM)
was studied to add breadth of impact of this project. This peptide was chosen as there
are links between Alzheimer’s disease and TIIDM which are described in Section 1.3.3.
Additionally there is evidence of Aβ codeposition with hIAPP in the islets of Langerhans
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which suggests Aβ my have a role in TIIDM pathogenesis [220].
1.3.2 Introducing hIAPP: an important IDP in Type II Diabetes Mel-
llitus
The extent of physiological roles of hIAPP in humans is still not fully defined, but
it is known that hIAPP is associated with insulin and glucagon regulation as well as
regulating the reactivity of small molecule indolequinone precursors of melanin, a skin
pigment [106] in melanosome. The 37-residue peptide, Figure 1.11, has a hormonal role
in influencing gastric emptying and satiation [221] by interacting with the Area Postrema
of the brain which is located just outside of the blood-brain barrier [222]. hIAPP signals
cause the stomach to slow gastric emptying [223], which delays absorption of glucose from
the small intestine into the circulation, such functions have been reviewed extensively
in rat models [224] and clinical studies [225, 226].
Figure 1.11: The hIAPP peptide sequence.
The 37 amino acid sequence which composes hIAPP is shown. Important
postranslational modifications are highlighted; a Cys2-Cys7 disulfide bridge (blue) and
an amidated C-terminus (green).
Due to the presence of hIAPP amyloid plaques located in the islets of Langerhans of
pancreases in TIID patients, studies of the effect of hIAPP on glucagon secretion, as well
as the effect of hIAPP on insulin response to blood glucose level, have been performed.
There are contradictory results concerning the effect of hIAPP on glucagon secretion:
the majority agree that hIAPP acts in a complementary way to insulin and suggest
hIAPP suppresses glucagon secretion by islet α-cells [224, 227, 228] and is generally
accepted that hIAPP limits glucose-induced insulin production [229]. Indeed, in hIAPP
knockout mice an elevation in glucose-stimulated insulin secretion is observed [230].
One major function of hIAPP is to prevent the self-association of insulin in β-cell insulin
storage granules. β-cells require the storage of large amounts of hIAPP and insulin in
preparation for fast release to quickly alter blood sugar levels via hormonal signalling.
Association of hIAPP with insulin begins with their location in the human genome;
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Insulin is located on the short arm of chromosome 11 and hIAPP is located on chromo-
some 12 which is thought to have been duplicated from chromosome 11 during evolution
[231].
Insulin is stored as pro-insulin in these β-cell granules at concentrations of approximately
118 mM [232, 233] and, like hIAPP and its precursor pre-pro-hIAPP, has the potential
to aggregate into amyloid aggregates. The ratio of pro-insulin:pre-pro-hIAPP in β-
cell granules, under physiological conditions, is between 1:25 and 1:50. Susa et al.,
[234] concluded that an insulin:hIAPP molar ratio between 1:5 and 1:100 would have
strong inhibition of amyloid aggregation. The crystalline structures observed inside β-
granules show a strictly ordered, hexameric, zinc-associated, pro-insulin core with a halo
of pre-pro-hIAPP [235]. The two peptides mutually prevent each other from aggregating
[229, 234, 236] despite both being able to form amyloid independently based on evidence
from ThT fluorescence assays (see Section 1.4.1).
1.3.3 Links between Alzheimer’s Disease and Type II diabetes Mellitus
There are epidemiological and physiological correlations between Alzheimer’s disease and
TIIDM, summarised in Figure 1.12. Epidemiology studies have shown that individuals
with TIIDM have a 2 to 5 times greater risk of developing Alzheimer’s disease than
healthy patients [237–241], with approximately 70 % of TIIDM patients developing
Alzheimer’s disease within their lives [220, 242, 243]. There is clinical, transgenic, and
physiological evidence for the Aβ-hIAPP correlation based on long term population
studies [237, 244], murine maze performance tests [245, 246], and resting-state functional
magnetic resonance imaging [247, 248] studies respectively. Physiologically, both diseases
are associated with amyloid formation and deposition [249]. Although Aβ deposition
mostly occurs in the brain there is evidence to suggest that Aβ has a role in regulating
the ability of peripheral tissues to respond to insulin [250–253].
Recently, many studies have identified the physiological actions of soluble hIAPP in
brains, such as stimulating neuron growth and function, maintaining cerebral glucose
homeostasis, inducing Aβ degradation and inhibiting its neurotoxicity. However, dur-
ing the progression of TIIDM, there is a decreased level of soluble hIAPP due to its
aggregation. This reduction of soluble IAPP may result in loss of the protective effects
of hIAPP on the brain and stimulating the progression of Alzheimer’s disease [255]. In
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Figure 1.12: Physiological links between Alzheimer’s disease and TIIDM.
A Venn diagram showing some of the shared physiological impacts of TIIDM and
Alzheimer’s disease. [254].
accordance with this, it has been shown that elders with Alzheimer’s disease have lower
concentrations of soluble hIAPP in their plasma compared to healthy individuals in the
same age group [255, 256].
1.3.4 Aβ40 and hIAPP interactions
hIAPP oligomers and mature fibrils are found deposited as independent plaques in the
brain as well codeposited in Aβ neural plaques in the brains of TIIDM subjects with
cognitive impairment [257–259]. Cross-seeding has been observed in in vivo studies
[258, 260]. One study showed fibrillation from injection of either Aβ or hIAPP seeds
leads to hIAPP fibril deposition in hIAPP transgenic mice [258]. There is a similar cross-
seeding effect when Aβ transgenic mice were injected with hIAPP seeds [260]. hIAPP has
51 % sequence homology, and 27 % sequence identity to Amyloid-β42 [261, 262] (Figure
1.13) with segments important for self-aggregation displaying the greatest similarity
[263]. Sequence similarity may permit cross-seeding and/or codeposition of these two
peptides when they form amyloid.
There are two regions of hIAPP (residues 8 to 20 and residues 21 to 37) which have high
binding affinity for Aβ [262]. Correspondingly, Aβ also has two regions (residues 11 to
21 and residues 23 to 37) with high binding affinity for hIAPP [262]. A low-nanomolar
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Figure 1.13: Alignment of Aβ42 and hIAPP pepide sequences.
Identical residues are highlighted in bold and red, and similar residues in orange. The
boxed residues correspond to the fibril spine residues according to [257].
affinity interaction between early non-fibrillar and non-toxic Aβ40 and hIAPP species,
which was identified in vitro, has been shown to suppress cytotoxic self-association and
amyloidogenesis by both Aβ40 and hIAPP [190] using mutagenises experiments.
Interestingly, the transcription level of hIAPP in the brain is undetectable [259, 264] so it
is thought that cerebral hIAPP is generated in the pancreatic β-cells and is transported
to the brain [259]. hIAPP oligomers can cross the Blood Brain Barrier by inducing
inflammatory cytokines to destroy the integrity of the barrier [265, 266]. Transgenic
murine studies are ongoing to help reveal the TIIDM-AD link [220, 238, 267, 268].
Aβ40 and hIAPP appear to interact not only in their monomeric states, but also can
interact once aggregated. Aβ40 fibrils cross-seed hIAPP fibril formation, suggesting that
the 3D fibril structure of Aβ40 is able to template hIAPP aggregation [261]. The ability
for the same peptide mimetics and small molecules to inhibit amyloid formation from
hIAPP and Aβ also implies that their underlying, amyloid-prone conformer structures
are similar [262], leading to the hypothesis that drugs to treat TIIDM could be used to
treat Alzheimer’s (reviewed in [269]).
1.3.5 Current understanding of the Aβ40 and hIAPP monomer roles
in the amyloid pathway
As discussed in the previous sections, amyloid formation is an intricate process and in-
volvement of an IDP as the monomer unit of aggregation add another layer of complexity.
This project focused on two examples of amyloidogenic IDPs: hIAPP and Aβ40. Figure
1.14a shows structure prediction results and aggregation prediction for both peptides.
Aβ40 consists of a charged N-terminal region, followed by a hydrophobic central region
and then a C-terminal domain, Figure 1.14b. The central region, sometimes referred to
as the central hydrophobic core (CHC) is thought to be important for amyloid formation
as it has been shown to form amyloid in isolation [24, 270], but the limits of this region
are not definitive (e.g. residues 14-23 [271], 16-21 [272, 273] or 16 to 22 [274]).
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Figure 1.14: Structural predictions for Aβ40 and hIAPP.
a) Structural prediction (α-helical prediction in pink, β-sheet prediction in yellow) was
calculated using PSIPRED (http://bioinf.cs.ucl.ac.uk/psipred) from University College
London Department of Computer Science: Bioinformatics Group. AmyPred2 was used
to find regions of predicted amylodogenicity (black boxes)
(http://aias.biol.uoa.gr/cgi-bin/AMYLPRED2) which uses 10 separate prediction
algorithms for amyloid propensity (including TANGO and WALTZ), consensus from 5
or more methods is required to determine a residue as being in an amyloidogenic
region. b) Each peptide can be considered in three parts, Aβ40 has an N-terminal
region (light blue), central hydrophobic region (mid blue), and C-terminal region (dark
blue), and hIAPP also has an N-terminal region (light green), central hydrophobic
region termed the ‘amyloidogenic region’ (mid green), and C-terminal region (dark
green). The disulfide bridge is shown (blue) and the amidated C-terminus of hIAPP
(green).
hIAPP has more structural features than Aβ40: a disulphide bridge between cysteines 2
and 7, and an amidated C-terminus, which are both important for amyloid aggregation
[229]. The amino acid sequence of hIAPP can also be split roughly into three parts, Fig-
ure 1.14b: the N-terminal region, the amyloidogenic region, and the C-terminal region
similarly to Aβ40. The N-terminal region, hIAPP1-19, is able to bind to cell membranes
[275]. Such an interaction can induce a transient, predominantly α-helical structure [276]
to the otherwise randomly coiled peptide. This can bias the IDP conformation distri-
bution prior to amyloid aggregation. hIAPP20-29 is known as the amyloidogenic region
[275], which is believed to lie at the inter-peptide interface when fibrillation occurs. Of
this region of hIAPP, the shortest segment to form amyloid fibrils is NFGAIL [277] which
is found to be essential for amyloid formation [229]. When comparing amyloidogenic hI-
APP with non-amyloidogenic rat IAPP (rIAPP), 1.15, five residue substitutions are
found in the amyloidogenic region and one substitution in the N-terminal region. This
helps understand the lack of amyloid behaviour in the Pro-rich sequence. Interestingly,
earlier isoforms of IAPP contain more Proline residues than hIAPP suggesting that in
humans, hIAPP has developed the ability to aggregate due to an evolutionary driver,
potentially this could well be for dense storage in β-granules. Finally, the C-terminal
region of hIAPP is thought to positively modulate amyloid formation [275].
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Figure 1.15: Sequence comparison of hIAPP and rIAPP.
Altered residues are highlighted in blue. The disulfide bridge is shown in green and the
amidated C-terminal in red.
Replica-exchange molecular dynamics (REMD) [278, 279], NMR [196, 280–285], electro-
spray ionisation ion mobility mass spectrometry (ESI-IMS-MS) [278, 286] and circular
dichroism (CD) [197, 287–289] have all been used to gain insight into monomeric con-
formations of Aβ40/42. Baumketner et al., [278] used IMS-MS and REMD to categorise
Aβ42 conformations into three general groups. In each group the N-terminal part of the
peptide exists mostly as loops and turns (e.g. A2-R5, A21-D23), but the groups differ
in their propensity for structure in the hydrophobic C-terminal domain: greater propen-
sity for α-helical structures, greater propensity for β-sheet structures, or a propensity
for both types of structure [278]. Despite this, the ordered regions still only constitute
10-20 % of the total peptide sequence [278]. Prior NMR studies identified the CHC
as having a high structural propensity to form α-helical fragments [196, 284] which is
supported with MD simulations [279].
Molecular dynamics simulations on Aβ40 based on NMR-guided metadynamics [290]
were used to create a conformational landscape (Figure 1.16) of the IDP monomer and
from this a library of structures which could be used as targets to design inhibitors which
bind to Aβ40 and prevent oligomerisation and fibrillation. The simulations are supported
with biophysical data from size exclusion chromatography and pulse-field gradient NMR
diffusion experiments to ascertain conformation diameters [129]. As expected for an
IDP, the lowest energy states are least structured and as temperature increased, more
structural motifs were simulated. The surface of the conformational landscape has many
small undulations which enable the peptide to convert between different structures on
minor energetic changes (in vivo such changes could be caused by the interaction of cell
components or a change in ion concentration in the peptide environment).
Currently, it is unknown which structural propensities and features are essential for the
initiation of Aβ40 or hIAPP amyloid formation. The induction of α-helical structure
in hIAPP has been linked to an increase in aggregation rate but it has not yet been
probed on an atomic level, and it is not understood why this feature encourages amyloid
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Figure 1.16: Free energy landscape predicted for Aβ40.
The free energy landscape shown is based on three variables (anti-parallel β-sheet
content (X-axis), α-helical content (Y-axis) and number of hydrophobic contacts (or
compactness, Z-axis)) used in an NMR-guided metadynamics simulation [129]. Levels
of energy are discriminated at 5 (red), 10 (blue), 18 (yellow) and 25 kJ/mol (cyan) on
the energy landscape whereas white regions are not visited as they have unsampled,
high free energies. Representative structures sampled during the simulation are
illustrated outside the landscape in cartoon ribbon presentation. For increasing free
energies, Aβ40 becomes more structured by populating both α-helical and β-sheet
conformations. Some conformations are more prone to amyloid formation than others
(black arrows). Adapted from [29, 129].
formation. Despite this, evidence of a transition of hIAPP to aggregate through β-
sheet conformers without involving α-helical intermediates has been observed [291]. An
α-helical structural transition has however also been noted in Aβ40 whereby a helical
intermediate is formed prior to a β-sheet containing monomer which is amyloid-prone.
1.4 Strategies for Studying IDPs in Amyloid Formation:
Approaches for Trapping Amyloid Species for Struc-
tural Analysis
The complex nature and incomplete understanding of both IDP conformational land-
scapes and the mechanism of amyloid formation makes studying IDP-amyloid transitions
challenging, but potentially, enlightening. Much progress has been made in both fields
and there is already a plethora of literature which combines them [292, 293]. Structural
analysis can already be limited for structured amyloid precursors due to the timescale
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of aggregation, the addition of monomer interconversion is yet more of a challenge. To
aid the investigation of important monomer conformations of Aβ40 and hIAPP in their
amyloid trajectory, specific conformations can be trapped, or stabilised to allow more
time for structural analysis.
In the literature there are three major strategies which have been applied to trap, or
skew, conformer population distributions of short-lived species on- or off- the amyloid
pathway; use of peptide mimetics, peptide sequence mutagenesis, and small molecule
stabilisation.
Using Peptide mimetics to investigate amyloid aggregation:
Peptide mimetics are usually peptides with similar sequences to the protein of interest,
but are not compatible with further aggregation and thus can form and trap small
oligomeric species. This approach has been used by Zhao et al. [275] and Westermark et
al. [229] to identify different functions of different parts of hIAPP in amyloid formation.
Recently peptide mimetics have been used to study the interaction of hIAPP and insulin
[294]. The hIAPP-fibrillating core (N22FGAIL27) fragment was used to inhibit insulin
fibrillation [294]. NMR spectroscopy was used to analyse the inhibitory interaction at
atomic resolution. Another study designed two small peptides (VVVVV and VIFYT)
which, respectively, have a high and moderate predisposition for forming β-sheets, but
both showed inhibitory behaviour in insulin amyloid aggregation [295]. In a study by
Ratha et al., [294], a derivative the N22FGAIL27 region created whereby the Ile was
substituted for a residue mimetic, 2-aminobenzoic acid. This residue breaks β-sheet
configurations and has been shown to prevent hIAPP from forming amyloid [296].
Using peptide sequence mutant or analogues to investigate amyloid:
Sequence alterations have also been insightful. Mutagenesis is generally a front-line
approach for gaining information on peptide features and has been used in the amyloid
field. A key example is the D76N mutant of β2-microglobulin which is a familial mutant
leading to strongly enhanced amyloid aggregation [297, 298]. Pramlintide is an analogue
of hIAPP which is currently used in the treatment of diabetes [299]. It prevents amyloid
formation by binding to fibrils and preventing their elongation due to three proline
substitutions (A25P, S28P, and S29P) which make pramlintide more similar to rIAPP
(Figure 1.17) and prevent close β-sheet stacking.
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Figure 1.17: Sequence comparison of hIAPP, pramlintide and rIAPP.
Pramlintide differs by three residues from amyloidogenic hIAPP and
non-amyloidogenic rIAPP. Residue substitution which are dissimilar to hIAPP are
highlighted in red, the Cys2-Cys7 disulfide bridge is represented in blue, and the
amidated C-terminus in green.
Altering residue side chains has also been used to probe for important chemistry in
amyloid formation. For example, Abedini et al. [300] used acetylation (and truncation)
experiments to show that if His18 of hIAPP is deprotonated, the rate of amyloid ag-
gregation is faster than for the protonated form. At a monomer level, incorporation of
additional chemistry into a peptide chain can be used to aid the study of amyloidogenic
IDPs, for example, Click chemistry groups or groups for the addition of dye/FRET
molecules. Or mutagenesis has been used to incorporate unnatural disulfide bridges to
stabilise and bias peptide folds to encourage the formation of turns and secondary struc-
tural motifs which can be important ion amyloid formation. Interestingly, work has been
done to probe the importance of IDP sequence on amyloid propensity, Vadukul et al.,
[301] used a combination of biophysical methods to observe changes in fibril morphology
when the Aβ42 sequence was reverse or scrambled.
Use of small molecules to investigate amyloid:
Use of small molecules to probe amyloid formation is a vast area with a huge bank
of scientific literature which is continually growing [302]. Small molecules have been
used to bind and stabilise some conformations of IDPs [302, 303]. These compounds
may act as inhibitors of aggregation by fixing the IDP monomer or oligomer in an
off-pathway conformation, or may sterically exclude monomer addition to fibril forms.
Alternatively compounds could accelerate amyloid formation by increasing the likelihood
that the IDP samples an amyloid-prone conformation and thus increase the population of
amyloidogenic forms. Many small molecules have been identified that affect the protein
aggregation pathways. Of these, polyphenols, such as curcumin, EGCG, and resveratrol
have been studied and shown to inhibit amyloid fibrillation [304–306]. In fact, certain
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epigallocatechins have been used in clinical trials for the treatment of Alzheimers disease
[307]. More recently, several quinones, such as benzoquinones, naphthoquinones, and
anthraquinones, have been investigated and shown to modulate protein fibrillogenesis
[304, 308, 309]. Small molecules do not effect all amyloid proteins in the same manner
or to the same extent [302]. This is perhaps unsurprising given the breadth of proteins
with amyloid-potential. Despite this, some large proteins can inhibit multiple amyloid
proteins, e.g. C-Phycocyanin from Spirulina inhibits α-synuclein and Aβ fibril formation
[310], may share a common mode of action or may cause similar structural perturbations
which can be analysed to shed light on important conformers in amyloid aggregation.
Additionally, there are many innovative methods, which can be used in conjunction with
these three strategies, being developed to help explain the monomer and small oligomer
phases of amyloid formation. Some examples of such methods are single molecule ap-
proaches (e.g. two colour coincidence [311, 312], fluorescence correction spectroscopy and
FRET [313]); single molecule force measurements [314, 315], and novel mass spectrom-
etry methods [316]. Furthermore various antibody-based approaches, reviewed by De
Genst et al., [317] have been used to stabilise partially structured species and folding in-
termediates of peptides involved in amyloid formation and Clark et al., [252] developed a
combinatorial method using two-photon scattering with time resolved fluorescence spec-
troscopy to create a novel way of monitoring the conformational dynamics of the early
stages in aggregation of Aβ (this is largely similar to CD but with enhanced sensitivity).
In particular, NMR and MD methods are particularly suited to the study of IDPs.
Today there is an abundance of further biophysical methods which can be used in com-
plementary analysis of amyloid formation mechanism. Table 1.3 lists some of these.
Table 1.3: Biophysical methods for monitoring IDP behaviour at various stages of
amyloid formation. Adapted from [3–6] and references therein.
Technique Applications Species (Unfolded (U),
Oligomeric (O), Aggre-
gate (A))
Overall Structure/stoichiometry:
TEM Overall Shape A
MS Stoichiometry and important
charge states
A O
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Technique Applications Species (Unfolded,
Oligomeric, Aggregate)
solid state NMR Shape A
Xray diffraction Repetitive aggregate struc-
ture
A
chemical staining Changes in surface exposure A O U
H / D exchange Changes in surface exposure A O U
Cryo EM Overall morphology A
SDS + native PAGE Stoichiometry O U
DLS Conformation A O U
Specific structural info:
solution NMR Conformation, O U
AFM Formation/loss of secondary
structure
O
H/D exchange Highlight potential reactive
hydrogens
A O U
Chemical crosslinking Initial intermolecular interac-
tions, surface exposure
O U
CD (near and far) Formation/loss of secondary
structure. Aromatic packing.
O U
Raman Resonance
Spectroscopy
Surface exposure, aromatic
interactions
O U
Intrinsic dynamics:
Fluorescent probes
(e.g. FRET, FPOP)
Degree of flexibility, rate of
dis/association
A O U
ANS binding Degree of flexibility, rate of
dis/association
A O
solution NMR Binding affinities and rates of
folding
O U
AFM Interaction strength O U
H/D exchange Surface exposure in alternat-
ing conformational states
A O U
EPR Rate of dis/association O
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Technique Applications Species (Unfolded,
Oligomeric, Aggregate)
Calorimetry Rate of un/folding O U
For this project a selection of these methods were chosen: ThT fluorometry, TEM, the
β-lactamase tripartite assay, ESI-IMS-MS, and solution NMR. Choice of these methods
is discussed in Chapter 3, Section 3.4. Provided here is a summary of how these methods
have been used to study amyloidogenic IDPs.
1.4.1 ThT Fluorescence as a Reporter for Amyloid Aggregation in
vitro
Although multiple dye-binding assays have been widely used to discover small molecule
modulators of amyloid formation, use of the benzothiole dye Thioflavin-T (ThT) is by
far the most popular [318, 319]. ThT can be added to an amyloidogenic system and
changes in its fluorescence can indicate the extent of β-sheet formation. The popularity
of the ThT fluorometry assay is likely due to its ease of use, small sample volumes, and
the fact that a single experiment can provide a large amount of information about the
system reaction kinetics [66]. The ThT assay is amenable to relatively high throughput
data collection and thus is a commonly used as a screening technique.
In solution ThT emits a very low level of fluorescence (at 480 nm), however this increases
greatly when the rotational freedom between its benzothiazole and dimethylaminoben-
zene ringed structures is limited. Associated with β-sheet conformations, such as those
found within amyloid fibrils, is one type pf interaction which can do this. Hence fib-
rillation can be monitored indirectly through the change in ThT fluorescence. Binding
of ThT to amyloid fibrils, Figure 1.18, restricts the rotation of the benzothiozole and
benzaminic rings of ThT which permits the fluorescence emission [320]. The interac-
tion between ThT and β-sheet structures remains controversial [321–323] but the most
widely accepted theory is that ThT can bind to β-sheet structures using a combination
of electrostatic and hydrophobic interactions between ThT and the repetitive grooves of
a β-fibril [324]. It is thought that ThT interacts hydrophobically with aromatic residues
which are ≥4 β-strands apart and this restricts ring rotation on ThT and this enables
fluorescence [321, 324, 325].
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Figure 1.18: ThT ring orientation is restricted when bound to β-sheets.
a) the chemical structure of ThT. b) The orientation of the benzothiazole and
dimethylaminobenzene structures differs when ThT is in its excited state. c) ThT
(orange) between two β-sheets (green and blue) in a β2-microglobulin amyloid fibril
showing restricted bond rotation. Adapted from [326].
Despite being the ‘Gold standard’ technique for monitoring aggregation, the ThT assay
is not infallible. When used in conjuction with small molecules, compound-ThT interfer-
ence can result in misleading fluorescence read outs. For example, a small molecule may
interact directly with ThT and exhibit fluorescence regardless of the β-sheet content of
the protein sample, or conversely, a compound may sequester and/or quench ThT fluo-
rescence. Such interactions are particularly likely when screening aromatic compounds
similar to many published amyloid inhibitors, e.g. EGCG, bexarotene, naphthoquinones
etc. Additionally, there may be compound-peptide interactions which sterically block
ThT from binding to β-sheet structures. For a screening assay, false positives which can
be filtered out after further testing are less problematic than false negatives which could
exclude hit compounds from analysis. For example, a false positive result is observed
on the interaction of rifamycin with hIAPP in the presence of ThT [327]. Rifamycin
interrupts the ThT-fibril interaction so no increase in fluorescence is observed implying
inhibition of fibril formation. Use of additional biophysical methods, such as electron
microscopy [328] or atomic force microscopy (AFM) [329] can be used subsequently to
verify conclusions.
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Interpretation of absolute levels of ThT fluorescence when bound to amyloid fibrils has
been discussed extensively in the literature. There are conflicting claims on the corre-
lation between fibril yield and ThT fluorescence. Some research shows a reproducible,
linear correlation of fluorescence and fibril abundance (for example, Xue et al., [330]
showed this linear relationship between ThT intensity and Aβ40+42 or prion protein
Ure1 between protein concentrations of 0.2 to 500 µM). However, there are multiple
factors which could disrupt this relationship. One of the major factors relevant to amy-
loid is the non-uniform affinity of ThT to bind to fibrils of differing morphology. As
was discussed in Section 1.1, the structure of amyloid fibrils is heterogeneous and if the
morphology of fibril created has a larger pitch or groove of altering depth then this could
affect ThT affinity and fluorescence intensity. Work by Linse, Dobson and Knowles [66]
developed models for fitting amyloid formation using ThT which enables interpretation
of whether an aggregation process is dominated by fragmentation, primary, or secondary
nucleation.
Recently the ThT assay has been used to probe the effects of compounds found in day-
to-day life on Aβ40 aggregation [331], such as caffeic acid in coffee, EGCG in green tea,
resveratrol in red wine, and cumin in tumeric. Although a useful assay, there are flaws
and next generation fluorophores are being developed, such as some curcumin analogues
[332]. There are alternative dyes such as ANS and bisANS [333] and nezothiophenes
which can discriminate oligomers and amyloid. Amyloid formation kinetics of other
proteins, such as α-synuclein [334] and β2-microglobulin [335] have also been extensively
studied using ThT fluorometry.
1.4.2 Testing Small Molecule effects on Amyloid Aggregation in a
Physiological Environment
A notable in vivo study by Navarro et al. [336] developed a method of quantitative
detection of amyloid within cells using a combination of confocal microscopy, fluorescence
microscopy, and flow cytometry combined with a new dye called ProteoStat which can
bind and discriminate intracellular amyloid aggregates in E. coli. A particularly useful
in vivo method for the study of small molecules and their impact on aggregation, is the
tripartite-β-lactamase assay [337]. This assay, based in the periplasm of E. coli cells,
can be used as a small molecule screen and also to assess small molecule potency [337].
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There are other in vivo assay options for investigating compound effects on aggregation
in live cells but these experiments are limited to cytosolic environments [336, 338, 339].
These studies involved the fusion of aggregation-prone peptides to a reporter protein such
as green fluorescent protein (GFP) [336, 338–340]. The folding of such a large reporter
protein may influence peptide solubility and aggregation behaviour. The problem with
this is that only certain compounds can cross the cell membrane leading to multiple
false negative results. The presence of porins in the outer membrane of E. coli (and
other Gram negative bacteria), the membrane barrier is permeable to molecules of up
to approximately 600 Da [341]. A common theme for these assays is the genetic fusion
of a protein of interest in between two domains of a reporter protein. This reporter may
be a fluorescent protein [338, 339, 342] which can be detected directly or an enzymatic
function which can be easily observed by indirect monitoring.
A schematic for the tripartite β-lactamase assay is shown in Figure 1.20. For this assay
the peptide of interest, e.g. Aβ40 or hIAPP, is expressed into a linker region in between
the two domains of β-lactamase (Figure 1.19. β-lactamase is often used as a reporter
system due to its relatively small size (29 kDa) and monomeric nature [343]. The assay
is based on the assumption that if the test protein inserted is able to aggregate with
other β-lactamase tripartite fusions, the β-lactamase enzyme activity will be lost from
the periplasm. Hence, when aggregation of the test protein occurs, β-lactamase activ-
ity is reduced and the bacteria are consequently more sensitive to β-lactam-containing
antibiotics such as ampicillin or carbenicillin [337]. When the bacteria are grown in
the presence of small molecule inhibitors of protein aggregation, antibiotic resistance is
restored in a quantitative manner. For example, this assay has been implemented to
screen for small molecule inhibitors of hIAPP aggregation [337] and an earlier variant
has been used to screen for inhibitors of Aβ40 aggregation [344]. To date, the tripar-
tite β-lactamase developed by Saunders et al. [337], is the only in vivo method that
can be applied as a screen for the multitude of small molecules that cannot enter the
cytoplasmic space.
A major benefit of this assay is that purified protein is not necessary which avoids
time intensive steps in investigations. This meant the tripartite β-lactamase assay is
amenable for investigation of hard-to-produce peptides which may be aggregation prone
during the purification process. Furthermore, the assay can be used even when little
structural or functional information about the peptide of interest is available, principally,
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Figure 1.19: The Gly-Ser linker sequence between the two domains of β-lactamase
a) The sequence of the 28-residue linker and position of the test protein insert. b) The
64-residue linker sequence for control assay (for short peptides such as hIAPP or Aβ)
whereby the linker is solely Gly-Ser
Figure 1.20: The tripartite β-lactamase assay can identify aggregation-prone sequences.
a) In this schematic the test protein (green) is inserted into a glycine/serine-rich linker
(blue) within the loop region separating the two domains of β-lactamase (purple and
pink). b) Clarification of where the inserted protein sits within the β-lactamse enzyme
(green arrow). c) When β-lactamase can bring its two domains together, it can form
the active site for β-lactam cleavage. d) When an aggregation-prone sequence is
inserted β-lactamase enzymes are sequested and the two β-lactamase domains are
sterically prevented from forming the enzyme active site. e) Addition of a small
molecule which inhibits aggregation of the inserted peptide can restore β-lactamase
can function. Taken from [337].
the assay could be performed on a peptide for which only the primary sequence is known
[345, 346]. Caveats to this assay included its ineffectiveness when compounds are highly
toxic, or if a small molecule is able to stabilise a low order oligomeric state possibly
allowing β-lactamase to still function as it is not so sterically hindered to prohibit the
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formation of its active site [346].
1.4.3 The Value of Electron Microscopy in Amyloid Fibril Observation
There are various techniques which can be used to monitor the nature of mature ag-
gregates as was indicated in Figure 1.1. Some aspects of mature fibrils lend themselves
to biophysical analysis, such as their stability, and repetitive structures, where as oth-
ers present challenges, such as polymorph heterogeneity and contrasting fine structures.
Cryo-EM has propelled the extent of structural information which can be obtained from
the study of fibrils to near atomic resolution, even for ex vivo samples [347, 348]. Other
microscopy techniques, including the comparatively low resolution, transition electron
microscopy (TEM), still have value as a rapid method to check for aggregate presence
and overall morphology, i.e. amorphous or amyloid [337].
A caveat of TEM is the inability to accurately quantify aggregates species. The number
of fibrils observed is difficult to quantify from EM techniques due to the varying lengths
of fibrils observed, the inconsistent affinities of fibril morphologies to bind to the carbon
grids or stain. Quantitative methods for fibril yields include sedimentation velocity AUC
analysis, or RP-HPLC. Sedimentation velocity AUC analysis can characterise interme-
diate species in amyloid fibril formation in exceptional detail, particularly oligomers and
protofibrils [349, 350]. RP-HPLC has been used to quantify early species in Aβ40 amy-
loid aggregation such as oligomers [351]. In 2014, Arosio et al., [352] noted that many
conventional methods for detecting amyloid forms were not sensitive to events taking
place early in the lag phase. As described earlier, secondary nucleation plays a role in
amyloid formation and it is important to note that low levels of some fibrillar species
will be present in the early stages of amyloid formation. Quantification of such fibrillar
species of Aβ42 has been measured using carefully conducted seeding calibrations and
ThT fluorescence [352].
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1.4.4 Use of Electrospray Ionisation Ion Mobility Spectrometry Mass
Spectrometry (ESI-IMS-MS) to Observe Monomer and Small
Oligomers in IDP ensembles
ESI-IMS-MS is one of the leading techniques for the study of heterogeneous, lowly
populated, and transient species in biochemical reaction pathways [353, 354]. This is
due to the specific ability to detect multiple species within a sample with great sensitivity
even when species are low in concentration [316, 355, 356]. ESI-IMS-MS can separate
ions not only by their mass:charge ratio, but also by their collisional-cross section area.
This allows alternative conformational states of isobaric oligomers to be detected [316,
356, 357]. A further advantage of ESI-IMS-MS is the speed of data acquisition. This
enables reaction progress to be monitored such as the disappearance of monomer and
change in oligomer distribution as amyloid formation pregresses [354]. The method has
been used in the amyloid field [358, 359] and also in wider areas, such as in determining
the reaction intermediates formed in chemical reactions [360].
In the amyloid field, ESI-IMS-MS has been demonstrated to be an ideal method for
studying small compound interactions with intrinsically disordered peptides such as
Aβ40 [358] and hIAPP [316]. In the most recent study by Young et al., [358] the
method was used to probe the binding mode and interaction stoichiometry (Figure
1.21) and to screen for small molecules which interact with monomeric and low oligomer
forms of amyloidogenic peptides [316]. Despite the small sample requirements and great
insight which this technique can provide on small molecule interaction and conformer
distributions, one downfall is that all analysis is conducted in the gas phase rather than
in a liquid solution and results thus need to be validated with other methods in solution.
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Figure 1.21: A schematic of the ESI-IMS-MS set up.
Aβ40 was mixed with small molecules and the samples were infused into the mass
spectrometer wherein separation occurs based on the mass to charge ratio (m/z) and
collisional cross-sectional area (CCS) of the protein-small molecule complexes. Output
data can generally be classified into four distinct outcomes: No small molecule
interaction (black), specific small molecule interactions (blue), non-specific interaction
(pink) or a colloidal mass wherein the compound bind to itself (green) based on [361].
Figure adapted from [358].
The power of ESI-MS in elucidating information on the early stages of amyloid formation
was highlighted earlier with studies by Bleiholder et al., [215]. Furthermore, IMS has
been used, in conjunction with gas phase infra-red spectroscopy, to indicate that more
expanded conformers, with a larger collisional crossection (CCS), tend to contain more
β-sheet and β-sheet-like architectures than smaller conformers [86, 92]. This observation
implies the transition towards a fibril-like architecture may occur at a very early stage
on the aggregation pathway for short amyloid-forming peptides.
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1.4.5 Residue Specific Effects of Small Molecules Can be Monitored
by Complementary NMR Methods
NMR spectroscopy is well-suited to the study of IDPs owing to there extensive flexibil-
ity and is highly compatible with small molecule-peptide interaction studies. Research
on IDPs has led to development and adaption of NMR techniques to extract structural
information on these disordered states [362]. The selection of NMR methods available
to IDP biologists is extensive (PRE, RDC, T1,2, CPMG, Pulse-filed gradients, NOEs,
13C-direct detected experiments, 1H15N-HSQC, TROSY and anti-TROSY experiments)
[363] and therefore a considered approach is required to select an complementary subset
of techniques which can shed light on different peptide attributes. Often the informa-
tion obtained by NMR can be interpreted using molecular modelling tools to generate
conformational ensembles which represent IDP conformations [362]. Measurement and
comparison of separate parameters can reveal insight into IDP behaviour which may be
overlooked in a single type of analysis. Atomic level structural characterisation of IDP
drug targets enables the development of more effective treatments [364, 365]. For ex-
ample, small molecules have been designed to inhibit binding to IDP oncoprotein c-Myc
[366], and to interfere with amyloid formation [364].
Assignment of chemical shifts of resonances of IDPs is essential for specific residue analy-
sis. The intramolecular motions of IDPs cause slow relaxation rates giving rise to narrow
linewidths which reduce spectral overlap. This is particularly useful given the narrow
dispersion in the 1H dimension of 1H15N-HSQC spectra of IDPs [367, 368] which can
result in signal overlap. This can be problematic, but NMR methods have been devel-
oped to overcome spectral overlap issues. For example, 5D and 7D experiments were
used to resolve signal overlap for the Tau protein (another amyloid IDP associated with
Alzheimer’s diseases) [369] but often resonance distributions for 13C and 15N nuclei can
be exploited sufficiently to assign IDPs. Chemical shift changes of specific resonances
on the addition of small molecule modulators of aggregation can pinpoint binding site
locations, the binding affinities.
Secondary structure in IDPs is usually transient and confined to short segments [362].
Residual Dipolar Couplings (RDCs) and chemical shift perturbations are commonly
used to infer information on secondary structure propensity due to their sensitivity to
structure formation. For example, RDCs have been used to reveal structural information
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on IDPs including α-synuclein [370] and Aβ40 and fragments [371–373]. Interestingly
there is a lack of literature demonstrating the use of RDCs to investigate IDPs in the
presence of small molecules. Such experimentation would enable comparison of peptide
properties in apo states and small molecule bound states. RDCs can provide insight
into long-range intrapeptide interactions on up to a ms timescale [374, 375].
Where RDCs can indicate regions of structural propensity, temperature coefficients can
indicate probability of involvement of backbone amides in hydrogen bonding [376, 377].
This correlates with secondary structure formation propensity and can lead to inference
of flexibility along the backbone of an IDP. If an amide proton is involved in hydro-
gen bonding, indicative of secondary structure, there is a negative correlation between
strength of hydrogen bond and the size of the temperature coefficient (a strong hydrogen
bond gives rise to a small temperature coefficient) [376]. This is because it is more likely
that amide protons in hydrogen bonds will not exchange with solvent hydrogens, and
solvent exchange is very temperature dependent [378]. Again, there are few examples
of using this parameter to monitor changes in structural conformations of IDPs on the
addition of small molecules, but the method theoretically should be amenable to such
measures. Okazaki et al., [378] developed a method for classifying disorder in IDPs
based on temperature coefficient scores which can aid the interpretation of measured
values.
Heteronuclear relaxation experiments can probe peptide dynamics which is vital for
consideration of IDPs. T2 relaxation can give insight into ps-ns movements as well as on
conformational exchange on the µs-ms timescale [370, 379, 380]. T2 relaxation is based
on how quickly nuclei lose alignment after a magnetic pulse in the NMR spectrometer. If
a peptide region is more flexible and able to move around more then the rate of relaxation
will be fast, so T2 will be shorter. This is explained in more detain in Chapter 5.
Taken together, these methods provide a detailed glimpse of IDP structural and dy-
namic properties which can indicate important transitions induced by small molecules.
Used in conjuction with other methods, and if the small molecules can perturb amyloid
aggregation, NMR can reveal important conformer steps in monomer folding neccassary
for amyloid aggregation. This topic has been extensively reviewed in [363, 381, 382] and
many others.
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1.5 Thesis Aims
Amyloid aggregation has a role in some of the most prevalent diseases in today’s society.
A great deal of research has focused on elucidating the key structures underpinning
these diseases in the hope of revealing more about the mechanism of aggregation. The
conformation of monomers in the amyloid pathway are particularly difficult to define
structurally as many of the species are dynamic, existing only as transient states in a
vastly heterogeneous population.
This thesis describes a multi-method approach which was used to investigate the aggre-
gation of the amyloidogenic IDPs; Aβ40 and hIAPP. Small molecules were then sought
that are able to modulate the aggregation of Aβ40.
Chapter three describes the construction of a method toolbox which was later used to
screen and then evaluate the effects of 67 small molecules on amyloid formation of Aβ40.
Initially Aβ40 and hIAPP were recombinantly expressed and purified as a prelude to
testing small molecule effects on aggregation. The small molecule screening process must
be relatively high throughput and data analysis will need to be efficient for revealing
effects on amyloid formation. The toolbox will need to bring together a selection of
methods which can then be used to probe small molecule effects on aggregation more
thoroughly. On choosing which methods to be incorporated into the toolbox, key control
experiments were conducted for each method to ensure compatibility with IDPs and
small molecules. It is hoped that this toolbox will become an invaluable set of measures
which can be used to find and then probe how specific small molecules can alter the
amyloid aggregation pathway of IDPs. This will ultimately lead to greater understanding
of amyloid diseases and may yield therapeutic directions in the future.
In chapter four, the method toolbox, was applied to screen a compound library to search
for modulators of Aβ40 aggregation. First a compound library for screening was selected
using ROCS analysis of compound leads: 1,2-naphthoquinone, adapalene, bexarotene,
MM3003, and UV11523. Next the screening method chosen in chapter three was used
to find small molecules which perturb amyloid formation. Promising results from the
screen were then investigated using the other methods in the toolbox (ESI-IMS-MS,
TEM, quantiatived fibril yield assessment, and NMR).
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In preparation for residue specific analysis of small molecule interactions with Aβ40
chapter five describes a set of NMR methods which were used to define a set of structural
parameters to describe the Aβ40 apo conformational ensemble. Rather than bringing
these measures together to create a modelled ensemble as has been performed already
[129], the parameters will be used directly to compare with measures of Aβ40 in the
presence of small molecule modulators of amyloid aggregation. The purpose of this
was to reveal any changes in structural propensity on the addition of small molecules.
Direct comparison of Aβ40 apo and small molecule bound measures were used to reveal
key structural transitions which may be important in monomer transitions in amyloid
formation.
Overall this work aimed to prepare a strategy for the structural investigation of monomeric,
amyloidogenic IDPs, which are susceptible to the induction or stabilisation of semi-
structured states on addition of small molecule compounds. Such information will clarify
part of the enigma of how IDP monomers enter the amyloid pathway. Understanding
amyloid formation will ultimately aid the development of future therapeutic approaches
for the prevention of amyloid diseases in the future.
Chapter 2
Materials and Methods
2.1 Materials
2.1.1 Technical Equipment
Centrifuges
Avanti J-26XP Centrifuge (Beckman Coulter, Brea, CA, USA)
Eppendorf 5810R Centrifuge (Eppendorf, Hauppauge, NY, USA)
MiniSpin plus F-45-12-11 (Eppendorf, Hauppauge, NY, USA)
GenFuge 24D Centrifuge (Progen Scientific, London, UK)
Incubators, Mixers, and Shakers
Innova 43R shaking incubators (New Brunswick Scientific, NY, USA)
Innova 44R shaking incubators (New Brunswick Scientific, NY, USA)
Gallenkamp Economy Incubator Size 1 (Sanyo, Watford, UK)
Stuart Magnetic Stirrer SB161 (CamLab, Cambridge, UK)
Orbital Incubator S1500 (Stuart, Staffordshire, UK)
Orbital Incubator S1600 (Stuart, Staffordshire, UK)
Vortex Mixer SA8 (Stuart, Staffordshire, UK)
Tube Roller (Starlab, Milton Keynes, UK)
Protein Purification Equipment
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AKTAprime plus (GE Healthcare, Buckinghamshire, UK)
HiLoad 26/600 Superdex 75 PG gel filtration column (GE Healthcare, Buckinghamshire,
UK)
Superdex 75 10/300 gel GL filtration column (GE Healthcare, Buckinghamshire, UK)
Pharmacia Biotech XK 26 packable column (GE Healthcare, Buckinghamshire, UK)
Buhner funnel glas columns fo iapp prep vivaspins filters HPLC machine
Gel Electrophoresis Equipment
Techne Dri-Block DB-2A Heather (Bibby Scientific, Stone, UK)
UVITEC cambridge Nine Alliance Q9 Software (BioSPX, Abcoude, The Netherlands)
Slab Gel Electrophoresis Chamber AE-6450 (ATTO, Tokyo, Japan)
PowerPac Basic (Bio-Rad, Hercules, CA, USA)
KS-250 Basic Shaker (IKA Labortechnik, Oxford, UK)
UVITEC Cambridge Q9 Alliance (BioSPX, Abcoude, The Netherlands)
Vari-Gel midi system (CamLab, Cambridge, UK)
PCR thermocycler
T100 thermal cycler (Bio-Rad, CA, USA)
Spectrophotometers
UltroSpec 2100 pro UV/Visible Spectrophotometer (GE Healthcare, Buckinghamshire,
UK)
UV-1800 UV/Vis Spectrophotometer (Shimadzu, Kyoto, Japan)
Nanodrop 2000 UV/Vis Spectrophotometer (Thermo Scientific, Surrey, UK)
Microplate readers
Fluostar OPTIMA Plate Reader (BMG Labtech, Aylesbury, UK)
CLARIOstar Plate Reader (BMG Labtech, Aylesbury, UK)
Corning Costar 3881 96 Well, Half Area with Clear Flat Bottom Polystyrene NBS
Microplate (Corning Life Sci, The Netherlands)
Microscopes
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JEOL JEM-1400 Transmission Electron Microscope (JEOL Ltd, Tokyo, Japan) with
Gatan US1000XP 2k x 2k CCD camera (Gatan Inc., Pleasanton, USA)
Mass Spectrometers
Synapt high definition mass spectrometry (HDMS) quadrupole-time-of-flight mass spec-
trometer (Micromass UK Ltd., Waters Corpn., Manchester, UK), equipped with
a Triversa automated nano-electrospray ionisation (ESI) interface (Advion Bio-
sciences, Ithaca, USA)
NMR Spectrometers
750 MHz NMR magnet (Oxford Instruments, Abingdon, UK)
QCl-P-cryoprobe and an Avance III HD console (Bruker Corp. Coventry, UK)
Kits
Wizard Plus SV Minipreps DNA Purification system (Promega, Hampshire, UK) Q5
Site-Directed Mutagenesis Kit (NEB, Hertfordshire, UK)
HPLC
Jupiter 5u C-18 300A column (Phenomenex)
ASI-100 Automated Sample Injector
FoxyJr automated fraction collector
HPLC machine: Dionex system consisting of a p580 pump with a PDA-100 Photodi-
ode Array detector, an RF 2000 fluorescence detector and a DEGASYS DG-2410
equipment
Other
Ultrasonic Processor (Cole Parmer, St. Neots, UK)
Constant Cell Disruption Systems (Constant Systems, Northants, UK)
Grant JB1 Unstirred Waterbath (Grant Instruments, Shepreth, UK)
Ultrawave U50 Bath Ultrasonic (Ultrawave Ltd, Cardiff, UK)
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Series 2100 Media Autoclave (Prestige Medical, Minworth, UK)
Heto PowerDry PL3000 Freeze drier (Thermo Scientific, Surrey, UK)
Snakeskin Pleated Dialysis Tubing: 3500 MWCO (Thermo Scientific, Surrey, UK)
Precisa 180A Scales (Precisa Ltd, West Lothian, UK)
Kern Electronic Scales PLS 360-3 (Kern, Northants, UK)
Satorius Electronic Scales TE 12000(Satorius, Surrey, UK)
Orion Versastar Pro pH meter (Thermo scientific, Surrey, UK)
TripleRed Purite Water System (Avidity Science, Bucks, UK)
2.1.2 Chemicals
A
Acetic acid, glacial (Fisher Scientific, Loughborough, UK)
Acrylamide 30 % (v/v) (Severn Biotech, Kidderminster, UK)
Adapalene (Merck, Gillingham, UK)
Agar (Fisher Scientific, Loughborough, UK)
Agarose (Melford Laboratories, Suffolk, UK)
L-(+)-Arabinose (Sigma Life Sciences, MO, USA)
Ammonium Chloride (15N) (Cambridge Isotope Libraries, UK)
Ammonium persulphate (APS) (Sigma Life Sciences, MO, USA)
Ammonium bicarbonate (Sigma Life Sciences, MO, USA)
Ampicillin sodium salt (Formedium, Norfolk, UK)
B
Benzamidine dihydrocholride (Sigma Life Sciences, MO, USA)
Bexarotene (Merck, Gillingham, UK)
Bromophenol blue (Sigma Life Sciences, MO, USA)
C
Carbenicillin disodium (Formedium, Norfolk, UK)
Calcium chloride (CaCl2) (Melford Laboratories, Suffolk, UK)
Chloramphenicol (Sigma Life Sciences, MO, USA)
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Compound 1-67 (Provided by Dr Richard Foster, University of Leeds, UK)
Compound A12a (ChemDiv, CA, USA)
Compound A13a (ChemDiv, CA, USA)
Compound A14a (ChemDiv, CA, USA)
Compound A21a (ChemBridge, CA, USA)
Compound Q06a (ChemBridge, CA, USA)
Coomassie Brilliant Blue (Fisher Scientific, Loughborough, UK)
D
Dithiothreitol (DTT) (Formedium, Norfolk, UK)
Deuterium oxide (D2O) (Fluorochem, UK)
E
Ethanol (Sigma Life Sciences, MO, USA)
Ethidium bromide (EtBr) (Sigma Life Sciences, MO, USA)
Ethylenediaminetetraacetic acid (EDTA) (Fisher Scientific, Loughborough, UK)
G
Glucose (Fisher Scientific, Loughborough, UK)
Glucose (13C) (Cambridge Isotope Libraries, UK)
Glycerol (Fisher Scientific, Loughborough, UK)
Guanidine hydrochloride (Sigma Life Sciences, MO, USA)
H
HEPES (Sigma Life Sciences, MO, USA)
Hydrochloric acid (HCl) (Fisher Scientific, Loughborough, UK)
I
Instant Blue Stain (Expedeon Protein Solutions, UK)
Isopropanol (Fisher Scientific, Loughborough, UK)
Isopropyl -D-1-thiogalactopyranoside (IPTG) (Melford Laboratories, Suffolk, UK)
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L
Lysogengy broth (LB), granulated (Melford Laboratories, Suffolk, UK)
M
Magnesium Sulfate (Melford Laboratories,Suffolk, UK)
N
1,2-Naphthoquinone (Merck, Gillingham, UK) (Melford Laboratories)
P
Phenylmethanesulfonyl fluoride (PMSF) (Sigma Life Sciences, MO, USA)
Potassium phosphate (monbasic) (Fisher Scientific, Loughborough, UK)
Precision plus protein dual colour standards protein ladder (Bio-Rad, CA, USA)
S
10 % SDS Solution (Severn Biotech Ltd,Kidderminster,UK)
Sodium azide (NaN3) (Sigma Life Sciences, MO, USA)
Sodium chloride (NaCl) (Fisher Scientific, Loughborough, UK)
Sodium hydroxide (NaOH) (Fisher Scientific, Loughborough, UK)
Sodium dodecyl sulphate (SDS) (Severn Biotech, Kidderminster, UK)
Sodium phosphate dibasic, Na2HPO4 (Thermo Scientific, Surrey, UK)
Sodium phosphate monobasic, NaH2PO4 (Sigma Life Sciences, St. Louis, USA)
T
Terrific Broth (Melford Laboratories, Suffolk, UK)
Tetramethylethylenediamine (TEMED) (Sigma Life Sciences, MO, USA)
Thiamine (Merck, Gillingham, UK)
Tris (Fisher Scientific, Loughborough, UK)
Tetracycline (Formedium, Norfolk, UK)
U
Urea (MP biomedicals, Loughborough , UK)
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2.2 Methods
All buffers were filter sterilised using a 0.22 µm filter (Durapore). All water used was
deionised and taken from a Purite system. All pHs were altered using 10 M NaOH
(Fisher Scientific) and/or 34 % (v/w) HCl (Fisher Scientific).
2.2.1 Molecular Biology
2.2.1.1 E.coli Bacterial strains and plasmids
E. coli DH5α (Invitrogen, Pailsey, UK) F φ80lacZ∆M15 ∆(lacZYA-argF) U169 recA1
endA1 hsdR17 (rK, mK+) phoA supE44 λ thi-1 gyrA96 relA1
E. coli BL21 (DE3) (Stratagene, Cambridge, UK) F - dcm ompT hsdS(rB mB) gal
λ(DE3)
E. coli BL21 (DE3) pLysS (Stratagene, Cambridge, UK) F - dcm ompT hsdS(rB mB)
gal λ(DE3) [pLysS Camr]
A pETSAC plasmid encoding Aβ40 was provided by Dr Katie Stewart, University of
Leeds. A pTXB1 plasmid encoding a quadripartite construct which contained hIAPP
was provided by Prof. Andrew Miranker (University of Yale, USA) (was used for hI-
APP expression. The tripartite β-lactamase construct was encoded in a pBM1 plasmid
provided by Dr Janet Saunders (University of Leeds).
2.2.1.2 Preparation of competent E. coli cells
Communal stocks of competent cells are made using the following protocol. A 10 ml
overnight culture is prepared using the desired cell strain. This was used to inoculate,
at a ratio of 1:20, 100 ml LB which was shaken at 180 rpm, 37 oC until the OD600 was
0.4-0.45. Cells were harvested at 4000 rpm (3220 xg), 4 oC for 10 min using a chilled
A-4-62 Eppendorf rotor in a chilled Eppendorf centrifuge 5810R. The supernatant was
discarded and the cell pellet gently resuspended in 10 ml of pre-chilled 100 mM CaCl2
and incubated on ice for 10 min. Cells were harvested again by centrifugation in the
same way and the supernatant was discarded. The cell pellet is resuspended in 2 ml
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of 100 mM CaCl2, 30 % (v/v) glycerol. The cell suspension was separated into 50 µl
aliquots in 1.5 ml eppendorf tubes and frozen on dry ice. Cells were stored at -80 oC.
2.2.1.3 LB medium and Agar Plate Preparation
LB medium was prepared in all instances by mixing LB powder with d.H2O to create a
25 g/L solution in an appropriately sized conical flask (i.e. a 2 L flask for a 500 ml 1 L
volume, a 25o ml flask for 100 ml volume, a 100 ml flask for a 50 ml solution) capped
with a foam bung and foil. The flask was then autoclaved at 121 oC, 100 kPa for at
least 20 minutes.
LB agar plates were prepared by mixing 1.5 mg agar and 2.5 mg of LB powder with 100
ml d.H2O and then steralising the solution via autoclaving at 121
oC, 100 kPa for 20
minutes. Once cooled to approximately 50 oC relevant antibiotics were added (100 µg/ml
ampicillin/carbenicillin for pTXB1 and pETSAC plasmids, or 10 µg/ml tetracycline for
pMB1 plasmids) and plates were poured in a sterile environment and left to solidify.
Plates were wrapped in parafilm and stored at 5 oC until required but no longer than 6
weeks.
2.2.1.4 Transformation of E. coli cells
50 µl aliquots of competent E. coli cells (see Section 2.2.1.2) were defrosted on ice for
five minutes before 2 µl of the construct-containing plasmid was added (pETSAC for
Aβ40, pTXB1 for hIAPP, or pBM1 for β-lactamase constructs). After incubation on ice
for 30 min with intermittent mixing, cells underwent heat shock for 45 s in a water bath
(Stuart, SWB series) at 42 oC and were then returned to ice for 5 min. 500 µl of sterile
LB medium was added to the cells. The cell solution was incubated at 37 oC, 200 rpm
(Stuart, Orbital incubator S150) for 30 minutes. 50 µl of cell solution was plated onto
LB agar plates (see Section 2.2.1.3) containing the relevant antibiotic and incubated
overnight at 37 oC (Gallenkamp incubator).
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2.2.1.5 Plasmid Amplification
Colonies of transformed E. coli DH5α cells (see Section 2.2.1.4) present on antibiotic-
containing LB agar plates (see Section 2.2.1.3) were selected and used to inoculate starter
cultures (see Section 2.2.1.3) of 10 100 ml of LB medium which contained the relevant
antibiotics (100 µg/ml ampicillin/carbenicillin for cells containing pTXB1 or pETSAC
plasmids, or 10 µg/ml tetracycline for cells containing pMB1 plasmids). Starter cultures
were grown overnight at 37 oC, 200 rpm (Stuart, orbital incubator S150). DNA was
extracted and purified according to the kit protocols for either a miniprep (Promega) or
midiprep (Qiagen). To determine the concentration of amplified DNA the absorbance at
260 nm was measured using a Nanodrop 2000 (Thermo Scientific) and used to determine
DNA concentration: concentration (µg/ml) = (A260 - A320) x 50 µg/ml. A320 absorbance
is a measure of the noise level and 50 µg/ml is a standardised coefficient (an A260 equal
to 1 is equivalent to 0.5 µg/ml pure dsDNA). DNA was stored in an airtight container
at -20 oC.
2.2.1.6 Agarose Gel Electrophoresis to Indicate DNA Size and DNA se-
quencing
To verify the production of complete plasmid amplification a sample of the DNA was
subject to agarose gel electrophoresis. Agarose gels were made by dissolving 1.5 % (w/v)
agarose in 1 x Tris-acetate-EDTA (TAE) buffer [40 mM tris HCl (Fisher Scientific), 20
mM acetic acid (Fisher Scientific), and 1 mM EDTA (Acros Organis), pH 7.5] and
heating the solution using a microwave until the solution was transparent. Once cooled
to approximately 45 oC, ethidium bromide (0.5 µg/ml) (Sigma Aldrich) was added. The
gel was then poured into an 8 x 15 x 2.5 cm gel tray with a well comb, and allowed
to solidify. The DNA sample was diluted in 10 x agarose loading buffer [2.5 mg/mL
bromophenol blue (Sigma Aldrich), and 50 % (v/v) glycerol (Fisher Scientific)] and
30 µL was loaded into the gel well. Alongside the loaded lane, 5 µl of the 1 KB+
ladder solution was added [10 µl 1 KB+ ladder (NEB), 90 µl 10 mM tris, pH 8.5 (Fisher
Scientific), and 20 µl 10x agarose loading buffer]. Agarose gel electrophoresis was carried
out in 1 x TAE buffer at 100 V. Finally the gel was visualised using ultra violet (UV)
illumination and photographed using a Syngene InGenius gel documentation system
(Syngene, UK).
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On observation of a band indicating successful plasmid amplification, another sample for
the DNA was sent to Genewiz (formerly Beckman Cogenics) for sequence confirmation
using commercial T7 primers:
Fwd: TAA-TAC-GAC-TCA-CTA-TAG-GG
Rev: CTA-GTT-ATT-GCT-CAG-CGG-TG
2.2.2 Protein Expression and Purification
2.2.2.1 Expression of unlabelled Aβ40
BL21 (DE3) cells were transformed with the pETSAC plasmid encoding Aβ40 (Section
2.2.1.4) and plated into 100 µg/ml ampicillin/carbenicillin-containing LB agar (Section
2.2.1.3). At least 16 hours later a single colony was transferred from the agar plate into
100 mL of LB with 100 µg/ml ampicillin/carbenicillin to create an innoculated starter
culture under sterile conditions. These were incubated at 37 oC with shaking at 200 rpm
overnight. 10 x 10 mL was removed from this culture and was used to inoculate 10 x 0.5
L sterile solutions of LB medium (prepared as detailed in Section 2.2.1.3). 100 µg/mL
ampicillin/carbenicillin was added prior to innoculation. The cultures were incubated
at 37 oC, with 200 rpm agitation until the optical density at 600 nm (OD600) reached
0.5-0.6. Protein expression was induced through the addition of 0.5 ml of 1 M isopropyl
β-D-1-thiogalactopyranoside (IPTG) resulting in a final concentration of 1 mM IPTG.
Cultures were then incubated for a further 3.5 h or until the OD600 reached a plateau
(typically around OD600 = 1.2). Cells were harvested by centrifugation at 6000 x g for
15 min at 4 oC. The cell pellets were extracted and stored at -20 oC.
2.2.2.2 Expression of 15N/13C-labelled Aβ40
15N/13C-labelled, M9 minimal medium was used to culture E. coli BL21(DE3) cells
which had been transformed with a pETSAC plasmid (Section 2.2.1.4) in order to gen-
erate 15N/13C-labelled Aβ40 for NMR experiments. M9 media was prepared as a 5x
salts solution (15 g monobasic potassium phosphate (KH2PO4), 34 g anhydrous dibasic
sodium phosphate (Na2HPO4, and 2.5 g sodium chloride (NaCl) made up to 1 L in
d.H2O) which was diluted five times with d.H2O into conical flasks, i.e. for the starter
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culture 10 ml of the 5x salts solution and 40 ml d.H2O were poured into a 100 ml conical
flask. This solution was steralised via autoclaving at 121 oC, 100 kPa, for at least 20
minutes. The following components ( all filtered using a 0.22 µm filter (Bio-rad)) were
added immediately prior to innoculation of the 50 ml starter culture:
Component stock Volume added to 50 ml Volume added to 500 ml
100 mg/mL carbenicillin 50 µl 500 µl
1 M CaCl2 5 µl 50 µl
1 M MgSO4 100 µl 1 ml
20 % (w/v) 12/13-glucose 0.5 ml 5 ml
20 % (w/v) 15N-NH4Cl 0.25 ml 2.5 ml
10 mg/mL thiamine 5 µl 50 µl
To innoculate the starter culture a single colony was taken from an LB-containing agar
plate (as for expression in LB medium, Section 2.2.2.1) under sterile conditions. The
50 mL culture was incubated at 37 oC, with 200 rpm agitation for 24 h. At this time,
4 mL of the cell culture was extracted and used to innoculate each of 11 baffled 2 L
flasks containing 500 mL of sterile M9 medium which had been prepared similarly as
for the starter culture above (whereby the volumes of each component are scaled by a
factor of 10 to maintain concentrations, Column 3 in the table above). Cultures were
incubated overnight at 15 oc with 120 rpm shaking. In the morning, the temperature
and shaking were increased to 37 oC and 180 rpm respectively. when the OD600 reached
0.5-0.6, construct expression was induced using 0.5 mL of 1 M IPTG to each flask. The
temperature was lowered to 24 oC and cultures were left shaking (at 180 rpm) overnight.
Cells were harvested similarly to preparation in LB medium; centrifugation at 6000 x g
for 15 min at 4 oC. The cell pellets were extracted and stored at -20 oC.
Expression was confirmed and yields were estimated using SDS-PAGE (Section 2.2.3).
2.2.2.3 Multistep Purification of Aβ40
A schematic workflow for the purification of Aβ40 can be found in Chapter 3, Figure
3.4. Throughout this process, purity was monitored using SDS-PAGE (Section 2.2.3).
Isolation and Lysis of Aβ40-containing Inclusion Bodies
12.5 mL of 1 x Buffer A was added to the cell pellet from Section 2.2.2.1. Approximately
0.5 mg DNase, 1 mM phenylmethanesulfonyl fluoride (PMSF) and 2 mM benzamidine
were added to the suspension and mechanically stirred at 4 oC until an homogeneous
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Buffer Composition
10 x Buffer A 100 mM Tris-HCl (Fisher Scientific)
10 mM EDTA (Fisher Scientific)
pH 8.5
1 x Buffer A 1:10 dilution of 10 x Buffer A in d.H2O
Inclusion Body Solubiliser 8 M urea (MP Biomedicals) in 1 x Buffer A
solution was obtained (typically after 1 h). The solution was next passed through a
blunt syringe needle (Terumo Global Pharmaceutical Solutions, NJ, USA) to increase
homogeneity before sonication for 30 s (7.5 mm probe, 10 µm amplitude). The ho-
mogenate was centrifuged at 30,000 x g for 15 min at 4 oC, and the supernatant was
removed. The pelleted cell material was resolubilised in 12.5 ml 1 x Buffer A and the sy-
ringe homogenisation, sonication, and centrifugation processes were repeated once more.
The pellet was lastly solubilised, using a magnetic stirrer, in cold (4 oC) inclusion body
solubiliser until homogeneous (approximately 1 h). The suspension was sonicated and
centrifuged a third time (as before) and the supernatant (containing solubilised Aβ40)
was collected and diluted 1 in 4 with 1 x Buffer A to reduce the urea concentration from
8 M to 2 M in preparation for anion exchange purification.
Anion Exchange Purification using Q-Sepharose Resin
All the buffers used in the following steps of the Aβ40 purification were pre-cooled to 4
oC to reduce the aggregation potential of the peptide.
35 mL of Q-Sepharose Fast Flow resin (GE Healthcare) was equilibrated with 1 x Buffer
A, before it was mixed with the 1 in 4 dilution of soluble cell lysate prepared in the
previous section. Lysate and resin were incubated together for 30 min at 4 oC with
gentle rocking. Positively charged petides, including Aβ40 at pH 8, bind to the resin.
Anion exchange purification of Aβ40 was then performed using a batch format to avoid
problems associated with Aβ aggregation during column chromatography [383]. The
batch purification was conducted in a 250 ml Bu¨chner funnel, with Whatman 1 filter
paper, fitted to a conical flask with a side arm. This arm was attached to a water-flow
vacuum system. The loaded resin was poured into the Bu¨chner funnel and the flow
through was collected and set aside at 4 oC. The resin was washed twice with 50 ml
pre-chilled 1 x Buffer A, containing 0 then 25 mM NaCl. Peptide elution was initiated
with 5 x 50 ml washes of 1 x Buffer A containing 125 mM NaCl. Finally, a high-salt (1 x
Buffer A, 250 mM NaCl) and high-salt with urea (1 x Buffer A, 250 mM NaCl, 8 M urea)
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wash were applied to the resin to remove any remaining bound proteins. Each eluate
was stored at 4 oC to avoid aggregation before buffer exchange into 50 mM ammonium
bicarbonate by dialysis. Dialysis was conducted using 3,500 MWCO snake-skin dialysis
tubing which was prepared by soaking in 50 mM ammonimum bicarbonate. The Tubing
was filled with the Aβ40-containing eluates and placed in 5 L of 50 mM ammonium
bicarbonate with a total 4 x 5 L changes over 2 days. Fractions were then lyophilised.
The stored flow through was re-incubated with freshly equilibrated resin and subjected to
the same batch anion exchange, buffer exchange, and lyopholisation processes (although
only 3 x 50 ml elutions of 1 x buffer A containing 125 mM NaCl were used rather than
5 x 50 ml elutions due to time:yield compromise).
Size Exclusion Chomatography Purification of Aβ40
All SEC was performed at 4 oC. The lyophilised, partially-purified Aβ40 was resolubilised
in 3-4 x 5 ml of 50 mM Tris-HCl, pH 8.5, containing 7 M guanidinium-HCl. The 5 ml
solutions were aliquoted into 5 x 1.5 ml eppendorfs and centrifuged for 10 min at 14,000
rpm at 4 oC. The five aliquots were loaded together onto a pre-equilibrated (in 50 mM
ammonium bicarbonate) HiLoadTM 26/60 Superdex 75 prep grade gel filtration column
(GE Healthcare), connected to an A¨KTA prime Liquid Chromatography system. 50
mM ammonium bicarbonate was also the mobile phase in which the protein was eluted.
The A¨KTA programme used is outlined in Table 2.1 and Aβ40 was eluted in a single
peak at approximately 180 ml which was collected and lyophilised. The typical yield
from this Aβ40 preparation was 5-6 mg/L culture.
Breakpoint (ml) Flow Rate (ml/min) Fraction Size (ml) Injection Valve Position
0 2 0 Load
4 2 0 Inject
20 2 0 Load
50 2 4 Load
360 2 0 Load
362 0 0 Load
End
Table 2.1: The programme used to purify Aβ40 by SEC.
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For some experiments, namely the ThT fluorometry assay Aβ40, the purity of the peptide
is essential for reproducibility of results as the assay is highly sensitive to contaminants.
To prepare Aβ40 for this assay, the lyophilised powder resulting for the SEC purification
was subjected to another SEC run. 2.5-3.0 mg of lyophilised peptide was solubilised in
0.5 ml of 50 ml Tris-HCl, pH 8.5, containing 7 M analytical grade guanidinium-HCl (as
previously, all buffers and SEC runs are conducted at 4 oC). This was centrifuged for 10
min at 14,000 rpm before being loaded onto a Superdex 75 GL column (GE Healthcare)
which was pre-equilibrated with 50 mM ammonium bicarbonate. The A¨KTA programme
was set so 1 ml fractions were collected as up to 0.4 ml/min of 50 mM ammonium bicar-
bonate flowed through the column. The Aβ40 eluted in fractions 11-13 at approximately
1 hr depending on flow rate. Aβ40-containing fractions were immediately flash-frozen
using dry ice and EtOH or in liquid nitrogen and lyophilised.
Yields were measured using absorbance at 280 nm using samples in a quartz cuvette.
Samples were sent to the Mass Spectrometry facility to verify the final product and
indicate final purity (approximately 98 % when two SEC steps were applied).
2.2.2.4 Expression of the hIAPP-containing Quadripartite Construct
The expression and purification protocols for recombinant hIAPP was based on the
published protocol by Williamson and Miranker in 2007 [384] which is summarised in
Figure 3.8 in Chapter 3.
BL21(DE3) cells transformed with the pTXB1 plasmid (Section 2.2.1.4) were selected
from ampicillin/carbenicillin-containing LB agar plates (Section 2.2.1.3) and used to
inoculate 100 ml LB medium with 100 µg/ml ampicillin/carbenicillin. Cells were grown
at 37 oC, 200 rpm (Stuart, Orbital Incubator S150) overnight. Glycerol stocks were
prepared (0.5 ml of the overnight cultures were taken and added to 0.5 ml 30 % (v/v)
glycerol and mixed). Glycerol stocks are stored at -80 oC and were used as an alternative
for repetitive cell transformation.
4-10 ml of the overnight culture was taken and used to inoculate 1 L of sterile LB medium
with 100 µg/ml ampicillin. Cultures were grown at 37 oC, 200 rpm (Sanyo orbital
incubator, Panasonic) until the OD600 was between 0.6-0.8 (measured using UV-micro
cuvettes, Brand, Germany, and a Jenway spectrometery, Genova). At this point protein
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expression was induced by addition of 1 ml of 1 M isopropyl β-D-1-thiogalactoyranoside
(IPTG) (Formedium) to a final concentration of 1 mM and flasks were cooled to 15
oC (Innova 44, New Brunswick Scientific) and shaken overnight, 200 rpm. Cells are
harvested after 15-20 hours by centrifugation at 5000 rpm (6238 xg) for 30 min, 4 oC,
(using a JLA-8.1000 Beckman rotor in a Beckman Coulter Avanti J-26XP centrifuge)
and the cell pellet was stored at -20 oC.
Expression was monitored using SDS-PAGE as detailed in Section 2.2.3.
2.2.2.5 Multistep purification of hIAPP
Cell Lysis and Removal of Insoluble Cellular Material
Buffer Components
Equilibrium Buffer 20 mM HEPES (Sigma Aldrich), pH 8
0.1 mM EDTA (Acros Organics)
50 mM NaCl (Fisher Scientific)
2 M urea (MP Biomedicals)
The harvested cell pellet was resuspended in 20 ml Equilibrium buffer via gentle rocking
(Stuart Roller Mixer) for approximately 30 min at 4 oC. 40 µl of 50 mM phenylmethyl-
sulfonyl fluoride (PMSF) (Sigma Aldrich) is added as well as 1-5 mg of bovine DNAse1
(Sigma Aldrich). Sonication was used to lyse the cells using sonication (10 cycles of
15 s pulse, 45 s pause at 22 % amplitude). Lysed cells are then centrifuged at 20,
000 rpm (48384 xg) for 30 min, 4 oC (JA25.50 Beckman rotor in a Beckman Coulter
Avanti J-26XP centrifuge) to separate soluble and insoluble cell material. The pellet
was discarded and the supernatant taken forward for the next steps in purification.
Chitin-Affinity Purification to Extract the Quadripartite Construct from
Other Soluble Material
The supernatant was loaded onto a glass column of 2.8 cm diameter which was packed
with a bed volume of 20 ml chitin beads (NEB). The column was equilibrated using
d.H2O followed by Equilibrium buffer (Section 2.2.2.5) prior to supernatant loading.
The chitin resin was then washed with 300 ml of Equilibrium buffer to remove any
unbound proteins.
C-terminal Amidation by Intein Cleavage
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Buffer Components
Cleavage Buffer 20 mM HEPES (Sigma Aldrich), pH 8.5
0.1 mM EDTA (Acros Organics)
50 mM NaCl (Fisher Scientific)
2 M urea (MP Biomedicals)
0.1 M DTT (Formedium)
2 M ammonium bicarbonate (Sigma Aldrich)
Three column volumes (3 x 20 ml) of Cleavage buffer were added quickly to the column.
Before the final 20 ml of Cleavage buffer ran off of the column, the column was closed
and incubated at 4 oC overnight. Protein was eluted from the column in three separate
column volumes of Equilibrium buffer (Section 2.2.2.5), the first of which is taken forward
for purification.
To regenerate the chitin resin for future purifications, the column was stripped of residual
bound proteins using 0.3 M NaOH. Firstly three column volumes of 0.3 M NaOH were
washed through the column. The column was then closed and the chitin beads incubated
with the 0.3 M NaOH for 30 min. Subsequently seven column volumes of 0.3 M NaOH
were flowed through the column to ensure no protein was left bound to the chitin beads.
The column was finally washed using 20 column volumes of d.H2O, and stored in 20 %
(v/v) ethanol.
Buffer exchange and Filtration to Prepare for Release of hIAPP by V8 Cleav-
age
Buffer Components
Dialysis Buffer 1 20 mM HEPES (Sigma Aldrich), pH 8
0.1 mM EDTA (Acros Organics)
2 M urea (MP Biomedicals)
50 mM NaCl (ThermoFisher Scientific)
In anticipation of the final cleavage of the protocol, the 20 ml first elution volume was
dialysed in a 1000 Da MW cut off membrane (Spectra/Por 6) against 5 x 1 L of Dialysis
buffer to remove ammonium bicarbonate and DTT. To prepare for V8 cleavage, the
solution was concentrated (VIVASPIN 20, MWCO 3 kDa) using an A-4-62 Eppendorf
rotor, in an Eppendorf centrifuge 5810R at 4000 rpm (3220 xg), 4 oC to 5 ml.
Site Directed Mutagenesis to Improve V8 cleavage Efficiency
Materials and Methods 67
Site Directed Mutagenesis (SDM) was carried out to change two glutamic acid residues
in the leader sequence of the hIAPP expression construct to a glutamine and a histi-
dine (E4Q and E5H). SDM was performed adhering to the protocol provided in the
commercial Q5 kit (NEB).
Firstly, primers were designed using the NEB online tool (http://nebasechanger.neb.
com/) and purchased from Eurofins MWG Operon (boldening denotes changed codons):
Primer Sequence Residues % GC Tm (
oC)
Forward AATGAAAATTCAACATGGCAACG 29 41 56
CGAACC
Reverse ATGTATATCTCCTTCTTAAAGTG 23 30 55
The primers were incorporated into the following reaction mixture in 0.2 ml PCR tubes:
Reagent Volume (µl)
Q5 Hot start high-fidelity master mix (2X) 12.5
10 µM Forward primer 1.25
10 µM Reverse primer 1.25
Template DNA (1-25 ng/µl) 1
Nuclease free water 9
The solution was subjected to the following Polymerase Chain Reaction (PCR) cycle:
Step Temperature (oC) Duration (s)
Initial denaturation 98 30
PCR 98 10
50-72* 30
72 kbx25
Final extension 72 120
Hold 4 ∞
*Annealing temperature was determined based on the mutagenic primers as calculated
by NEBaseChanger (http://nebasechanger.neb.com/)
An agarose gel, Section 2.2.1.6, was used to confirm successful PCR. After confirmation
of DNA of the correct molecular weight (7˜ kbs) the plamid was subjected to kinase
digestion, ligation, and DpnI (KLD) enzyme treatment in a clean 0.2 ml PCR tube:
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Reagent Volume (µl)
PCR product 1
KLD reaction buffer (2x) 5
KLD enzyme mix (10x) 1
Nuclease free water 3
5 µl of the reaction product was used to transform competent E. coli DH5α cells (Sections
2.2.1.2) using the protocol described in Section 2.2.1.4. An individual colony was picked
and used to inoculate 10 ml LB medium with 100 µg/ml amplicillin/carbenicillin. The
culture was grown overnight at 37 oC, 180 rpm (Stewart orbital incubator, UK) A Pure
Yield Plasmid Miniprep kit (Wizard) was used to extract plasmid DNA. Samples were
subsequently sent to Genewiz (formerly Beckmen Cogenics), for sequence determination
to verify the incorporation of the two amino acid substitutions.
E. coli BL21(DE3) cells were transformed with this plasmid as described in Section
2.2.1.4 and used to express the modified quaripartite construct in the same way as the
original construct (Sections 2.2.2.4 and 2.2.2.5).
Release of hIAPP by V8 Cleavage and Separation by HPLC
2 mg of V8 protease (Endoproteinase Glu-C from Staphylococcus aureus V8, Sigma
Aldrich) was added to the 5 ml sample and incubated at 4 oC for 1 hour with rocking,
setting 18 on a mini see-saw rocker, SSM4, Stuart. The reaction was quenched by flash
freezing using dry ice with ethanol (Sigma Aldrich) and then protein was lyophilised
(Heto, PowerDry PL3000, Thermo Electron Scientific).
Buffer Components
Eluant A 10 % (v/v) acetonitrile (Fisher Scientific)
0.1 % (v/v) trifluoroacetic acid (Fisher Scientific)
Eluant B 90 % (v/v) acetonitrile (Fisher Scientific)
0.1 % (v/v) trifluoroacetic acid (Fisher Scientific
Next the leader (2.0 kDa) and hIAPP (3.9 kDa) peptides were separated using Reverse
Phase High Performance Liquid Chromatography (RP-HPLC) using a Jupiter 5u C-18
300A column (Phenomenex). The HPLC apparatus used was Dionex system consist-
ing of a p580 pump, ASI-100 automated sample injector, PDA-100 photodiode array
detector, RF 2000 fluorescence detector, DEGASYS DG-2410, and FoxyJr automated
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fraction collector. The lyophilised sample was dissolved in 300-500 µl 100 % DMSO
and loaded on to the column in multiple injections of volume no greater than 100 µl.
A gradient from 0 - 100 % Eluent B was applied and hIAPP was eluted in one 5 ml
fraction between 16-17 min. The protein was then flash frozen and lyophilised.
The final step in the purification protocol was to oxidise and form the disulfide bond
between Cys2 and Cys7 in hIAPP. This was attempted by dissolving the reduced hIAPP
powder in 3 ml of 30 mM acetic acid, pH 5.3, forming a solution of ∼0.215 mM hIAPP.
H2O2 was added to a final concentration of 2 mM. The sample was incubated at 4 oC
for 4–6 h and quenched by flash freezing and lyophilisation.
2.2.3 SDS-PAGE
Tris-Tricine buffered SDS-PAGE was used due to its aptitude for resolving small peptides
(as low as 2 kDa in size) such as Aβ40 (4485 Da) and hIAPP (3907 Da). SDS-PAGE
was used to monitor peptide purification throughout the expression and purification
methods, as well as for measueing fibril yields. Gels were prepared as follows in all
cases:
Component Resolving gel (ml) Stacking gel (ml)
30 % (w/v) acrylamide: 0.8 % (w/v) 7.5 0.85
bisacrylamide (Severn Biotech Ltd.)
3 M tris-HCl (Fisher Scientific), 5.0 1.55
0.3 % (w/v) SDS (Sigma Aldrich), pH 8.45
Glycerol (Fisher Scientific) 2.0 0
10 % (w/v) ammonium persulfate 0.1 0.1
(Sigma Aldrich)
TEMED (Sigma Aldrich) 0.01 0.01
Gels were placed vertically in a gel stand and seals were assured between buffer com-
partments. The following buffers were diluted to a 1x solution and added:
Buffer Components
10x Anode buffer 242.3 g tris in 1 L d.H2O, pH 8.8 (Fisher Scientific)
10x Cathode Buffer tris-tricine-SDS running buffer, pH 8.3 (Alfa Aesor)
All electrophoresis was carried out at 35 mA and then increased to 70 mA once the gel
front had moved through the stacking gel.
SDS-PAGE Sample Preparation and Staining
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Buffer Contents
4x SDS Loading Buffer 100 mM tris, pH 6.8 (Fisher Scientific)
4 % (w/v) sodium dodecyl sulfate (Sigma Aldrich)
0.2 % (w/v) bromophenol blue (Sigma Aldrich)
20 % (v/v) glycerol (Fisher Scientific)
2x SDS Loading Buffer 1:1 dilution of 4x SDS Loading Buffer in d.H2O
Aβ40 gel samples (except fibril yield assays, see Section 2.2.5.3) were prepared as 20 µl
samples with a 1:1 ratio of sample to 2x SDS Loading buffer. Of these samples, 12 µl (or
6 µl when necessary to avoid overloading) was loaded into the SDS-PAGE gel alongside
6 µl of PrecisionPlus ProteinTM Dual Xtra Standards protein ladder (Biorad).
For monitoring protein expression, 1 ml samples were taken from the expression cultures
and pelleted by centrifugation at 14,100 xg (Eppendorf MiniSpin Plus) for 10 min at 4
oC. The pellet was resuspended in a volume of d.H2O so that the OD600 was equal to
1. This sample was then mixed to form a 1:1 ratio solution of sample to 2x SDS-PAGE
as above.
After electrophoresis, gels were stained using Instant Blue (Biorad) overnight and de-
tained for 2 h in d.H2O before imaging. Gels were visualised using a Syngene InGenius
gel documentation system (Syngene, UK).
Due to poor binding of hIAPP to SDS-Loading buffer and Instant Blue (Biorad), an al-
ternative sample preparation method and stain were used. To prepare hIAPP samples,
5 µl of 4 x LDS loading buffer (Biorad) with 8 M urea was added to 15 µl of sample.
Samples were boiled for four minutes and then spun briefly (Eppendorf Benchtop cen-
trifuge 5418) to collect all condensation in the sample. 15 µl of the prepared samples
were loaded (except when this led to lane overloading, i.e. for supernatant samples with
large amounts of protein, in which case 7.5 µl of sample was loaded) in wells alongside 6
µl of PrecisionPlus ProteinTM Dual Xtra Standards protein ladder (Biorad). After elec-
trophoresis, the gels were stained using Coomassie Brilliant Blue as follows; Gels were
submerged in fresh stain and microwaved for three 8 s bursts, with gentle shaking in
between, before being left to stain for 20 minutes on a shaker (AOS manufacturing Ltd).
The same procedure was carried out with a destaining solution (50 % (v/v) d.H2O, 40
% (v/v) methanol (Fisher Scientific), and 10 % (v/v) acetic acid (Fisher Scientific)) and
the gels were left gently shaking in destaining solution overnight. Gels were visualised
using a Syngene InGenius gel documentation system (Syngene, UK).
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2.2.4 Computational ROCS
Virtual screening was performed by Dr Charlotte H. Revill and Dr Richard J. Fos-
ter (University of Leeds). The structure of each of the five query molecules (1,2-
naphthoquinone, adapalene, bexarotene, MM11253, UVI3003) was inputted into the
virtual Rapid Overlay for Chemical Structures (vROCS) user interface and reduced to
the lowest energy conformer using LigPrep [385]. This conformer was used as the query
scaffold for in silaco screening of an in-house library of 50,000 structurally diverse, small
molecules using Rapid Overlay of Chemical Structures (ROCS) [385]. ROCS is a 3D
method that compares the molecular steric arrangement of multiple compounds. The
method can quickly identify potentially active compounds by shape comparison based
on a smooth Gaussian-function fit model of structure volume comparison. Any volume
mismatch is measured as an indication of compound dissimilarity. Additionally, the
vROCS software can also incorporates a ROCS Combiscore assessment which compares
the pharmological characteristics of compounds and provides a measure of their shape
similarity. 67 compounds were selected for screening based on a qualitative assessment
of structural diversity by Dr Charlotte H. Revill.
2.2.5 Biophysical Techniques
2.2.5.1 ThT fluorometry
400 µL samples were prepared in 1.5 mL eppendorfs containing 100 µM thioflavin T
(from a 0.2 µm filtered 1.2 M stock in d.H2O), 20 µM Aβ40 (from a 20 mg/mL stock in
100 % DMSO), 100 µM compound (from a 10 mM stock in 100 % DMSO) in 50 mM
ammonium acetate, pH 6.8, and a 2 % (v/v) final concentration of DMSO. These were
aliquoted into four 100 µl samples in wells on the same opaque, half area, 96-well plate
and sealed with clear film. Plates were incubated in a FLUOstar OPTIMA plate reader
for 21 hours at 37 oC without agitation. Fluorescence was excited using a 440 5 nm
filter, and emission intensity was measured every 300 s using a 485 5 nm filter.
For compound titration ThT assays, the compound concentration was varied to 4 µM,
20 µM, or 200 µM.
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2.2.5.2 Transmission Electron Microscopy Techniques
Samples were extracted from 96-well plates which were used to conduct the ThT fluo-
rometry experiments at the end of the aggregation reaction. To prepare sample grids
10 µL of each sample was loaded onto a carbon-coated, copper specimen grid (Agar
Scientific Ltd, UK) and left for 30 s before blotting against filter paper. The copper
grids were subjected to irradiation used UV light prior to sample addition. Next 2 x 10
µL drops of H2O were loaded to briefly wash the grid, before blotting again and staining
with 10 µL 2 % (w/v) uranyl acetate for 30 s. The uranyl acetate had been centrifuged
at 14000 rpm for 10 min to remove uranyl acetate precipitate. The grid was then finally
blotted completely to leave negatively stained samples on the grids and allowed to dry
completely in air. Incomplete blotting led to positive staining.
Transmission electron microscope images were acquired on a JEOL JEM-1400 transmis-
sion electron microscope (JEOL Ltd., Japan) equipped with a Gatan Orius camera or a
Gatan Ultra Scan 1000 XP camera.
2.2.5.3 Measuring Fibril Yield
To quantify the extent of aggregation and SDS-PAGE method was used. To prepare
samples, 100 µl of sample was removed from the 96-well plates in which the ThT fluo-
rometry experiments were conducted. This was placed in a 200 µL eppendorf. 20 µL
was removed and mixed with 7 µL of 4 x SDS-Loading buffer (Section 2.2.3) as the
‘Whole’ sample. The remaining 80 µL were subject to centrifugation at 14,000 rpm for
20 min to separate insoluble and soluble material. Using a precision tip, 20 µL from the
top of the spun sample was removed and mixed with 7 µL of 4 x SDS-Loading buffer
in a 200 µL eppendorf as the ‘Soluble’ sample. Using a precision tip the remaining 60
µL of liquid was removed from the centrifuged samples with care not to disturb pelleted
material. The pellet was suspended in 80 µL of d.H2O and 20 µL was taken and mixed
with 7 µL 4x SDS-Loading buffer in a separate 200 µL eppendorf as the ‘Pellet’ sample.
Each of the Whole, Soluble and Pellet samples were boiled for 10 min using a heat block
set to 100 oC. Samples were briefly spun to collect any condensation within the eppendorf
and then 20 µL was loaded onto an SDS-PAGE gel, Section 2.2.3. The gel was stained
overnight in Instant Blue (Biorad) and destained for 2 h in d.H2O prior to imaging using
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a Syngene InGenius gel documentation system (Syngene, UK). Image J, Fiji, was used
to measure the band intensity. To enable gel-to-gel comparison, measurements were
made relative to the density of the ‘Whole’ sample for each preparation.
2.2.5.4 ESI-IMS-MS
Protein desalting and mass analysis to confirm protein purity and mass was performed
by LC-MS using a nanoACQUITY UPLC (Waters UK, Manchester, UK) interfaced
to a Synapt G2S Q-IMT-TOF mass spectrometer (Waters UK, Manchester, UK) by
Dr Rachel George in the Astbury Centre for Structural and Molecular Biology, Mass
Spectrometry Facility.
All further mass spectrometry was carried out at the University of Leeds by Dr Patrick
Knight and Dr Yong Xu using a Synapt high definition mass spectrometry (HDMS)
quadrupole-time-of-flight mass spectrometer (Micromass UK Ltd., Waters Corpn., Manch-
ester, UK), equipped with a Triversa automated nano-electrospray ionisation (nESI)
interface (Advion Biosciences, Ithaca, USA). To monitor ligand binding to Aβ40, the
peptide was dissolved in 20 mM ammonium acetate, pH 6.8 to form a 32 µM solution,
and 10 mM stocks of compounds in 100 % DMSO were diluted into this to provide a final
concentration of 160 µM. For analysis of these samples by nESI-MS, a sampling cone
voltage of 30 V was used to preserve protein-ligand interactions, and a backing pressure
of 1.6 mbar was applied. Data were acquired and processed by Dr Patrick Knight and
Dr Yong Xu using MassLynx and Driftscope software. The m/z scale was calibrated
with aqueous CsI cluster ions.
2.2.5.5 Nuclear Magnetic Resonance techniques
A. NMR Sample Preparation and Data Processing
For all NMR experiments, unless otherwise specified, the protein sample was composed
of 50 µM 15N-labelled, recombinant Aβ40 (expressed and purified as described in Sections
2.2.2.1 and 2.2.2.3) from a 7 mg/ml stock in 10 mM NaOH, 20 mM sodium phosphate,
0.5 mM EDTA, 0.02 % (w/v) NaN3, 10 % D2O, pH 7.4. Data were acquired at 4
oC
using a 750 MHz spectrometer with an HCN triple resonance cryoprobe and Bruker
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Advance III HD console. All raw NMR data were processed using nmrPipe [386] before
further analysis, including peak fitting, using CCPNmr Analysis [387].
B. Optimisation of Sample Conditions for NMR Experiments
Analysis of the effects of pH, DMSO, temperature and buffer were carried out by obtain-
ing 1H15N-HSQC experiments using a HN Enhanced Sensitivity HSQC pulse sequence
[388, 389]. Spectra were recorded with 512 points in the indirect dimension (15N) and
1024 points acquired in the direct dimension (1H) and 2 scans. To monitor effects of pH,
a single 50 µM Aβ40 sample was prepared as described and split into four samples. The
pH was decreased in three of the samples to pH 7.2, 7.0, and 6.8 using HCl. Samples
were stored in ice before and after loading and acquisition in a 750 MHz spectrometer.
To ensure no change in spectrum was caused by the increased time of incubation at 4
oC before acquisition, the first sample that was acquired (pH 7.4) was repeated at the
end of all of the experiments to ensure no spectral alterations occurred. Each spectrum
was processed in nmrPipe [386] and analysed using CCPNmr Analysis [387].
To monitor the effects of DMSO percentage on Aβ40 a single, 450 µl sample was pre-
pared as described at the start of Section 2.2.5.5, but excluding DMSO. A 1H15N-HSQC
spectrum was acquired using a 750 MHz spectrometer with an HCN triple resonance
cryoprobe and Bruker Advance III HD console. Spectra were recorded with 256 points
in the indirect dimension (15N) and 1024 points acquired in the direct dimension (1H)
and 8 scans. DMSO was titrated into the sample to 2 %, 4 %, 6 % and each acquired us-
ing the same acquisition procedure. Higher percentages caused deterioration in baseline
shape evident using TopSpin.
Temperature effects on the Aβ40 spectrum were monitored by acquiring multiple
1H15N-
HSQC spectra for a single sample of Aβ40. Spectra were recorded with 256 points in
the indirect dimension (15N) and 1024 points acquired in the direct dimension (1H) and
8 scans. Acquisition was conducted at 37 oC, 5 oC, and then 37 oC again to ensure no
ther was no alteration to the sample over the course of the experiment.
Spectra quality of Aβ40 in a solution of 50 mM ammonium acetate, pH 6.8, and in
the buffer described at the out set of Section 2.2.5.5, were compared. For this, NMR
lyophilised samples of Aβ40 were solubilised directly in 50 mM ammonium acetate, pH
6.8, to create 50 µM peptide and a 1H15N-HSQC was acquired using a HN Enhanced
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Sensitivity HSQC pulse sequence [388, 389]. Spectra were recorded with 256 points in
the indirect dimension (15N) and 1024 points acquired in the direct dimension (1H) and
8 scans.
C. Backbone Assignment of Aβ40
To assign the Aβ40
1H15N-HSQC spectrum, a triple labelled sample of 1H13C15N-Aβ40
was recombinantly expressed (Section 2.2.2.1), purified (Section 2.2.2.3), and prepared
as described in Section 2.2.5.5A. Data were collected using a 950 MHz Bruker Ascend
Aeon NMR spectrometer, Next-generation ultra-high field NMR magnet with actively
shielded and with helium recycling technology, fitted with a TXO-cryoprobe (5mm) and
operated using a Bruker Advance III HD console. The Bruker Best Trosy HNCA pulse
sequence was used [389, 390]. The pulse sequence was run twice sequentially with 256
points in the indirect dimension (15N), 128 points acquired in the direct dimension (1H),
and 1622 points for F3, the 13C dimension. 16 scans were made for each experiment.
The two spectra were combined using nmrPipe [386]. Assignment was conducted using
CCPNmr Analysis [387] to identify sequential peaks. To validate assignments, published
backbone assignments [367, 372, 391] were referenced.
D. Calculating ∆δCα Chemical shifts
Using the δ13Cα chemical shifts obtained from the Best Trosy HNCA experiments which
was conducted for the assignment of the Aβ40 peptide in the preceding section. The
∆δCα Chemical shifts were automatically generated within CCPNmr Analysis. The
software calculates the difference in measured δCα and the predicted chemical shift of
the amide were it to be in a random coil [392, 393].
E. Measuring 1HN Chemical Shift Temperature Coefficients
To calculate temperature coefficient values for each backbone amide in Aβ40, a series of
1H15N-HSQC spectra were obtained using the 750 MHz spectrometer. Each spectrum
was recorded with 256 points in the indirect dimension (15N) and 1024 points acquired
in the direct dimension (1H) and 8 scans. Aβ40 was expressed and purified as described
in Sections 2.2.2.1 and 2.2.2.3, and a single sample was prepared in 20 mM sodium
phosphate, pH 7.4, as described in Section 2.2.5.5A.
Data were acquired using a using a HN Enhanced Sensitivity HSQC pulse sequence
[388, 389] at the following temperatures, in the presented sequence: 5 oC, 37 oC, 15 oC,
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20 oC, 25 oC, 5 oC. Collection of spectra are 5 oC at the start and end of the experiment
enabled spectral comparison to ensure peptide concentration was unaltered.
Spectra were processed using nmrPipe [386] and analysed using CCPNmr Analysis [387].
Spectra were referenced using water with the temperature correlation shift of -0.0119
ppm/o [394]. Peaks were picked on each spectrum in CCPNmr Analysis and the δ15N
positions were plotted, and linearly fit, for each residue. The gradient of the linear fit
gives the 1HN chemical shift temperature coefficient for each residue.
F. Measurement of Residual Dipolar Couplings
To measure RDCs two Aβ40 samples were prepared; an unaligned sample, and an aligned
sample (whereby the peptide orientation is biased through interaction with an alignment
medium). The unaligned sample was prepared as described in Section 2.2.5.5A. To
prepare the aligned sample an alignment medium, bacteriophage Pf1, was used to bias
the orientation of the Aβ40 peptide ensemble.
Commercial bacteriophage Pf1 (NEB, UK) was supplied in 53 mg/ml in 10 mM potas-
sium phosphate. In order to prepare the Pf1, it was precipitated out of ther potassium
phosphate using 1.25 M NaCl and centrifugation (1 hr at 30 oC, 14,100 xg in a microcen-
trifuge) to separate the soluble and insoluble fractions. The supernatant was discarded
and the insoluble pellet washed three times in dH2O before resuspension in 250 mM
sodium phosphate, pH 7.4, over 2 hours at 4 oC. This was used to prepare a sample of
Aβ40 (Section 2.2.5.5A) with an addition of 26 mg/ml Pf1.
RDCs were measured using a in-phase-anti-phase (IPAP) amide HSQC experiment [395]
set up with the aid of Dr Arnout Kalvada (University of Leeds) using the 750 MHz
spectrometer (Section 2.2.5.5A). 640 points in the indirect dimension (15N) and 1024
points in the direct dimension (1H) were acquired 32 times (32 scans). Data were
processed using nmrPipe [386] before further analysis using CCPNmr Analysis [387] for
peak picking.
G. Measuring Transverse, R2, Relaxation Rates by NMR
R2 rates were calculated from a set of T2 relaxation experiments carried out at 750 MHz.
Spectra were recorded with 160 points in the indirect dimension (15N) and 2048 points
acquired in the direct dimension (1H) and 16 scans. R2 is related to T2 by the following:
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R2 =
1
T 2
(2.1)
A sample of 50 µM Aβ40 was prepared in 20 mM sodium phosphate according to Section
2.2.5.5A. Using this, a series of 1H15N-HSQC experiments - set up with the aid of Dr
Arnout Kalvada (University of Leeds) using the 750 MHz spectrometer - were collected
using a HN Enhanced Sensitivity HSQC pulse sequence [388, 389] with a range of time
delays: 7.5, 14.9, 29.8, 44.7, 59.9, 74.5, 89.4, and 104.3 ms. Data were collected in a
randomised order with two duplicate experiments (for delay times of 14.9 and 74.5 ms)
for error estimation.
Peak intensities for each residue (measured using CCPNmr Analysis [387]) were plotted
over time with error bars (which represent the error from the peak fitting). Data were
fit to an exponential decay function to extract the R2 as:
f(t) = Ae−t.R2 (2.2)
Where t is the delay time.
H. Measurement of heteronuclear Nuclear Offenhauser Effects
Using a sample of 50 µM Aβ40 in 20 mM sodium phosphate (fully described in Section
2.2.5.5A), heteronuclear NOE information was obtained. With the aid of Dr Arnout
Kalvada (University of Leeds), two HSQC NOE experiments were set up. Data were
acquired at 750 MHz at 5 oC using 148 points in the indirect dimension (15N) and 248
points acquired in the direct dimension (1H) and 48 scans. NMR data were processed us-
ing nmrPipe [386] and peak intensities were extracted, after peak fitting, using CCPNmr
Analysis [387]. The ratio of the two intensities gives rise to the hetNOE value.
2.2.6 In vivo β-lactamase assay
Using the same transformation protocol as in Section 2.2.1.4 competent BL21(DE3) E.
coli cells were made to take up an expression pMB1 plasmid (Figure 2.1a) contain-
ing the gene encoding either TEM1 β-lactamase with an hIAPP insert, Aβ40/42 insert
(βla-hIAPP or βla-Aβ40/42 respectively or βla-construct generically) (Figure 2.1b) or
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β-lactamase with a non-aggregative glycine/serine-rich linker (βla-linker) (Figure 2.1c).
However, due to the different selection markers in the pMB1 plasmid and the pTXB1
plasmid 50 µL of transformed cells were plated onto agar plates containing 10 µg/mL
tetracycline rather than agar containing ampicillin. Plates were incubated overnight at
37 oC. Single colonies were picked and used to inoculate 100 ml of LB containing 10
µg/ml tetracycline overnight (37 oC, 200 rpm).
Figure 2.1: A map of the pMB1 plasmid encoding the β-lactamase construct.
a) Map of the pMB1 plasmid into which the sequence encoding either β-lactamase
with a Gly-Ser (non-aggregative) linker incorporated. The plasmid encodes for
tetracycline resistance which is used for selection. The plasmid also encodes the
L-arabinose operon which is transcribed when arabinose is present. Transcription of
the inserted construct is under the control of the pBAD promoter which is part of the
L-arabinose operon and is activated when arabinose if present, this arabinose is used to
induce construct expression. Plasmid kindly provided by Professor J. Bardwell
(Department of Biological Chemistry, University of Michigan, USA) and figure drawn
by Dr J. Saunders, University of Leeds. b) Schematic of the βla-construct, where the
‘Test protein’ is either hIAPP, Aβ40 or Aβ42. Taken from [346]. c) Schematic of the
βla-linker construct. Taken from [346].
The in vivo tripartite β-lactamase assay [337] was be applied to study of the amyloid
aggregation inhibition capacity of small molecule.
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Two sterile 48 well plates (Greiner Bio-One, Germany) were prepared (one for βla-
construct and one for βla-linker). Tetracycline (10 µg/ml final concentration), filter
sterilised arabinose (0.02 % (w/v) final concentration), and 200 µM compound in 100
% DMSO (or pure DMSO) were added to 100 ml of sterile 1.5 % (w/v) agar cooled to
5˜0 oC. 300 µl was pipetted into each well in the first row of two 48-well plates. Filter
sterilised ampicillin (10 mg/ml stock) was then added to the agar stock to give the
required concentration for the next row of wells. This procedure was repeated until
the plate contained 8 columns of agar containing increasing concentrations of ampicillin
from 0 - 140 µg/ml (20 µg/ml increments) for βla-hIAPP. For the optimised assay for
βla-Aβ40/42 constructs the ampicillin increments were reduced to a lower range: 0, 2.5,
5, 10, 15, 20, 25, 30 µg/ml in each column. Agar plates were left to set in a sterile
environment.
The overnight cultures were used to inoculate fresh flasks of 100 ml sterile LB containing
10 µg/ml tetracycline, which were incubated at 37 oC, 200 rpm. Once an OD600 of 0.6
was reached the expression of βla-linker or βla-construct was induced by the addition of
arabinose stock (final concentration of 0.02 % (w/v)). 392 µl aliquots of the cultures were
taken and mixed in 1.5 ml Eppendorf tubes with sterile LB and 10 mM stock compound
stock to give a final volume of 400 µl culture containing 200 µM small molecule. These
aliquots were incubated for 1 hour (37 oC, 200 rpm). Next, 100 µl serial dilutions of
10-fold increments of these cells were made using filter sterilised 170 mM NaCl. 3 µl of
each cell dilution was spotted onto the prepared 48 well plates and incubated at 37 oC
for 18 h. The maximal cell dilution at which growth can occur (MCDGrowth) was scored
at each concentration of ampicillin on each plate. Scoring was done in a binary manner
of either growth or no growth, where no growth is defined as agar wells with fewer than
10 colonies. To control for any intrinsic effect of small molecules on bacterial growth,
the growth of E. coli BL21 (DE3) cells transformed with βla-linker in the absence or
presence of small molecule was compared. Any effect on bacterial growth was subtracted
from the βla-construct assay, at each concentration of ampicillin.

Chapter 3
Creating a Toolbox of Methods to
Study Small Molecule Effects on
Amyloidogenic Peptides
3.1 Objectives
The primary aim of this project is to create a strategy, or toolbox of methods, which
can be used to screen and investigate the effects of small compounds on IDP amyloid
aggregation. This chapter describes the recombinant expression and purification of two
IDPs, Aβ40 and hIAPP (Sections 3.2 and 3.3 respectively). It also outlines the rationale
behind choosing each method which was incorporated into the toolbox (Section 3.4).
Additionally, key optimisation steps and control experiments, which were conducted
using published small molecules and antibiotics (Table 3.1 such as epigallocatechin-3-
gallate (EGCG) and aspirin) are included in this chapter to demonstrate the effectiveness
of each method (Section 3.5).
Table 3.1: Example small molecules used.
Compounds based on adapalene structure
Name Structure Molecular formula MW (Da)
Ampicillin C16H19N3O4S 349
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Continuation of Table 3.1
Name Structure Molecular formula MW (Da)
Aspirin C9H8O4 180
Curcumin C21H20O6 368
EGCG C22H18O11 458
Rifampicin C43H58N4O12 822
Aβ40 and hIAPP were chosen as exemplar amyloidogenic IDPs due to their roles in hu-
man diseases (Section 1.3.1) and because of the observed links between the two peptides
which has been highlighted in the literature (Section 1.12). A key challenge in the pro-
duction of amyloid peptides is preventing uncontrolled, irreversible aggregation during
expression and purification. Published work shows that each of these peptides can be
expressed and purified using contrasting approaches: Aβ40 via an insoluble, inclusion
body-based protocol [383], and hIAPP using a quadripartite construct method [384, 396]
whereby the hIAPP sequence is surrounded by a solubility tag and additional domains
for purification and post-translation modification steps.
3.2 Recombinant Expression and Purification of Aβ40 from
Insoluble Inclusion Bodies
The system used for producing Aβ40 recombinantly in E. coli is summarised in the
schematic in Figure 3.1. The Aβ40 produced is in a close-to-native state as there are
no post-translational modifications on human Aβ40. However, there is an N-terminal
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methionine (Met0) which has been shown not to affect fibril formation kinetics or fibril
morphology [383]. In this chapter Met-Aβ40 will be referred to as Aβ40.
Figure 3.1: Expression and purification protocol for Aβ40.
A schematic of steps followed to express and purify Aβ40 (purple) from inclusion
bodies (star-shaped arrangement).
Aβ40 is expressed using E. coli transformed with a pETSAC plasmid (Section 2.2.1.4)
which encoded Aβ40 under the control of the T7 promoter. Aβ40 expression was induced
by addition of isopropyl β-D-1-thiogalactopyranoside (IPTG) as described in Section
2.2.2.1 leading to the formation of Aβ40 inclusion bodies, Figure 3.1, (step 1). Cells
were lysed (step 2) and the insoluble and soluble components separated by centrifugation
(step 3). The insoluble inclusion bodies were solubilised using 8 M urea (step 4). To
purify Aβ40, batch ion exchange chromatography was conducted using Q-Sepharose
resin (step 5), followed by buffer exchange (step 6), and either one or two size exclusion
chromotography steps (steps 7 and 8).
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Although the method described in detail in Section 2.2.2.1 was well established, a few
optimisation steps were investigated for Aβ40 expression and the purification thereof.
3.2.1 Optimisation of Expression Conditions of Aβ40 to Maximise Yield
Initially the expression conditions for Aβ40 were varied to ensure efficient protein pro-
duction. Growth medium and culture aeration were altered to find the highest yielding
combination of conditions. The optical density for each culture variation was monitored,
Figure 3.2, and the typical expression level for Aβ40 was shown via SDS-PAGE.
Figure 3.2: Expression of Aβ40 in various cultures.
Left: OD600 of cultures of Aβ40 grown in either 0.5 L or 1 L of either LB or TB media,
in baffled ‘baff’, or unbaffled, ‘-’, flasks. Right: Typical expression of Aβ40 (red arrow)
is shown by SDS-PAGE at the time of induction and harvest. L = ladder.
From the plot, higher cell densities are attainable when using TB medium. This was
improved further with a culture volume of 0.5 L rather than 1 L. This indicated that
reducing the volume was more effective at improving the aeration of the growth culture
than use of baffled flasks. A higher cell density meant there were more cells present
which could express the Aβ40 peptide. However, it was also important to check the
expression using SDS-PAGE as cell expression levels may alter when the cells are in
high-density solutions. Similar expression levels were observed at the harvest time for
each culture (data not shown), typical of that shown in Figure 3.2. Thus, the more cells
in the solution, the higher the protein yield after the overnight incubation period.
As Aβ40 would eventually be required for NMR studies, it was important to ensure
expression was possible in M9 minimal medium. In contrast to growth in LB media, the
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growth period after induction with IPTG is incubated at 15 oC overnight rather than
37 oC for 2-4 hours. The results shown in Figure 3.3 show that a comparable yield can
be obtained using 15N - and 13C15N-labelled M9 media.
Figure 3.3: Aβ40 can be expressed in labelled M9 medium.
An SDS-PAGE gel showing the expression levels of Aβ40 (red arrow) in
15N- (40N) or
15N13C-labelled (40NC) M9 media, before (-) and after(+), induction with IPTG.
For this work, the expression of unlabelled Aβ40 was conducted in 0.5 L cultures of
TB medium grown in baffled flasks. For isotopically-labelled samples (15N - or 13C15N-
Aβ40), 0.5 L cultures of M9 medium were grown in baffled flasks.
3.2.2 Optimisation of Ion Exchange Chromatography in Aβ40 Purifi-
cation
High levels of Aβ40 expression in inclusion bodies was essential as a starting material
for the purification process. Despite reports of obtaining 10-20 mg/L yields using this
purification method [383], the Aβ40 yield obtained was 2-4 mg/L. To improve this the
affinity purification step was probed and optimised.
Figure 3.4 shows a typical SDS-PAGE gel which tracks the purification throughout the
steps in Figure 3.1. The gel shows some loss of Aβ40 in the second supernatant fraction
after two centrifugal separations, (see Section 2.2.2.3, and Figure 3.1 step 3). This was
discarded as most of the Aβ40 was retained in the inclusion body solubilisation solution
(Figure 3.4, lane IC). This was loaded onto Q-Sepharose resin which binds to Aβ40
through electrostatically-mediated interactions. Good binding was evident from the
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decreased intensity of the Aβ40 band in the flow through fraction (Figure 3.4, lane FT).
Next, the resin was washed twice (Figure 3.4, lanes W1 and W2) to remove unbound
protein contaminents. Aβ40 was eluted from the resin in five batches of 125 mM NaCl,
then the sixth fraction of 250 mM (Figure 3.4, lanes E1, E4, and E6*). After elution of
Aβ40, a 1 M NaCl solution was applied and collected to reveal any protein left on the
resin (Figure 3.4, lane HS).
Figure 3.4: SDS-PAGE gel to show the protein profile at each stage in the Aβ40 purifi-
cation procedure.
Aβ40 is indicated byt the red arrow. Lanes are as follows: L=ladder, S1-supernatant
after the first centrifugation step, S2=supernatant after the second centrifugation step,
IC=inclusion body solubilisation solution, FT=flow through when loading the chitin
resin, W1 and W2=wash fractions, E1-E6=elution fractions, HS=high salt-containg
column wash. Gels were loaded as described in Section 2.2.3 whereby S1, S2, and IC
are loaded with half as much sample as other lanes.
To optimise yield, the ‘flow through’ and ‘Wash 1’ fractions were collected and pooled.
Re-application of these fractions to fresh Q-Sepharose resin and repetition of the wash
steps and three elution volumes, Figure 3.5, increased the total Aβ40 yield (of fully
purified Aβ40) to 5-7 mg/L.
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Figure 3.5: SDS-PAGE gel to show the protein profile at each stage in the optimised
Aβ40 purification procedure.
Aβ40 indicated by red arrows. Lanes labelled as in Figure 3.4, additionally HSU=high
salt and urea containing column wash. Samples collected on the second round of
affinity chromatography are preceded with a ‘2’
Other optimisation steps were tested including increasing the number of elution frac-
tions collected, and including fraction S2 (the supernatant after the second centrifugal
separation) in the loading of the Q-Sepharose resin. As more elution fractions were col-
lected, Aβ40 was still present, however, the yield of protein in these latter fractions was
low and caused the overall collection volume to increase. Combined, these decreased the
time efficiency of the purification due to collection time and time for lyophilisation of the
increased volume. Inclusion of S2 for resin loading caused severe reduction in the column
flow rate, even under vacuum. This was possibly due to the nearly two-fold increase in
non-target proteins in the resin mixture. Based on these findings it was decided not to
include either of these amendments in the protocol.
To increase the time efficiency of the affinity ion exchange chromatography purification
step, trials to improve the flow rate of liquid through the Q-Sepharose resin were con-
ducted. The recommended method is to use a light vacuum created by running water
through a T-tap attached to a bu¨chner funnel flask to pull the unbound proteins in
solution through the Q-Sepharose resin. Utilisation of a stronger force was tested using
a vacuum pump, but this disrupted the resin-Aβ40 interaction and decreased yield to
a negligible level. Other flow optimisations could be tested such as use of a peristaltic
pump, or controlled flow in an A¨kta system, however, preliminary trials of these were
not promising and thus not pursued in this work.
No further optimisation steps were taken to improve the published protocol. Thus the
final improved purification yield of Aβ40 was 5-7 mg/L.
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3.2.3 Completion of Aβ40 purification
Subsequent to ion exchange chromatography, the Aβ40-containing solution undergoes
buffer exchange into 50 mM ammonuim bicarbonate to remove non-volatile salts (e.g.
NaCl) and residual urea before lyophilisation. The final steps in the purification protocol
was size-exclusion chromotography, Figure 3.6a. Aβ40 elutes as a single, resolved peak
between 95–110 minutes (28–33 ml). Mass spectrometry (Figure 3.6c) confirms the
production and purification of Aβ40 (sequence shown in Figure 3.6d).
Figure 3.6: Confirmation of Aβ40 purification.
a) Size Exclusion Chromatogram showing Aβ40 eluted as a single peak between 95–110
mins, with a flow rate of 0.3 ml/min. b) SDS-PAGE showing the proteins present in
the sample before SEC (load) and in the collected peak seen in a (peak fractions). c)
Mass spectrum to confirm peptide mass and infer identity as Aβ40. d) Amino acid
sequence of Aβ40 purified with N- and C- termini highlighted in green.
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3.2.4 Summary of Aβ40 Production
Aβ40 was successfully expressed and purified. Incorporation of the optimisation strate-
gies discussed in this section led to an approximate 150 % increase in yield of Aβ40.
However, the batch step of the purification process was still laborious and the time:yield
ratio remained sub-optimal. Additionally the requirement to run two SEC steps was
shown to be necessary for reproducibility in measuring aggregation kinetics (Section
3.5.1.3) but decreased protein yield by approximately 40 %. For other assays, the sec-
ond SEC run was not necessary which was especially important for isotopically-labelled
samples for NMR.
Recently a new approach to purifying Aβ40 was published which utilised RP-HPLC
as the final step [397]. This method was modified in house (Dr M. Walko, University
of Leeds) leading to nearly 10 mg/L peptide yield. This procedure is now being used
routinely, but was not adopted here as it was published only recently in 2018 [397].
3.3 Production of IAPP for in vitro Aggregation Studies
The method for expression and purification of hIAPP used in this project was based
on the protocol originally published by Williamson et al. [384]. This paper presents a
method to express hIAPP as part of a quadripartite construct Figure 3.7a in E. coli.
The plasmid containing the expression construct, which was used in this thesis, was
kindly provided by Prof. A. Miranker at Yale University. Intrinsically disordered, wild-
type hIAPP has two important post-translational, structural features: a disulfide bridge
between Cysteines 2 and 7, and an amidated C-terminal (Figure 3.7b). These are both
required for full biological activity when forming amyloid fibrils and for normal functions
[229].
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Figure 3.7: Anatomy of the quadripartite construct for the expression of hIAPP.
a) The schematic shows the quadripartite construct; leader sequence (pink), hIAPP
sequence (purple), intein domain (blue), and chitin biding domain (orange). b) post
translational modification to the hIAPP sequence. Amino acids are represented with
circles, the Cys2-7 disulfide bridge is marked in blue and the amidated C-terminus in
green.
The construct had already been designed to increase the solubility of hIAPP through the
addition of an N-terminal leader domain. This leader domain contained codons which
were highly expressed in E. coli (MKIEEG) [384] and a (NANP)3 domain which had
previously been used to increase the solubility of Aβ42 [398]. This 2 kDa leader sequence
(Figure 3.7a) contains multiple proline residues which interfere with the formation of
β-sheets [399], which are vital for fibril morphology and close packing of peptides. A
Glutamic Acid residue was included at the C-terminus of the leader sequence, immedi-
ately adjacent to the N-terminal of the hIAPP codon sequence, to enable detachment
of the leader from hIAPP using a V8 protease. V8 protease cleaves after acidic residues
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(Aspartic Acid or Glutamic Acid) without leaving any additional residues N-terminal
to hIAPP.
On the C-terminal side of hIAPP, an Mxe intein was incorporated as the third section
of the quadripartite construct. An intein is a self-cleaving sequence; for this construct,
a mini-intein of 198 residues from Mycobacterium xenopigyrA has been used. The se-
quence included in the vector can undergo a thiol-mediated cleavage at its N-terminal,
induced by a thiol reagent [400]. Cottingham et al. [401] showed that the addition of
ammonium bicarbonate in the reducing, ‘intein cleavage buffer’, would result in the sub-
stitution of an amide group rather than a hydroxyl group at the point of cleavage, thus
creating the amidated C-terminus of hIAPP. Finally a Bacillus circulans chitin binding
domain is encoded at the C-terminal of the quadripartite construct to enable affinity
chromatography in the purification process (Section 2.2.2.5).
Since the expression system uses E. coli (Section 2.2.2.4), the post-translational mod-
ifications must be incorporated in the multi-step purification process after expression,
Figure 3.8. These post-translational modifications - and aggregation propensity of the
peptide - has meant that hIAPP has been challenging to produce recombinantly and
synthetically.
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Figure 3.8: Workflow of the expression and purification of hIAPP.
Steps in the production protocol are summarised in the flow diagram and changes to
the expression construct highlighted. The disulfide bridge between cys2-7 is
represented in red.
After expression of the soluble construct, Figure 3.8 (step1), cells were lysed and the
construct was purified from the cell lysate using centrifugation (step 2) followed by a
chitin affinity step (step 3). Whilst on the chitin resin, the bound construct is incubated
at 4 oC in the presence of 2 M ammonium bicarbonate and 0.1 M DTT to induce
the intein cleavage reaction (step 4). The intein cleavage generates an amidated C-
terminus on hIAPP and released the leader-hIAPP part of the construct leaving the
chitin-binding domain and intein attached to the chitin resin. The amidated two-part
construct (leader and hIAPP) was eluted from the column and undergoes filtration to
remove any large species (such as low levels of co-eluted CBD-intein construct) and
buffer exchange where salts were removed and the construct was exposed to a redox
system, allowing the formation of the Cys2-Cys7 disulphide bridge in hIAPP (step 5).
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The sample volume was reduced (step 6) in preparation for V8 cleavage. The leader
sequence was then removed from hIAPP using the Staphylococcus aureus V8 protease
(step 7) and then the solution was filtered again to remove the 29 kDa V8 protease
from the 3.9 kDa hIAPP and 2.0 kDa leader sequence (step 8). The hIAPP and leader
solution was lyophilised (step 9). The dried material was then suspended in 100 %
DMSO and HPLC was used to separate the leader from hIAPP (step 10). Finally the
disulfide bridge must be formed by an oxidising environment (step 11).
Optimisation of the expression and purification of hIAPP was necessary to obtain a
high yield of the peptide required for this project. The original protocol was expected
to yield 2.0 mg/L of hIAPP [384]. In 2015, an optimised version of the expression and
purification was published [396]. This reported an improved yield of 2.5-3.0 mg/L of
purified native hIAPP when recombinantly-expressed in 1 L of LB medium. This section
describes the steps which were taken towards optimising the expression and purification
of hIAPP for use in in vitro biophysical investigation into the mechanism of how IDPs
form amyloid.
3.3.1 Recombinant Expression of hIAPP as a Soluble Quadripartite
Construct
hIAPP was expressed recombinantly using E. coli which was transformed (Section
2.2.1.4) with a construct-encoding, pTXB1 plasmid, shown in Figure 3.9. This plas-
mid was kindly provided by Prof. A. Miranker (University of Yale, USA) [384].
In order to increase the yield of hIAPP obtained recombinantly, attempts were made
to increase the over-expression of the four-part construct. This was done through opti-
misation of cell strain, growth medium, culture aeration, and length of incubation after
induction.
3.3.1.1 Variation of Cell strain to Increase Peptide Expression Yield
Expression of the quadripartite construct in E. coli BL21(DE3) cells was controlled
under a T7 promoter which can be manipulated simply using IPTG to induce a high
level of protein expression [402]. The T7 promoter is commonly referred to as a ‘leaky
promoter’ meaning that there is a low level of basal expression of the inserted construct
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Figure 3.9: The pTXB1 plasmid encoding the hIAPP-containing quadripartite con-
struct.
Bases encoding the leader and IAPP sequences were incorporated at the Multiple
Cloning Site (red) using the Nde1 and Sap1 restriction sites immediately 5 to the gene
encoding the intein and the chitin binding domain (CBD). LacI, the Lac repressor is
encoded and expressed to minimise basal expression at the T7 promoter site. There is
a rop (Repressor of Primer) for regulation of plasmid copy number and an M13 phage
origin of replication. The plasmid also has ampicillin resistance as a selection marker.
The plasmid was kindly obtained from Prof. A. Miranker (University of Yale, USA)
[384].
prior to IPTG addition. Other cell strains prevent ‘leaky’ expression, for example, E.
coli BL21(DE3) pLysS, contain additional plasmids encoding phage T7 lysozyme, which
is a strong repressor of the T7 promoter [403].
For toxic or bulky proteins, early protein production may hinder cell growth or health,
leading to lower protein yields. Promoter leakage can be especially problematic if there
are long time periods between culture innoculation and induction. Promoter leakage is
commonly an issue for protein expression in minimal media where, due to the reduced
availability of nutrients, growth rates are slower and thus the time required to reach
optimal cell density is often extended.
For this project hIAPP needed to be prepared by a suitable method compatible with
isotopic labelling. In order to achieve this, minimal medium must be used. To ascer-
tain whether toxicity due to promoter leakage could be an issue for the quadripartite
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construct a comparison of protein expression in BL21(DE3) cells and BL21(DE3) pLysS
cells was performed.
Firstly cell transformations of BL21(DE3) and BL21(DE3) pLysS cells were conducted
according to Section 2.2.1.4 whereby construct-encoding, pTXB1 plasmids were inserted
into competent cells (Section 2.2.1.2) of each cell type via a heat-shock procedure (Sec-
tion 2.2.1.4). BL21(DE3) and BL21(DE3) pLysS cells were plated onto solid agar con-
taining 100 µg/ml ampicillin/carbenicillin or 100 µg/ml ampicillin/carbenicillin with 25
µg/ml chloramphenicol respectively.
After plate incubation overnight at 37 oC, colony growth was observed and single colonies
were selected and used to inoculate starter cultures of 100 ml LB medium containing
the antibiotics as above. These cultures were incubated for 16 h at 37 oC with 200 rpm
shaking for aeration. Next, 4 ml of the small cultures were transferred into 1 L of LB
medium under the same conditions (Section 2.2.2.4). After 3-5 h the OD600 reached 0.6
and 1 ml of 1 M IPTG was added in order to induce expression of the construct. Figure
3.10 shows the SDS-PAGE gels comparing the expression of the construct in BL21(DE3)
and BL21(DE3)pLysS E. coli strains before and after induction.
Figure 3.10: Expression of the quadripartite construct in different E. coli strains.
SDS-PAGE showing the expression of the quadripartite construct in BL21(DE3)pLysS
or BL21(DE3) cells grown in 1 L of LB medium in 2 L, non-baffled flasks. The final
OD600 for BL21(DE3)pLysS culture was 1.88 after 15 h, and 1.69 for BL21(DE3) cells.
Samples were taken at 0, 5, and 15 h after induction with IPTG and run on an
SDS-PAGE gel. The red arrow highlights the quadripartite construct. L = ladder.
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By comparing expression in BL21(DE3) pLysS cells and BL21(DE3) cells it was con-
cluded that BL21(DE3)pLysS cells did not express the quadripartite construct as well
as BL21(DE3) cells. Thus further optimisation of expression conditions was conducted
in BL21(DE3) cells.
3.3.1.2 Optimisation of Growth Conditions for Efficient Peptide Production
To maximise yield, expression trials were conducted to find optimal conditions for cell
growth and construct expression. Three variables were investigated; Type of medium
(LB or M9), aeration by two methods (flask baffling and media volume), and growth
time, Figure 3.11 and Table 3.2. Samples were prepared similarly to Section 3.3.1.1.
Gel Volume (L) Baffled flask? Medium Final OD600 (AU)
a 1 No LB 1.69
b 0.5 No LB 1.70
c 0.5 Yes M9 2.27
d 0.5 Yes LB 1.60
e 1 Yes LB 1.57
f 0.5 No M9 1.74
g 1 Yes M9 1.79
h 1 No M9 1.39
Table 3.2: hIAPP expression conditions and final OD600.
Figure 3.11 shows the expression gels obtained when all the growth conditions in Table
3.2 were tested. In light of all the expression conditions investigated, optimal protein
expression was performed using 1 L cultures of M9 media in baffled flasks.
To test whether 16 h was the optimum time for expression after induction three inde-
pendent time trials were conducted. Cell cultures were left for up to 28 h to express
the quadripartite construct (Figure 3.12). From the SDS-PAGE gels, maximal levels of
expression were reached after approximately 15 h after induction of protein expression
and maintained up to 28 h. The four-part construct (39.2 kDa) runs below the 37 kDa
MW marker at approximately 30 kDa. Below the four-part construct there is a thinner
band which likely represents the intein-CBD fragment only. This is created by the intein
cleavage reaction occurring within the cells during the expression period. The leader-
IAPP fragment is not visualised on the SDS-PAGE gel due to its poor ability to bind
to the gel stains including coomassie blue [404] and references therein.
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Figure 3.11: SDS-PAGE showing the effect of culture conditions on the expression of
the quadripartite construct.
Samples were taken at 0, 5 or 10, and 15 h after induction with IPTG and run on an
SDS-PAGE gel. The culture conditions and final OD600 are listed in Table 3.2. The
red arrows highlights the quadripartite construct in each gel image. L = ladder.
An extension to the expression trials conducted would have been to test the effect of in-
cubation temperature for protein expression. Caution to keep temperatures low in order
to reduce protein degradation must be balanced with the need for the temperature to be
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Figure 3.12: Time course of the expression of the quadripartite construct.
Expression of the quadripartite construct (red arrow) was induced at OD600 = 0.6 by
IPTG addition. Cultures were grown in 1 L of M9 in non-baffled flasks at 15 oC for the
time shown. Samples were normalised to the optical density. L = ladder
high enough for protein expression and cell division to occur at an efficient rate. Prelim-
inary investigations suggested that increasing the temperature to 37 oC after induction
would produce yields of the quadripartite construct after 2 h that were comparable to
the yields of the construct after approximately 8 hours when incubated at 15 oC (data
not shown). The recommended temperature of 15 oC for the post-induction period [384]
was used for protein expression in this project and cells were harvested after 15-20 h by
centrifugation for 20 min at 5000 rpm to form a cell pellet which was stored at -20 oC.
3.3.2 Multi-step Purification of IAPP from the Soluble Quadripartite
Construct
Once the quadripartite construct was reliably expressed to a significant yield the con-
struct had to be purified and then the hIAPP fragment isolated. The multi-step pu-
rification method used is described in this subsection and optimisation steps tested and
incorporated are discussed. Figure 3.8 summarised the purification protocol which is
described in detail in Section 2.2.2.5.
Firstly cells were resuspended by stirring the cell pellet in 20 ml of 20 mM HEPES, 0.1
mM EDTA, 2 M ure, 50 mM NACl, pH 8, at 4 oC. PMSF and DNAse1 were added
to prevent protein degradation. Once a homogeneous solution was obtained cells were
lysed using sonication on ice (Section 2.2.2.4).
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3.3.2.1 Optimising Flows for Chitin Affinity Purification
To separate the quadripartite construct from the cells two methods were used. Centrifu-
gation was used separate insoluble and soluble cell material and then the soluble fraction
was applied to a chitin-resin column. The chitin resin interacted with the chitin-binding
domain at the C-terminal of the quadripartite structure whereas other non-target pro-
teins and cell components, flowed through the column.
Purification through the use of affinity tags is widely used as an efficient method to
extract a protein of interest from a highly heterogeneous protein solution. For this
protocol, chitin interaction with a chitin-binding domain was exploited. Chitin is a
fibrous polysaccharide, often found in the exoskeletons of arthropods, which interacts
with the aromatic residues in protein chitin-binding domains [405].
An open column was packed with 20 ml of chitin resin and the mixture of soluble proteins
was loaded and washed using flows under gravitational force. This was a time intensive
step which was optimised in various ways: separation of the soluble and insoluble protein
fractions by more forceful centrifugation (Section 3.3.2.1A); increasing column width
from 180 to 280 mm (but maintaing the column volume of 20 ml); alternatives to loading
using gravity (peristaltic pump, and A¨KTA system, Section 3.3.2.1B).
Finally the recommended column washing procedure was optimised (Section 3.3.2.1C).
A. Preparing Harvested Cells for Application to the Chitin Affinity Column
The frozen pellet of cells was suspended in 20 ml of Equilibrium buffer and both PMSF
and DNAse1 were added (Section 2.2.2.5). The sample was left for 1 h with gentle
agitation at 4 oC until a homogeneous solution was obtained. Cells were lysed (Figure
3.8, step 2) using a cell disrupter (Constant Systems, UK) at 30 kpsi and the lysate
was subject to a centrifugation step to separate insoluble cell material from the soluble
proteins. In the published protocol, this centrifugation step was performed at 5000 rpm
(3220 xg). However, it was found that more stringent separation of the soluble and
insoluble fractions could be achieved by increasing the force of the centrifugation step to
20,000 rpm (48384 xg) using a fixed angle Beckman JA25.50 rotor. This was important
to enable more efficient loading of the supernatant (which contained the quadripartite
construct) onto the chitin column.
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B. Flow in the Chitin Affinity Column
Originally column flow rates were determined by gravity only. However, this was time
intensive especially as there were multiple steps which required column flow: to load
the supernatant, to wash off unbound proteins/components, and eventually to elute
the amidated - and therefore cleaved - leader-hIAPP-CONH2 construct. A more time-
efficient method was investigated for the chitin affinity separation procedure (Figure 3.8,
step 3).
Of the optimisation methods trialled the most successful was the alteration in the prepa-
ration of the soluble fraction (Section 2.2.2.5) and increasing the column diameter from
180 mm to 280 mm. The use of pumps to increase flow rates disrupted the chitin-
peptide interaction and resulted in the presence of the quadripartite construct in the
flow-through and wash fractions (data not shown) causing a lower yield. From these
trials it was concluded that the column must be loaded, washed and eluted under grav-
itational flows due to the weakness of the chitin-peptide interaction.
C. Washing the Chitin Resin
The published protocol recommended 15 x 20 ml column volumes were required to wash
the unbound protein from the chitin column. By monitoring the composition of each
column volume used to wash the chitin resin (using SDS-PAGE shown in Figure 3.13)
it was shown that the first three of the wash volumes were sufficient. Additional wash
steps appeared to cause elution of some of the quadripartite construct which caused a
reduction in hIAPP yield.
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Figure 3.13: SDS-PAGE showing the protein contents of each wash step during chitin
affinity purification.
The quadripartite construct (red arrow) and the intein-CBD construct (blue arrow) is
detected in all wash steps indicating the chitin:CBD interaction is disrupted. The red
line shows where the column is fully washed of unbound proteins. For all lanes, 13 µl
of sample was mixed with 5 µl 4 x lithium dodecyl sulfate (LDS) loading buffer and 15
µl was loaded on to the gel except for the supernatant (S/N) and flow-through (F/T)
samples where only 7.5 µl was loaded to avoid overloading.
As a result of these experiments, chitin-affinity purification was performed using more
vigorously separated soluble and insoluble cellular protein fractions and only three wash
volumes (3 x 20 ml) prior to intein cleavage were used.
3.3.2.2 Solubilisation of Buffer Salts in the Intein Cleavage Solution Solu-
bilisation for C-terminal Amidation.
After washing the chitin column, the quadripartite construct remained bound to the
chitin resin. The self-cleavage reaction of the intein (Figure 3.8, step 4) was initiated
with the addition of ‘Cleavage Buffer’ (2 M ammonium bicarbonate, 0.1 M DTT, pH 8).
Incubation in this buffer at 4 oC overnight results in amidation of the C-terminal Tyr
residue on the leader-hIAPP construct. The intein-chitin-binding domain part of the
construct remained attached to the chitin resin but the leader-IAPP-CONH2 construct
is free in solution and can be eluted from the column (Figure 3.14).
Figure 3.14 shows efficient cleavage at this step. However, practically there were incon-
sistencies in whether the ammonium bicarbonate stayed in solution during the overnight
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Figure 3.14: SDS-PAGE showing efficient production of the leader-hIAPP construct by
intein cleavage.
Purification steps of hIAPP are shown. The purple box highlights the binding of the
quadripartite construct (red arrow) to the chitin resin as little of the construct is
present in the flow through fraction. Production of the leader-hIAPP construct (green
arrow) is evident on addition of the cleavage buffer. The blue arrow shows the
intein-chitin-binding-domain only construct.
incubation and even prior to addition to the column. Through increasing the pH of the
Cleavage Buffer from pH 8 to pH 8.5, the solubility was improved and the method
became more reproducible.
3.3.2.3 Optimisation of the Glu-C Endoprotease Cleavage for IAPP Release
Eluted fractions containing the leader-hIAPP-CONH2 construct were dialysed in a 1000
Da MW cut off membrane into dialysis buffer (20 mM HEPES, 0.1 mM EDTA, 2M urea,
50 mM NaCl, pH 8) at 4 oC (Section 2.2.2.5, Figure 3.8, step 5) to remove ammonium
bicarbonate and DTT. The sample was next passed through a 0.22 µm syringe filter to
remove any large aggregates which may have formed.
Creating a Toolbox of Methods to Study Small Molecule Effects on Amyloid Peptides103
The purification protocol suggested by Miranker and coworkers [384] suggested a V8:hIAPP
(w/w) ratio of 25:1 to separate the leader sequence from the N-terminus of hIAPP-
CONH2. The V8 protease used was Endoproteinase Glu-C from Staphylococcus aureus.
The more recently published protocol by Reif and coworkers [396] reported optimisation
steps which led to a V8:hIAPP (w/w) ratio of 1:1. Since purchase of the V8 protease
was costly, optimising its usage was a key focus. Optimisations were replicated in this
work as follows.
Endoproteinase Glu-C V8 is a serine protease which cleaves on the carboxyl side of the
acidic residues glutamic acid (E) and aspartic acid (D). The sequence of hIAPP is free
from both of these amino acids but the leader sequence has three glutamic acid residues
(Figure 3.7), only one of which is positioned N-terminal to the hIAPP sequence and
is required to release full length hIAPP from the expression construct. Owing to this,
site-directed mutagenesis was conducted (using a Q5 QuickChange kit 2.2.2.5) to remove
the two additional glutamic acid residues and replace them with glutamine (E4Q) and
histidine (E5H) (Figure 3.15) as suggested by Rodriguez-Camargo et al. [396].
Figure 3.15: Site directed mutagenesis of the leader sequence.
Sequencing data from Beckman Cogenics confirms the incorporation of the
substitutions GAAGAA (Glu-Glu) to CAACAT (Gln-His) in the leader sequence. The
agarose gel shows the production of the plasmid after PCR amplification visualised by
EtBr staining.
This substitution had the potential to reduce the number of unproductive catalysis
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events of the V8 by reducing the number of catalysis sites available. The protocol by
Reif and coworkers [396] recommended that additional sequence changes should also
be made whereby Gly-Ile-Glu was incorporated into the leader sequence after the final
Pro residue to enhance V8 cleavage (Figure 3.16). Rodriguez-Camargo et al. [396]
found the Gly-Ile-Glu addition enhanced V8 protease activity, however, the converse was
observed in this study (data not shown). Owing to this only the EE to QH mutation
was incorporated, expressed, and purified according to Figure 3.8.
Figure 3.16: Variations on the N-terminal leader sequence to improve V8 cleavage.
The amino acid code (pink circles) for the leader sequence is shown. Contrasts in
sequence are highlighted in red lettering.
Other optimisations for the V8 cleavage step (Figure 3.8, step 7) were tested focusing
on improving reaction conditions: the sample volume was decreased to 5 ml using cen-
trifugation (Figure 3.8 step 6) and sample agitation and temperature were investigated.
Various spin columns were trialled with different membrane compositions to try and
reduce loss of protein duing concentration due to binding to the filter. The best per-
forming filter tested was a 1 kDa MWCO VIVASPIN (Sartorius) spin column. Despite
this, there was still significant loss of product at this step in the purification protocol.
Reduction of the sample volume increased collision probability, which was exacerbated
by gentle solution agitation. Agitation is known to enhance the rate of enzyme catalysis,
but also the rate of aggregation of many proteins, including hIAPP [406]. Owing to this
the incubation period of the reaction was shortened.
Increasing the reaction temperature from 4 oC to 20 oC (as recommended by preliminary
work on hIAPP by Dr M. Panya at the University of Leeds (personal communication))
improved the probability of successful binding and cleavage of the leader-hIAPP-CONH2
construct with V8.
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Figure 3.17 shows the final impact of the combined optimisations on the V8 cleavage
of the leader-hIAPP-CONH2 construct. As a result of the optimisation trials for all of
the conditions considered, the V8 cleavage reaction was performed at 4 oC with gentle
rocking. When 2 mg of enzyme is added to a concentrated leader-hIAPP-CONH2 sample
(based on the 1:1 hIAPP:V8 (v/v) suggested in [396] and the predicted final yield of 2
mg of hIAPP), the reaction appears to be complete after just 15 min (Figure 3.17). To
alleviate the risk of amyloid formation, the duration of the V8 cleavage was shortened
to 15 min.
Figure 3.17: Optimisation of the V8 cleavage reaction to release hIAPP from the leader
sequence.
An SDS-PAGE gel shwoing a time course of the V8 reaction after implementation of
V8 cleavage optimisations. The band at 29 kDa represents V8 protease (black arrow).
Both gels show the presence of the leader-IAPP construct (green arrow) and the
formation of the hIAPP peptide (purple arrow). The Leader sequence is not detectable
as it cannot bind to Coomassie stain. All lanes were loaded with 15 µl of sample (13 µl
sample and 5 µl 4 x LDS loading buffer (Biorad)) which had been boiled for four
minutes. L = ladder.
The V8 cleavage reaction was halted by removal of the large (29 kDa) V8 protease from
the solution by filtration (Figure 3.8, step 8) using a VIVSPIN 5, 10 kDa MWCO tube.
However, some loss of hIAPP was observed, possibly due to attachment to the filter
membrane. Samples were lyophilised (Figure 3.8, step 9).
3.3.2.4 Separation of 4 kDa and 2 kDa Peptides using RP-HPLC
The final step in extracting hIAPP from the expression construct is to purify hIAPP-
NH2 from the cleaved leader sequence. RP-HPLC was used (Figure 3.8, step 10) to
separate the two peptides on the basis of hydrophobicity using a gradient of increasing
acetonitrile (ACN) concentration (Section 2.2.2.5). The absorbance at 280 nm was
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monitored as liquid exited the column to detect protein elution. Owing to the lack of
Trp residues and only a single Tyr, the absorbance at 280 nm of hIAPP is very low; red
= 1490 M-1 cm-1, ox=1615 M
-1cm-1 as determined by ExPASy - ProtParam tool [407].
This, combined with the limited loading volume of the HPLC system, created the need
for a high concentration of hIAPP to be applied to the column in a small volume. Owing
to the aggregation propensity of hIAPP, the peptide was solubilised in 100 % DMSO
prior to application on the HPLC column to ensure the peptide remained monomeric.
Care was taken as injection of 100 % DMSO onto the HPLC column may allow solubilised
peptides to pass through the column without interacting with the column surface. To
avoid this issue, multiple small injections (of up to 100 µl) of the DMSO solubilised
sample were made (Section 2.2.2.5).
The earlier optimisation whereby the sample volume was reduced prior to buffer ex-
change (Section 2.2.2.5) was important to reduce the sample volume for loading onto
the HPLC system. The smaller volume, which was lyophilised, produced a more dense
dried material after lyophilisation, making suspension in small volumes of DMSO pos-
sible. Even with multiple injections, the maximum volume which can be loaded onto
the HPLC column was 1.5 ml and at least 0.3 mg of hIAPP must be loaded onto the
column to observe a convincing absorbance peak when IAPP eluted from the column.
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Figure 3.18: Separation of Leader and IAPP by RP-HPLC
a) A chromatogram showing the elution of 1 mg of commercial hIAPP from the
RP-HPLC column. b) The chromatogram for recombinantly produced hIAPP. The
blue dotted lines represent the acetonitrile gradient applied to the C18 column. The
SDS-PAGE gels (right) show the contents of the major peaks of the chromatograms,
hIAPP (red), and leader-hIAPP (blue). c) The mass spectrum of recombinantly
purified hIAPP showing multiple impurities, with the hIAPP sequence below (N- and
amidated-C-termini are highlighted in green).
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Figure 3.18 (top) shows the elution profile of 1 mg of pure hIAPP (purchased from Sigma
Aldrich) when applied to the C-18 column. Comparison of this to the chromatogram
below which was obtained when approximately 0.3 mg of recombinant hIAPP and leader
was applied to the same column. This suggests that hIAPP has been successfully pro-
duced and purified at a low level.
When the commercial hIAPP was applied to the RP-HPLC column a single, sharp peak
is observed after 16.4 min indicating good purity and provides evidence that hIAPP can
be observed using 280 nm wavelength light. On application of recombinantly-produced
hIAPP a broader peak is observed with lower intensity despite application of the entire
preparation. Use of SDS-PAGE showed the composition of this peak consisted of a
mixture of hIAPP and uncleaved leader-hIAPP construct. There was no evidence of
the leader sequence by SDS-PAGE or from the 280 nm absorbance trace as there are
no aromatic residues in the sequece (refer to Figure 3.7). Absorbance detection at 220
nm revealled a peak eluting at 10.3 min (not shown) whis is presumabley the leader
sequence. Thus RP-HPLC could be used to separate hIAPP from the leader sequence,
however, preceeding steps needed further optimisation to ensure all leader-hIAPP had
been cleaved.
Due to the unsuccessful purification of hIAPP the final step in the purification protocol
- oxidation by H2O2 (Figure 3.8, step 11) - was not conducted.
3.3.3 Methods to Measure hIAPP Concentration
Due to a lack of aromatic residues in the sequence of hIAPP, detection of the peptide
using absorbance at a 280 nm wavelength was difficult with error-prone, very low read-
ings measured. Potential problems with calculating the concentration of hIAPP from its
A280 is its low extinction coefficients; ox=1615 M
-1cm-1, red=1490 M
-1cm-1 (calculated
using ExPASy ProtParam [407]). To confirm the validity of this calculated extinction
coefficient, samples were sent for Quantitative Amino Acid Sequencing (Abingdon Heath
Sciences, Birmingham, UK). Other absorbance techniques were trialled such as moni-
toring at 205 nm, 220 nm and use of the Bradford assay, but none proved to be reliable
for the detection of hIAPP. This is consistent with the literature where the difficulties
in quantifying small IDPs has been discussed [204].
Creating a Toolbox of Methods to Study Small Molecule Effects on Amyloid Peptides109
Non-absorption-based methods were then considered. Detection of hIAPP by different
stains which were compatible with SDS-PAGE could have been used routinely. IAPP
appears to stain very poorly with QuickStain (Generon) on SDS-PAGE gels, but an
improvement in staining sensitivity was observed when using Coomassie Brilliant Blue
stain (Biorad). As a result of this finding, all gels on which hIAPP was loaded were
stained using Coomassie Brilliant Blue rather than QuickStain (Generon), Section 2.2.3.
3.3.4 Summary of IAPP Production
The expression and purification of hIAPP from the soluble quadripartite construct was
improved by this work. Optimal growth conditions were found to ensure reliable, good
expression of the construct in BL21(DE3) cells. With more time the substitution of Thr
to Cys at the third residue of the intein sequence would have been incorporated as there
is evidence that this can improve the stability of the quadripartite construct [408]. This
would decrease the amount of cleaved construct during expression.
Regarding the purification method, the alteration in cleavage buffer pH had a significant
contribution to increasing the reproducibility of that part of the method. However,
overall, the purification of hIAPP was generally unreliable and low-yielding, as well as
time-intensive. Owing to the difficulties in producing hIAPP, the focus of this project
moved solely to to Aβ40 which was able to be produced reliably and in sufficient quantity.
To pursue hIAPP studies in the future an alternative construct could be created. Use
of a His tag rather than the Chitin-binding domain could enable use of a stronger
affinity purification step. Additionally the leader sequence could be expanded for easier
separation from hIAPP, e.g. through the use of filtration. An alternative approach
could be to emulate the Aβ40 preparation (see subsequent section) whereby hIAPP is
expressed in an insoluble form. The incorporation of the intein sequence is however
important for the amidation of the C-teminus. A lot of issues were encountered with
the reproducibility of the V8 cleavage. Alternative enzymes which cleaved N-terminal
to Lys or which could be used to create hIAPP with no additional amino acids was
looked into, however, few alternatives were viable. Another route to this could be to
express hIAPP with an N-terminal Met. Studies would be needed to ensure comparable
behaviours with the wild-type. If this was the case, significant amounts of Met-hIAPP
could be expressed and used for peptide-intensive biophysical methods.
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3.4 Compilation of Methods to Study IDP Amyloid For-
mation
A plethora of methods have been applied to the study of amyloid proteins and IDPs
[334, 409–411]. Small molecule approaches have already revealed insight in the aggrega-
tion processes of IDPs such as α-synuclein, hIAPP, and Aβ40 (Section 1.4). Moreover,
the breadth and number of methods that have been used to study amyloid (as discussed
in Section 1.4) is ever increasing with novel approaches and method enhancements being
developed continuously. New methods can probe previously untapped areas of amy-
loid formation. For example, Maity et al., [412] developed a nanosecond fluorescence
cross-correlation spectroscopy method to exploit changes in dynamics of hIAPP on the
addition of small compounds in the probing of how structural disorder can be used for
drug design. The level of active research in this field highlights the immense need for
better understanding of amyloid formation. Additionally, continual improvement to es-
tablished techniques (including single molecule [413] and fluorescence methods [414] as
well as solid and solution NMR techniques reviewed in [415] but especially molecular
dynamic simulations [416, 417]) has made these methods more versatile and increased
their compatibility with numerous protein systems [418].
The purpose of this Section was to justify the selection and assimilation of methods for
the toolbox, summarised in Figure 3.19, which can be implemented to investigate the
effects of small molecules on IDP amyloid aggregation.
At the outset, it was necessary to select a method which could be used to screen small
molecules for impact on Aβ40 aggregation. There are a wide variety of screening tech-
niques which could have been used including in silico based molecular simulations, in
vivo methods (such as the tripartite β-lactamase assay [337]), or in vitro methods such
as ESI-IMS-MS , or fluorescence-based assays [356]. For this work, a well-established,
ThT-based assay was used [330, 419, 420]. This assay was amenable to high-throughput
screening [410, 421, 422], and required small sample quantities. This assay generally
highlights the presence of β-sheet aggregates [423] as well as revealing the kinetic pro-
file of the aggregation reaction [424]. Subsequent to the use of this screening method,
perturbations in the mechanism of amyloid aggregation can be inferred (as detailed in
Section 1.4.1).
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Figure 3.19: Compilation of methods for investigating small molecule effect on amyloid
aggregation.
A schematic of the toolbox developed showing the incorporated methods and how they
contribute information into the investigation of small molecule effects on amyloid
aggregation.
On finding compounds which influence amyloid aggregation, a set of orthogonal meth-
ods was compiled to probe the small molecule effects on aggregation from complemen-
tary perspectives. To test the reproducibility of small molecule effects, a titration of
compound concentration was included in the toolbox. Additionally this could reveal
concentration dependent effects on ThT kinetics, for example, low concentrations of a
compound may affect one stage of amyloid aggregation, whereas high concentration of
a compound could form oligomeric states which perturb the amyloid aggregation in an
alternative way. Continued use of the ThT assay for the titration investigation enables
the kinetic profile of the aggregation reaction to be monitored.
To quantify the extent of aggregation and whether the addition of a specific compound
could effect this, an SDS-PAGE-based fibril yield assay (reviewed in [289] and described
in Section 2.2.5.3) was included in the toolbox. In the field the maximum fluorescence
intensity in the ThT assay has been used to indicate fibril quantity [330]. However, there
is debate regarding its reliability as a quantitative measure as maximum fluorescence
levels in the ThT assay can be affected by: interactions between the small molecules with
the ThT molecule; differences in binding affinity of ThT with different fibril polymorphs;
competition between the small molecule and ThT for binding sites on fibrils; as well as
variation based on the abundance of β-sheet formation.
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In order to distinguish fibrillar and amorphous aggregates, transmission electron mi-
croscopy (TEM) was used. TEM was chosen as aggregate shapes can be observed di-
rectly. TEM can probe whether aggregates formed in the presence of small molecules
can still adopt amyloid fibril morphology, or if amorphous aggregates are formed. Such
behaviour could be achieved by pushing monomeric or small oligomeric conformations
of Aβ40 into off-pathway states where amorphous aggregates are formed. TEM and
the SDS-PAGE fibril yield assay complement each other well as SDS-PAGE fibril yield
can report quantitatively on fibrils formed, and TEM reports qualitatively on aggregate
morphology. For the purpose of this toolbox, TEM was used to note the presence or
absence of fibrillar species, due to this the magnifications used did not probe the known
multi-morphological states of Aβ40 fibrils.
The β-lactamase assay (Section 1.4.2) was chosen to add a more physiological aspect to
the methods toolbox. The assay monitors small molecule ability to prevent aggregation
of a peptide using ampicillin resistance as a reporter. This assay was chosen over other
in vivo assays because it takes place in the periplasm of E. coli rather than in the
cytosol. Cytosol-based assays can be misleading when using small molecules as some
compounds have difficulty traversing the inner cell membrane. The β-lactamase assay
provides a quantiative platform for identifying which small molecules can inhibit amyloid
aggregation and to what extent.
To probe the effects small molecule modulators of aggregation had on the ensemble
of small Aβ40 species (monomer and soluble oligomers) ESI-IMS-MS was used. This
technique enabled the observation of distinct species of Aβ40 which were present in
solution. Relative quantification is also possible with this technique and can probe
whether a compound causes different states to be favoured or disfavoured. The ESI-
IMS-MS method in the toolbox was developed and used previously by Dr L. Young
at the University of Leeds to indicate compound binding and stoichiometries of small
molecule:peptides interactions [356]. The method distinguishes species based on their
oligomeric stage (monomeric, dimeric, hexameric etc.) and on the extent of species
compaction (cross section correlation) [356]. Such observations can imply the mode
of binding of the small molecule to the peptide, for example, if a 1:1 peptide:small
molecule ratio is consistently observed, this may indicate there is a single specific binding
site for the small molecule on the peptide. Conversely, the presence of a monomeric
peptide bound to multiple copies of the small molecule can imply a non-specific binding
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mode. This method provides a good indication of binding mode but cannot define the
mode for certain. For example, if ESI-IMS-MS identifies that the peptide:small molecule
stoichiometry is less than an arbitrary 1:4, this may be due to non-specific binding, or
it could also occur by non-specific self-assembly of the small molecule in the gas phase.
Nevertheless, this method was useful in combination with the other methods discussed
to create a substantially-supported impression on the small molecule:peptide interaction
in vitro.
Finally NMR was used to gain residue-specific, structural information. NMR was chosen
as it is very suited to the study of disordered, dynamic and heterogeneous populations.
To complete the toolbox of investigative methods to monitor small molecule effect on
amyloid aggregation, NMR was used as a probe to find specific binding sites, and affini-
ties of small molecule:peptide interactions. To do this 1H15N-HSQC experiments which
revealed alterations in the chemical shifts of the backbone amide peaks of Aβ40 on
addition of small molecules were used. More extensive use of NMR to explore the con-
formational propensities of monomeric Aβ40 is described in Chapter 5 where another,
NMR-specific, methods approach is created and applied. Presentation of NMR optimisa-
tion steps and experimental details are excluded from this chapter as they are discussed
in Chapter 5.
3.4.1 Summary and Outline of the Toolbox
In summary, these methods (Figure 3.19), have been chosen to create a multi-method
approach for investigating how IDPs interact with aggregation-perturbing compounds.
Biophysical methods which are compatible with heterogeneous systems are vital for
comprehensive understanding of how IDPs form amyloid. The orthogonal methods se-
lected can be used to investigate the nature of the amyloid-perturbation from different
perspectives in order to build up a robust understanding of how a compound is affect-
ing amyloid aggregation. In this work methods have been utilised and optimised for
the study of IDPs with compounds to make progress towards elucidating important
monomer conformations in the amyloid pathway.
Ultimately the combinatorial use of these methods can be used to gather evidence for
the selection of compounds which have potential to reveal information on Aβ40 monomer
conformations on and around the Aβ40 amyloid aggregation mechanism. Such promising
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compounds could be used to subject Aβ40 to more in depth investigation by NMR
methods which are particularly suited to the study of IDPs.
3.5 Method Optimisation for Monitoring Small Molecule
Effects on Amyloid Aggregation of Intrinsically Disor-
dered Peptides
Once Aβ40 had been produced, and the method strategy devised, it was important
to optimise each of the methods in the toolbox and ensure compatibility with control
compounds.
3.5.1 ThT Fluorometry to Screen for Small Molecule Effects on Aβ40
Aggregation
As with most well established methods, there are many variations on how the ThT
fluorometry assay is conducted. The precise method used in this thesis is described in
Section 2.2.5.1 and is based on the method used in [425]. Modifications to this protocol
are discussed in this section.
3.5.1.1 Validation of Fluorescence Detection Strategy
For this work, small molecules which perturb Aβ40 formation need to be detected even
if the effects are very subtle. ThT fluorescence was monitored using a single point in
the centre of each well as a representative value for fluorescence intensity. To verify the
validity of this method a complete wellscan was collected at the end of an aggregation
experiment to assess aggregate distribution in the well.
Use of the Clariostar (BMG biotech) apparatus enabled measurement of ThT fluores-
cence at different locations within the same sample well. Experiments were conducted
under quiescent conditions and thus the distribution of aggregates across each well were
expected to be relatively even. Figure 3.20 shows the level of ThT fluorescence across
four wells containing samples of 20 µM Aβ40 in 50 mM ammonium acetate with 10
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µM ThT, and two control wells containing buffer and ThT only (see Section 2.2.5.1).
Samples had been incubated quiescently at 37 oC for 21 h.
Figure 3.20: 3D representation of amyloid distribution in sample wells.
The x-y plane represents the well surface with ThT fluorescence shown on the z-axis
and through a colour gradient of low to high (blue-red) levels of ThT fluorescence.
As expected, there was a marked increase in fluorescence level for wells containing Aβ40
indicating that aggregation had occurred. The surface levels shown in the graphs indicate
that aggregate distribution across the wells is random. The intensity of ThT fluorescence
of the single centre point of the wells was similar to the average of all the data collected
on a full wellscan. Based on this, single point data collection was validated.
3.5.1.2 Assessment of the Effect of DMSO on Aβ40 Aggregation
Many compound libraries store and provide compound stocks in DMSO due to its ver-
satility as a solvent. As the methods toolbox was complied specifically for use with
small molecules, it was important to assess the effect of low levels of DMSO on the in-
cluded methods. Moreover, it was essential to measure the effect DMSO had on peptide
aggregation.
To this end, Aβ40 aggregation was monitored using ThT fluorometry in presence of a
titration of DMSO percentages, Figure 3.21.
Figure 3.21 implies that concentrations of up to 10 % (v/v) DMSO have no effect on the
shape ThT curves which represent Aβ40 aggregation. At 20 % (v/v) DMSO the ThT
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Figure 3.21: DMSO titration effects on Aβ40 aggregation measured by ThT fluorescence.
Graphs showing the absolute (left) and relative (right) fluorescence intensity measured
when Aβ40 aggregates in 50 mM ammonium acetate, pH 6.8, at 37
oC, under quiescent
conditions with various percentages of DMSO; 0 % (v/v) (black), 1 % (v/v) (red), 2 %
(v/v) (orange), 3 % (v/v) (yellow), 5 % (v/v) (green), 10 % (v/v) (cyan), and 20 %
(v/v) (blue).
profile exhibits a longer lag time, and a shallower gradient implying DMSO may have
interfered with elongation of Aβ40 fibrils. Generally the maximum fluorescence level
reached decreased as DMSO percentage increased.
This result contributed to the incorporation of 2 % (v/v) DMSO in all samples and
controls in the toolbox. This ensured consistency across biophysical methods as this
was high enough to permit addition of up to approximately 200 µM of compounds (from
10 mM stocks in 100 % DMSO) to peptide samples but low enough to avoid interference
of DMSO with other biophysical methods (Sections 3.5.4.2, 3.5.5 and 5.1).
3.5.1.3 Assessment of Varying Preparations of Aβ40
Aβ40 aggregation is sensitive to the effects of impurities in sample preparation. Many
methods are implemented in the sample preparation to ensure the starting material is
monomeric which is vital for experimental reproducibility. For example the double SEC
purification of Aβ40 increases the reproducibility of observed ThT kinetics as contami-
nation with oligomeric materials is removed [383]. Others have used 10 mM NaOH and
sonication for this purpose [372].
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To test the effects of sample preparation, ThT fluorometry was used to monitor Aβ40
aggregation of three samples of Aβ40 which were prepared differently, Figure 3.22. Aβ40
was prepared in three ways; direct solubilisation in 50 mM ammonium acetate after one
SEC or two purification steps, or from a 10 mM NaOH stock which was sonicated for 5
minutes in a water bath at 25 oC.
Figure 3.22: Effect of preparation methods of Aβ40 on aggregation.
ThT fluorescence of Aβ40 aggregation when Aβ40 is prepared from two sequential SEC
purification runs (black), one SEC purification (red), or from a sonicated sample
(blue). All samples contained 20 µM ammonium acetate, pH 6.8, 10 µM ThT, and 2 %
(v/v) DMSO. Samples were monitored at 37 oC, quiescently.
Figure 3.22 shows there are differences in the kinetics observed when Aβ40 is prepared
in different ways and thus it is important that samples are prepared by exactly the same
method for comparability. It was decided to use two rounds of SEC to prepare Aβ40 to
align with previous studies in our laboratory [425] and others [383].
3.5.1.4 Assurance of Sample Consistency through Testing of Aβ40 Solubil-
isation Methods
Within a single ThT assay, experimental variation is observed between replicates (e.g.
Figure 3.21). Minimisation of this variation would permit the detection of subtle changes
in the Aβ40 kinetic profiles caused by different small molecules. A possible cause of
variation between sample replicates within a plate was the incomplete solubilisation of
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lyophilised protein. Thus, an alternative Aβ40 solubilisation approached were consid-
ered.
At the end of the multi-step procedure for the purification of Aβ40 (Section 2.2.2.3),
the peptide is a dry, white powder. Owing to the aggregation propensity of Aβ40, it is
important to obtain complete solubilisation quickly on buffer addition to avoid areas of
local high concentration which would initiate aggregation. However on solubilisation of
this powder in aqueous buffers, e.g. 50 mM ammonium acetate, pH 6.8, insoluble flakes
were observed. For non-amyloid samples, proteins can be left to go into solution over
time or can be heated or agitated to encourage solubilisation. These are not possible
with Aβ40 due to its amyloidogenic potential.
To explore alternative solubilisation methods, Aβ40 powder was solubilised in 100 %
DMSO to form a 21 mg/ml solution and then diluted into the final buffer to form a
solution of 20 µM Aβ40 in 50 mM ammonium acetate, pH 6.8, with 2 % (v/v) DMSO.
DMSO was chosen as small molecule stocks are commonly solubilised in DMSO, thus
would be in the sample buffer when probing small molecule effects on aggregaiton.
Moreover, the results in Section 3.5.1.2 revealed that ThT fluorometry of Aβ40 could
tolerate DMSO addition upto 10 % (v/v).
Samples of 20 µM Aβ40 prepared by solubilisation directly into 50 mM ammonium
acetate or via DMSO, are shown in Figure 3.23.
The data presented in Figure 3.23 show that both methods of Aβ40 solubilisation lead to
the measurement of similar ThT data. As the change in ThT profile was not significant,
either method could be used for this project. Owing to the solvation efficiency of DMSO,
solubilisation into 100 % DMSO - to form a 21 mg/ml (4.7 M) stock - was used in this
work. This avoided the possibility of local high concentrations of Aβ40 forming on
solubilisation in aqueous buffer. Hence Aβ40 is more likely to be monomeric at the start
of the aggregation reaction
3.5.1.5 The Influences of Buffer Choice on Aggregation Kinetics
It is well known that aggregation kinetics can be highly sensitive to alterations in buffer
conditions [426, 427]. The majority of the ThT fluorometric assays in this thesis are
conducted in 50 mM ammonium acetate, pH 6.8, at 37 oC which is a compatible buffer
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Figure 3.23: Effects of different solubilisation techniques on the reproducibility of amy-
loid aggregation kinetics.
Absolute (left) and relative (right) ThT fluorescence monitoring of Aβ40 aggregation
when the peptide is prepared by solubilisation in DMSO (black) prior to dilution into
50 mM ammonium acetate, pH 6.8, with 10 µM ThT or when Aβ40 is solubilised
directly in aqueous 50 mM ammonium acetate, pH 6.8, with 10 µM ThT (red).
for mass spectrometry and the creation of TEM grids. However, to align with optimised
NMR conditions (Section 5.1) and published NMR data [372], 1H15N-HSQC experiments
presented later in this thesis were performed in 20 mM sodium phosphate, pH 7.4, at 5
oC. Owing to this it was important to monitor the effect of these changes in buffer on
Aβ40 aggregation to enable data interpretation between methods.
There are multiple contrasts between the two solutions: buffer components, pH, temper-
ature, ionic strength, and peptide concentration. Determination of contributions from
each contrasting component is not essential for this work. Rather, this section presents
some controls to aid data interpretation later on (Section 4.6.1).
Firstly aggregation of 20 µM Aβ40 in each buffer was monitored at 37
oC.
With equal amounts of Aβ40 present Figure 3.24 shows there is a shorter lag time for
Aβ40 aggregation in 50 mM ammonium acetate, pH 6.8 than for Aβ40 in 20 mM sodium
phosphate, pH 7.4 buffer. This could be due to the difference in ionic strengths of
the two solutions. There was a stark difference in ionic strength of these buffers; 50
mM ammonium acetate had an ionic strength of 50 mM, whereas the 20 mM sodium
phosphate buffer had an ionic strength of 3 M hence there are many more charged ions
in the sodium phosphate buffer.
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Figure 3.24: Effect of buffer on Aβ40 aggregation.
Absolute (left) and relative (right) fluorescence levels measured when Aβ40 aggregates
under quiescent conditions at 37 oC in 50 mM ammonium acetate, pH 6.8 (black) or in
20 mM sodium phosphate, 0.02 % (v/v) NaN3, 0.5 mM EDTA, pH 7.4 (red).
ThT fluorometry was also used to monitor Aβ40 aggregation in each buffer at varying
temperatures, Figure 3.25.
As expected, Aβ40 aggregates more quickly at higher temperatures in both buffers as is
evident from the decreased lag times at 37 oC. Interestingly there is a large increase in
maximum fluorescence for Aβ40 in ammonium acetate at 37
oC which is not observed
at the lower temperatures tested. This pattern is not evident in the sodium phosphate
buffer samples. One possible explanation for this is that, at 37 oC in ammonium acetate
buffer, Aβ40 forms β-sheet-containing fibrils with a morphology more conducive to ThT
binding and enhanced fluorescence.
The lag time for Aβ40 at 37
oC (∼ 2.5 - 3.5 h) in ammonium acetate is comparable with
Figure 3.24. For Aβ40 in sodium phosphate buffer at 37
oC the lag time is approximately
2 - 2.5 h, which is twice as fast as observed previously 4.0 - 6.5 h in Figure 3.24 which
can be explained logically due to the higher protein concentration leading to faster
aggregation. This concentration was tested to correlate with the NMR experimental
concentration described later in Chapter 5.
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Figure 3.25: Effect of temperature on Aβ40 aggregation in different buffers.
Absolute (left) and relative (right) fluorescence measured when Aβ40 aggregates in
either 50 mM ammonium acetate, pH 6.8 buffer (top), or 20 mM sodium phosphate,
pH 7.4 (bottom) under quiesent conditions. Measurements of aggregation at 37 oC
(red), 30 oC (purple), and 26 oC (blue) are shown on each graph.
3.5.1.6 Compatibility of ThT Fluorometry as an Indicator of Compound
Effects on Aβ40 Aggregation
There is a wealth of studies investigating how Aβ40 aggregation is affected by the addi-
tion of small molecules. EGCG (a known inhibitor of Aβ40 aggregation [381, 428]) and
aspirin (a compound known not to affect Aβ40 aggregation kinetics [429]) were used to
demonstrate that the ThT fluorometric assay set-up was functional, Figure 3.26. Each
compound was dissolved to form a 10 mM stock in 100 % DMSO to imitate the con-
ditions of library compounds which will be used later in this work. The Aβ40 peptide
(which had been purified from two sequential SEC experiments) was also solubilised in
100 % DMSO before dilution in 50 mM ammonium acetate, pH 6.8. Data were recorded
at 37 oC.
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Figure 3.26: Monitoring effect of EGCG or aspirin on Aβ40 aggregation by ThT fluo-
rescence.
The absolute (left) and relative (right) ThT fluorescence profiles of Aβ40 aggregation
alone (black), or with 100 µM EGCG (blue) or 100 µM aspirin (red).
From the absolute fluorescence graph it is evident that the addition of EGCG prevents
aggregation of Aβ40 whereas aspirin has no effect. However, the effect of EGCG is
masked in the normalised data, and in fact shows a faster rate for the fibril elongation.
This highlights the need to monitor both absolute and relative fluorescence levels to
maximise the information gain from ThT fluorometry.
3.5.2 Development of Quantification Strategies to Extract Objective
Measures of Aggregation Kinetics from ThT fluorometry
After use of ThT fluorometry as a screening method to identify small molecules which
perturb amyloid aggregation, the ThT assay can be used again to verify reliability of
compound effects and to analyse the effects on the kinetic profile.
Qualitative assessment of the ThT fluorometry profiles was used as a fast and clear
route to observe effects on Aβ40 aggregation. However, this assessment was subjective
and thus the extraction of measurable parameters - Maximum fluorescence, T50, and lag
time - which were altered by small molecule addition was necessary for more stringent
use of the assay.
There are three main measures used: Maximum fluorescence, T50, and lag time. The
maximum fluorescence level is the steady-state intensity value once the reaction has
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reached completion. The plateau observed is the fluorescence emitted at the final equi-
librium of Aβ40 in solution and in fibril form. In this work, the mean value of the final
20 data points measured was taken as the ‘maximum fluorescence level’. This could
represent fibril yield [330], but owing to the unreliability of this - as previously discussed
- should be regarded with care. As the reaction is usually fully aggregated after approx-
imately six hours, continued measurement until 21 h enables any decay in fluorescence
to be observed in case the fibrils or β-sheet rich aggregates formed are unstable. If such
decay is detected qualitatively from the curve shape then alternate routes to measure the
maximum fluorescence may be necessary. The fluorescence values on different plates can
vary 10-fold meaning error values are not comparable. Thus all quantitative analyses
were made relative to the mean of the Aβ40 alone readings on each plate on normalised
axes.
The T50 and lag time values are more linked. The T50 value is the time when the
intensity of the fluorescence reached half of the maximum fluorescence level. If the data
are normalised this is the time when the fluorescence reaches 0.5. In order to calculate
the lag time a script was created where upon a tangential line was extended from the
T50 coordinate to intersect with the x-axis (Figure 3.27a). Owing to noise in the data
collected, there were some clear anomalies reported (Figure 3.27b). Other routes were
considered for objectively calculating the lag time. Theoretically the T50 coordinate
should fall at the centre of the exponential segment of the sigmoidal curve at which
should also be the point of the maximum first differential (i.e. the steepest point on
the graph). In real data the T50 (point of half maximum fluorescence) and the point
of the maximum first differential often do not fully align. Owing to this difference, the
script was altered to extend a line from the point of maximum first differential to the
x-axis (Figure 3.27c). This provided a more accurate approximation of many of the lag
times. For data sets where neither calculation of the lag time was suitable, linear fitting
was used as is prominent in the field [76, 134, 430]. A major issue with linear fitting
is that the linear potion of the collected data can be as little as 10 % of the data set
and the boundaries of the linear potion must be monitored by eye which adds a level
of subjectivity to the quantitative measure. In this work linear fitting has been used
to obtain values of the lag time for curves which were not amenable to either of the
aforementioned script methods of calculation.
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Figure 3.27: Schematic for lag time measurement
Illustrative ThT profiles demonstrating challenges in quantification measurement. The
extended tangent (red line) is shown for the determination of lag time (green cross)
based on the T50 value (blue cross) in a) an ideal curve and b) a non-deal curve
whereby the method does not yield an accurate lag time approximation. c) Use of the
maximum first differential (pink cross) to determine lag time.
3.5.3 Development of an SDS-PAGE-based Method to Measure the
Yield of Aβ40 Aggregation
To quantify the extent of aggregation, a fibril yield assay was developed from an es-
tablished protocol used in our laboratory which relies on the different sedimentation
properties of large aggregates (e.g. fibrils) and soluble species (e.g. monomer or small
oligomers) when subjected to centrifugation. The simple technique consists of three
stages: centrifugation (14,100 rpm, at 25 oC for 10 minutes) to separate insoluble and
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soluble species, SDS-PAGE to visualise peptide location (i.e. in the insoluble or soluble
phase), and densitrometry to quantify the amount of peptide in each phase.
Optimisation steps which were implemented to achieve the reproducible assay results
demonstrated in Figure 3.28 included consideration of sample containers, centrifugation
speed, time, and temperature, use of precision Gel tips for phase separation, and amount
of sample loaded onto the SDS-PAGE gel. Initially, the protocol had only been applied
at the start and end of aggregation reactions, using samples directly transferred to and
from ThT fluorometry plates. Attempts were made to quantitatively probe the extent
of aggregation during different parts of the ThT fluorometry aggregation profile, but
these were not successful.
Figure 3.28 shows an example of the fibril yield assay (described in detail in Section
2.2.5.3) used at the end of an aggregation reaction (21 h after 20 µM Aβ40 as solubilised
in 50 mM ammonium acetate, pH 6.8, and incubated quiescently at 37 oC).
Figure 3.28: Demonstration of the Optimised Fibril Yield Sedimentation Assay.
SDS-PAGE gel showing the distribution of Aβ40 (red arrow) at the end of an
aggregation reaction. W = whole sample, S = soluble fraction, and P = the insoluble,
pelleted fraction. L = ladder.
The gel image shows Aβ40 in the ‘Whole’ sample taken before centrifugation. The
whole sample was centrifuged to separate ‘Soluble’ and insoluble, or ‘Pellet’, samples.
The ratio of band intensity of Aβ40 in the Soluble and Pellet lanes indicates the extent of
aggregation. The presence of strong band - corresponding to Aβ40- in the pellet sample
indicated that essentially all of the peptide is present as insoluble aggregates.
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3.5.4 Transmission Electron Microscopy to Qualitatively Observe Ag-
gregate Forms
TEM was incorporated in to the methods toolbox to probe for formation of fibrillar
aggregates as it can be used to directly observe aggregate forms. In this work TEM
was conducted at 1,500x and 10,000x magnifications to image aggregate morphology.
At these magnifications heterogeneous, fine fibril morphology (i.e. protofibril number,
or twist pitch) cannot be observed, however, variation in gross fibril polymorphs can be
noted (i.e. fibrillar or amorphous aggregates, and fibril lengths). As TEM was conducted
using ThT fluorometry samples at the end of the reaction period (after 21 h of quiescent
incubation at 37 oC), it was important to ensure that these samples were amenable to
grid preparation (Section 2.2.5.2) and imaging, Figure 3.29.
Figure 3.29: Gross morphology of Aβ40 fibrils visualised by TEM
. TEM images of negatively stained carbon coated grids with samples of Aβ40 taken
directly from ThT analysis after 21 h. Left: A TEM image which captures two distinct
fibril morphologies formed when Aβ40 aggregates in 50 mM ammonium acetate, pH
6.8, 2 % (v/v) DMSO, 10 µM ThT after 21 h at 37 oC. The image was taken at 1,500x
magnification. Middle and right: 10,000x magnification images of the fibril
morphologies, highlighted by black and red boxes.
This figure (Figure 3.29) shows two contrasting fibril deposits of Aβ40 next to each other
on the same grid. Highlighted in black are short (∼200–500 µm), bunched fibrils, and
in red, more disperse, elongated fibrils (> 2 mm in length) are observed. The images in
this figure confirm that the Aβ40 produced can form fibrillar aggregates, that the ThT
samples are amenable to TEM imaging and that fibril heterogeneity occurs and can be
observed.
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3.5.4.1 Investigation of the Diversity of Fibril Morphology in Different
Preparations using TEM
For some duplicate ThT experiments the final ThT signal observed was up to 10-fold
more intense than for other replicates. There is contrasting evidence in the literature
suggesting that such intensity changes could be caused by changes in fibril yield, or
variation in ThT interaction with fibrils of different morphology. To check whether there
were observable differences in morphology, TEM was conducted on two Aβ40 samples,
(Figure 3.30), one which exhibited a relatively low fluorescence intensity (5000 AU) and
one which exhibited high fluorescence intensity (60,000 AU) for the same 20 µM Aβ40
sample in 50 mM ammonium acetate, pH 6.8.
Figure 3.30: Aβ40 aggregate morphology for different scales of ThT fluorescence.
TEM images of negatively stained carbon coated grids with samples of Aβ40 apo taken
directly from ThT analysis after 21 h. Images on the top were from a ThT assay
sample which gave a relatively low maximum ThT fluorescence (5000 AU) and images
below were from a comparable ThT sample which gave a high ThT fluorescence
(60,000 AU). Black, blue, and red boxes show magnified images.
Fibrillar aggregates are present in both samples, however are there differences in their
distribution. For the low-intensity sample (Figure 3.30, top row) the fibril deposit is very
clumped whereas the high-intensity sample (Figure 3.30, bottom) show well dispersed
fibrils. This could affect ThT binding as there are more binding sites accessible in the
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dispersed fibril sample, thus this could explain the higher fluorescence levels. Moreover,
for the low-intensity sample, white circular deposits are visualised, (Zoomed image,
Figure 3.30, red box). It has been suggested these are oligomers which could also
be a contributing factor to the lower fluorescence observed as there was less protein in
fibrils for ThT binding. Both the low-intensity and high-intensity samples were prepared
similarly, and the grids were prepared after 21 h when a steady state of fluorescence was
reached. The contrasts observed show the sensitivity of Aβ40 amyloid formation to
minor variations in sample preparation.
The sensitivity of Aβ40 aggregation to subtle changes in solution implied the effect of
different buffers - which influenced Aβ40 aggregation kinetic reported by ThT fluorecence
(Section 3.5.1) - was likely to influence Aβ40 aggregate morphology. To test this, the
aggregates formed under the ThT, fibril yield, and MS conditions (20 µM Aβ40 in 50
mM ammonium acetate. pH 6.8), were compared to aggregates formed in NMR sample
buffer (50 µM Aβ40 in 20 mM sodium phosphate, pH 7.4) at a range of temperatures,
Figure 3.31.
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Figure 3.31: The effect of buffer on Aβ40 aggregate morphology by TEM.
Caption on next page.
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Figure 3.31: TEM images of Aβ40 aggregates on negatively-stained, carbon-coated grids.
Aβ40 samples were prepared at either 20 µM in 50 mM ammonium acetate, pH 6.8 (black
boxes) or at 50 µM in 20 mM sodium phosphate, pH 7.4 buffer (green boxes), in the
presence of 2 % (v/v) DMSO and 10 µM ThT. Samples were incubated quiescently at
37 oC (red), 30 oC (purple), or 26 oC (blue) for 21 h before grid preparation (Section
2.2.5.2). Top: Aβ40 aggregation profiles - by ThT fluorescence - reproduced from Figure
3.25. Bottom: TEM images of aggregates formed in each buffer at each temperature
denoted. The top row of images in the black and green boxes were taken at 1,500x
magnification and those below at 10,000x magnification.
The aggregation profiles recorded by ThT fluorescence in Section 3.5.1 are reproduced in
this figure for convenience. The fibrils formed in ammonium acetate at each temperature
tested are similar and are well dispersed within clusters. The fibrils observed at 10,000x
magnification - for fibrils formed in ammonium acetate - at 37 oC (zoom of red box),
are thicker (∼20–45 nm) than those observed at the lower temperatures (10–15 mm).
Fibrils which were formed in the sodium phosphate buffer contrast to those formed in
ammonium acetate. Here the fibril clumps have more defined edges with lots of short
(40–85 nm) fibrils forming ringed arrangements surrounding clusters of fibrils.
NMR data collection - later in this work - was conducted at 5 oC, however, no fibrils
were observed in TEM samples prepared in NMR buffer at this temperature after one
week.
Overall, these results confirm that fibrillar aggregates are formed in both the ammonium
acetate buffer and the sodium phosphate buffer.
3.5.4.2 Investigation of Effect of DMSO on Aβ40 Aggregate Morphology
Investigation of DMSO effects on Aβ40 fibril morphology was conducted as it was the
solvent that small molecules - which were used to modulate Aβ40 aggregation behaviour
- are solubilised in. According to the ThT analysis (Section 3.5.1, and reproduced here
for convenience) DMSO only perturbs fibril formation at 20 % (v/v) DMSO. However,
TEM was performed to assess whether lower levels of DMSO can have effects which are
invisible to ThT fluorometry. Figure 3.32 shows fibrils formed after 21 h of quiescent
incubation at 37 oC of 20 µM Aβ40 in 50 mM ammonium acetate, pH 6.8, with 10 µM
ThT, in the presence of increasing percentages of DMSO.
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Figure 3.32: Aβ40 aggregates formed in varying DMSO concentrations visualised by
TEM.
The Aβ40 aggregation profile by ThT fluorescence for the previous DMSO titration is
reproduced here from Figure 5.5. TEM grids were made and imaged for various DMSO
concentrations: 0 % (v/v) DMSO (black), 2 % (v/v) DMSO (orange), 10 % (v/v)
DMSO (cyan), and 20 % (v/v) DMSO (blue).
Figure 3.32 shows that samples containing 0 %, 2 %, and 10 % (v/v) DMSO present
typical fibrillar aggregates which are in well-dispersed clusters. In the presence of 20 %
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(v/v) DMSO however, the aggregate clusters are more indicative of amorphous aggre-
gates even though some fibrillar species are still clear.
The TEM data correlate well with the ThT fluorometry assay in Section 3.5.1 whereby
DMSO shows no effect on Aβ40 aggregation up to 10 % (v/v) DMSO. Thus TEM was
suitable for use in the toolbox as it was not perturbed by 2 % (v/v) DMSO which was
present in small molecule-containing samples on application of the toolbox.
3.5.4.3 Comparison of Small Molecule Effects on Aβ40 Aggregates
Previously, TEM has been implemented to study the effects of small molecules on Aβ40.
To confirm that use of TEM was compatible with small molecule investigation of Aβ40
aggregation in this work, two compounds with well-documented effects on Aβ40 aggre-
gation - Aspirin and EGCG - were used, Figure 3.33. As previously, ThT fluorometry
samples which contained a 5:1 ratio of compoud:peptide were used directly to create
TEM grids.
Figure 3.33 shows representative images from samples of Aβ40 aggregates in the presence
and absence of either Aspirin of EGCG (samples prepared from ThT fluorometry samples
as previously described). The Aβ40 apo sample (black) shows two morphologies and is
comparable to the Aβ40 apo samples previously shown (Figure 4.29). Aspirin shows no
effect on Aβ40 aggregation by ThT fluorometry (reproduced in Figure 3.33), however
when Aβ40 was left to aggregate in the presence of Aspirin the fibril morphology observed
was surprisingly different; only thin fibrils of ∼125–400 nm are observed. In contrast,
when EGCG was present, aggregate heterogeneity was evident. The top panel shows
within a single image the presence of short, clumped fibrils with a long narrow fibril
across the grid. There is also evidence of oligomeric species, which were prevalent across
the entire grid and exemplified in the middle panel. This is consistent with previous
literature in that EGCG is known to cause Aβ40 to form off-pathway aggregates. The
bottom panel shows an extended fibril indicating that not all of the Aβ40 is directed off
of the amyloid pathway despite the significant decrease in ThT fluorescence when Aβ40
aggregates in the presence of EGCG (reproduced in Figure 3.33). This could explain the
sigmoidal curve observed when ThT fluorescence was plotted on a relative scale (Figure
3.26).
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Figure 3.33: Aβ40 aggregate morphology formed in the presence of EGCG or aspirin
observed by TEM.
TEM images of Aβ40 aggregates on negatively-stained, carbon-coated grids.
Aggregates were formed from 20 µM Aβ40 in the absence (black) or presence of 100
µM EGCG (red) or aspirin (blue) in 50 mM ammonium acetate, pH 6.8, 2 % (v/v)
DMSO at 37 oC under quiescent conditions.
TEM is especially powerful in combination with ThT fluorometry data and thus is a
vital part of the investigative toolbox.
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3.5.5 ESI-IMS-MS Analysis of the Interactions Between Small Com-
pounds and Aβ40
ESI-IMS-MS was performed by Dr P. Knight and Dr Y. Xu at the University of Leeds
using a published protocol [356] without optimisation. It was important to validate the
reproducibility of the published method with the new samples of Aβ40 prepared herein.
The lyophilised powder was solubilised in 50 mM ammonium acetate, pH 6.8, to form
a 32 µM Aβ40 solution. The results of ESI-IMS-MS analysis, in Figure 3.34, show the
mass spectrum and drift scope of the newly prepared Aβ40 sample.
Figure 3.34: Mass spectrum and drift scope of Aβ40.
Observation of Aβ40 monomer, dimer, trimer and tetramer states by mass
spectrometry using ESI-MS (left) and ESI-IMS-MS (right). Mass spectrometry was
kindly conducted by Dr Patrick Knight (University of Leeds).
Figure 3.34 shows the expected profile of Aβ40 [356]. There is evidence of the monomer
in different charge states as well as low order oligomers; dimers, trimers and tetramers.
There is also evidence of larger oligomers, but these have poorer resolution. Using
IMS, the collisional cross section of species has been extracted. Analysis of these data
indicated the presence of two conformations of the Aβ40
4+ monomer. This is evident in
the drift scope by the extended band for Aβ40
4+. More compact species have a shorter
drift time than more extended conformers.
Evidently ESI-IMS-MS is a powerful technique for investigation of species formed in
the early stages in Aβ40 aggregation. Following the protocol developed by Young et al.
[358], two compounds - EGCG and Aspirin - were added at a 5:1 compound:peptide
ratio into the Aβ40 sample. These compounds were EGCG which is known to inhibit
Aβ40 aggregation, and aspirin which is expected not to interact with Aβ40, Figure 3.35.
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Figure 3.35: ESI-MS of Aβ40 in the presence of EGCG or Aspirin.
32 µM Aβ40 was mixed at a 5:1 compound:peptide ratio in 50 mM ammonium acetate,
pH 6.8 and applied to ESI-MS. Vertical bars highling Aβ40 monomer with different
charge states indicated (blue, green, and pink), and a dimer (red). L = ligand. Mass
spectrometry was kindly conducted by Dr Yong Xu (University of Leeds).
The ESI-MS results show evidence of multiple copies of EGCG binding to Aβ40 which is
similar to published data [316], and no evidence that aspirin binds to Aβ40. According to
[316] EGCG exhibited behaviour showing non-specific binding as multiple copies of the
small molecule bound to Aβ40, implying there is more than one binding site. Conversely,
EGCG may have interacted with Aβ40 a single, specific binding site and then associated
to more copies of EGCG, possibly through aromatic ring stacking interactions.
Incorporation of ESI-IMS-MS into the toolbox added insight into the stoichiometry of
small molecule interactions with monomer and oligomer states. Moreover, drift scope
analysis revealed the effects small molecules have on monomer and oligomer populations.
3.5.6 Tripartite Aβ-lactamase Assay to Provide in vivo Information
on Aβ40
The final method in the toolbox is the β-lactamase tripartite assay [337], described in
detail in Section 1.4.2. This provides a perspective into small molecule effects on peptide
aggregation in the E. coli periplasm. Originally developed to screen for mutants with
enhanced stability [431, 432], it was later applied to probe small molecule effects on
hIAPP aggregation, [337]. A great benefit of this assay is that it does not require purified
protein. However, without additional information provided by the other methods in the
toolbox, the mechanism of compound action cannot be deduced.
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Figure 3.36 shows the effect on E. coli growth when hIAPP is inserted into the β-
lactamase construct compared to when a non-aggregation-prone Gly-Ser linker is in-
cluded. The results show that the incorporation of hIAPP into β-lactamase reduces the
ampicillin resistance of the bacteria. This implies that aggregation of hIAPP inactivates
β-lactamase in the periplasm. The steric hindrance caused, prevents the two domains of
the enzyme from coming together and therefore the ability to cleave the β-lactam ring
in ampicillin is lost. On the addition of 200 µM curcumin, a known hIAPP inhibitor
[433, 434], some of the ampicillin resistance was regained as shown by the increase in
maximum cell dilution where growth was still observed. This suggested that curcumin
could interfere with and limit the extent of hIAPP aggregation as was consistent with
published literature [433, 434].
Figure 3.36: Demonstration of the tripartite β-lactamase assay with hIAPP and cur-
cumin.
The effect of incorporation of the hIAPP sequence in the β-lactamase construct on cell
survival (blue) and a non-aggregative Gly-Ser linker (black). The effect on cell growth
when 200 µM curcumin is added to the β-lactamase construct (red) shows some
restoration of cell survival. n=1.
Since the focus of this thesis moved to Aβ40 the DNA sequence of Aβ40 was inserted
into the β-lactamase construct. Preliminary results indicated that the assay needed some
optimisation in order to be used to investigate compound effects on Aβ40 aggregation.
On incorporation of Aβ40 into the construct, the bacteria were highly susceptible to
ampicillin and no growth was observed after the second increment of ampicillin was
added (Figure 3.37), even when the cell concentration was not diluted. It was important
to observe the level of cell growth so any improvements made by compounds could be
quantified.
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Figure 3.37: A comparison of the Tripartite β-lactamase assay with a hIAPP or Aβ40
insert.
Effect on cell survival when the Gly-Ser linker is in the β-lactamase construct (black),
and when it is replaced with either hIAPP (blue), or Aβ40 (red). n=1.
The conditions which were varied included the reduction in percentage of arabinose
used to induce expression of the construct. This was trialled under the hypothesis that
there would be a lower concentration of Aβ40-containing β-lactamase in the periplasm if
less was expressed, leading to a reduction in aggregation. To this end, the length of the
incubation period after induction of expression before plating the bacteria onto solid agar
was also reduced. After multiple optimisation trials, the most successful change was to
decrease the amount of ampicillin added. Reducing the increment concentration from 20
µg/ml to 2.5-5 µg/ml created assay conditions conducive to measurement, Figure 3.38.
The assay was concurrently optimised for used with Aβ42 to enable possible extensions
to this work.
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Figure 3.38: Optimised tripartite β-lactamase assay for use with an Aβ40 insert
Cell survival levels observed for the β-lactamase constructs with 2.5-5 µg/ml
increments of ampicillin are added. n=3.
Once the assay was optimised, EGCG and aspirin were used to test whether a distinction
could be observed between the two compounds in the β-lactamase assay. As a positive
control, a titration of EGCG was applied to the assay, Figure 3.39.
Figure 3.39: A titration of EGCG in the Aβ40 tripartite β-lactamase assay
Effect of EGCG on Aβ40 aggregation through cell survival. n=1.
This figure showed that as more EGCG was added, there was more cell survival at
higher cell dilutions. This implied that EGCG did indeed disrupt the aggregation of
Aβ40. As a negative control, 200 µM aspirin was also tested in the assay as shown in
Figure 3.40 where there is little alteration observed in the growth levels of cells with
the Aβ40 β-lactamase construct in the presence or absence of aspirin, suggesting that
aspirin does not interfere with Aβ40 aggregation.
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Figure 3.40: Cell survival monitored using the tripartite β-lactamase assay in the pres-
ence of aspirin
The effect of aspiring on Aβ40 aggregation monitored indirectly using the optimised
tripartite β-lactamase assay. n=1.
The β-lactamase assay was optimised for use with Aβ40 and tested using EGCG and
aspirin. The assay was therefore included in the methods toolbox as it probed unique
information on whether small molecules can affect Aβ40 aggregation in a more complex
environment.
3.6 Discussion
The overall aim of work in this chapter was to collate a complementary set of methods
to form a toolbox which could be applied as a work strategy in further research. The
brief for creation of the toolbox was that it needed to be able to screen for and verify
small molecule effects on amyloid aggregation and it needed to be compatible with the
study of small amyloidogenic IDPs. To this end, the work presented in this chapter has
not only brought together this toolbox, but has demonstrated its use and suitability for
purpose.
At the outset, two small amyloidogenic IDPs, Aβ40 and hIAPP, were selected as ex-
emplar peptides on which the toolbox could be applied. Purification of these peptides
enabled their use as a tool to aid in the preparation and optimisation of the toolbox.
Both IDPs had been purified in the literature by contrasting multistep purification meth-
ods [383, 384, 396]. Although optimisation of various steps enabled effective purification
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of Aβ40, hIAPP was more elusive and thus it was decided only to proceed with Aβ40
for this project. Further optimisation to the current hIAPP purification protocol should
focus on ensuring complete cleavage of the leader-hIAPP construct and stringent sepa-
ration of the leader-hIAPP-CONH2 construct from hIAPP-CONH2. This could be done
through thorough optimisation of the Endoproteinase Glu-C V8 enzyme cleavage step,
either by condition optimisation or further alterations in construct sequence to promote
V8 interaction. An alternative strategy could be to use a different cleavage enzyme.
Similarly to the Aβ40 preparation, the addition of an N-terminal amino acid may not
perturb aggregation but may improve purification success. For example the addition
of an N-terminal Met can be found on many recombinantly produced peptides, and
there are strategies for its removal if it influences peptide behaviour [435]. However,
exploration of this route may be impeded by the inability to successfully produce native
hIAPP which would be need for construct comparison. Such comparison would therefore
rely on the purchase or production of synthetic peptides.
Purification of Aβ40 was much more successful and the optimisation steps taken im-
proved yield from 2–4 mg/L to 5–7 mg/L, namely the reapplication of the flowthrough
and wash 1 fractions to chitin resin. Further optimisation of the Aβ40 purification to
reduce the temporal inefficiencies during the ion exchange step could be investigated. As
mentioned previously, recent publications by Warner et al., [436] and Huang et al., [397]
developed a RP-HPLC method to purify recombinant Aβ40 (and Aβ42). This method
was quicker and higher yielding than the purification strategy used in this work but
owing to the time of publication, and the effect of peptide preparation on aggregation
kinetics - observed by ThT fluorescence shown in this chapter-, the method was not
implemented in this study.
On successful purification of Aβ40, the methods which make up the toolbox were cho-
sen. Consideration of the orthogonal perspectives which each method could provide was
paramount to the creation of an efficient methods strategy to investigate small molecule
effects on Aβ40, the example amyloid IDP.
Firstly the screening method chosen was the ThT fluorescence assay. Use of this assay
to monitor amyloid aggregation kinetics is prevalent in the literature [321, 323, 425,
437] (and references therein) and have been used to assess small molecule effects on
amyloid peptides [304, 438–441] including Aβ40 [442, 443]. The assay was amenable to
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be relatively high throughput making it suitable for use as a screen. In spite of its speed,
the assay is highly data efficient in that a large amount of information can be interpreted
from the ThT fluorescence data including whether aggregation is inhibited or enhanced,
and if so whether the small molecule is acting during primary nucleation, secondary
nucleation or elongation [76, 134]. As discussed in section 1.4.1 and in this chapter, the
ThT assay is not infallible but has a propensity for false positive results when screening
for small molecule inhibitors of amyloid aggregation. This was not problematic as other
methods in the toolbox, such as TEM - which shows the qualitative morphology of
the aggregates formed-, and the SDS-PAGE fibril yield assay - which quantified the
aggregated species-, were able to verify implication reported by ThT fluorescence.
The assembled toolbox entailed both TEM and the SDS-PAGE fibril yield assay. Ad-
ditionally the β-lactamase tripartite assay was included to provide more physiological
insight into whether a small molecule could influence Aβ40 aggregation. Together these
methods could robustly confirm whether a small molecule was indeed able to affect Aβ40
aggregation. The final part of the toolbox included methods which could provide insight
into the ensemble of Aβ40. ESI-IMS-MS was incorporated to reveal binding stoichiome-
try and oligomer distribution, and 1H15N-HSQC were used to probe for residue-specific
information such as binding site and binding affinity. On amalgamation of data provided
by all of these methods, an informed decision could be made on which compounds to
take forward for extensive structural investigation by NMR (Chapter 5).
This chapter presented how each the methods were optimised for use in the toolbox and
key controls were conducted using EGCG and Aspirin to verify that the toolbox could
be used to find small molecule modulators of aggregation. For example, the Aβ40 insert
in the tripartite β-lactamase assay increased the sensitivity of the E. coli to ampicillin,
the concentration of which was therefore decreased. Also buffer conditions and peptide
preparation methods were considered, such as techniques to ensure peptide species were
monomeric at the start of experimentation. Moreover, methods to quantify the data
were developed, for example, determination of the lag time.
These experiments have demonstrated the readiness of the toolbox for monitoring com-
pound effects on Aβ40 aggregation. In the next chapter the toolbox will be applied to
compounds which have not been studied for effects on Aβ40 aggregation with the aim of
demonstrating the application of the tool box on compounds with unknown effects on
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Aβ40 aggregation. This toolbox also has the potential to identify novel compounds which
affect Aβ40 aggregation which could direct later research in the field and ultimately lead
to a better understanding of the Aβ40 aggregation mechanism.
Chapter 4
Screening for Novel Modulators
of Aβ40 Aggregation
4.1 Objectives
The previous chapter highlighted that the investigation of amyloidogenic, intrinsically
disordered peptides (IDPs), such as hIAPP and Aβ40, was possible with careful optimi-
sation of well-established, biophysical techniques. In this chapter these methods were
implemented together as a robust work-flow to identify small molecules which affect
the aggregation of Aβ40. After identifying small molecules which affect Aβ40 amyloid
aggregation, the effects the compound has on aggregation were probed. This ultimately
contributes to the identification of conformations of Aβ40 which are important for pro-
moting or perturbing the Aβ40 amyloid aggregation mechanism. For example, a small
molecule which causes an increased rate of aggregation may cause this by skewing the
conformation probability distribution of Aβ40 into a more aggregation-prone state. On
the other hand, if the small molecule stabilises an on - or off-pathway state, the rate of
aggregation observed will be reduced. Irrespective of the nature of the effect on the ag-
gregation rate, the ability of a small molecule to cause a change in aggregation in itself is
of interest and could reveal more information on the mechanism of amyloid aggregation.
In order to proceed, a considered collection of small molecules were selected. Based on
previous literature [444] and work conducted by Dr K. Stewart, Dr L. Young, and Dr
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J. Saunders at the University of Leeds [356], five molecules were chosen as query com-
pounds to be used in focused screening. The first part of this chapter details why these
compounds were chosen and how the initial library of compounds was selected based
on the query compounds. This focus was used to bias a large in silico screen towards
finding inhibitors of Aβ40 aggregation, thereby increasing the likelihood of discovering
a small molecule which had an effect on Aβ40 aggregation.
After compound selection, an initial screen was conducted using the Thioflavin-T (ThT)
fluorometry assay described previously (Section 2.2.5.1) and a subset of the molecules
was chosen based on the qualitative and quantitative effects on aggregation observed in
the initial screen as described in Section 3.5.2. The multi-method approach described
in Chapter 3 (and summarised in Figure 4.1) was used to produce orthogonal data sets
which confirmed robustly which small molecules affected the aggregation of Aβ40 reliably
and provided insight as to how the compound might be interacting with Aβ40.
On the completion of these analyses, compounds which show the ability to perturb
amyloid aggregation reliably may be used as future tools in the study of the Aβ40
aggregation mechanism.
4.2 Introducing Focused Screening and Compound Library
Selection using ROCS.
It is impossible to test every compound in existence for an ability to modulate amy-
loid formation. A considered subset of compounds must be chosen to focus research
endeavours in order to make the study viable, if not comprehensive. This study used
focused screening to create and justify the selection of a small library of compounds
based on structural similarity to compounds which were already known to modulate
Aβ40 aggregation.
Compound screening is the process by which a large quantity of small molecules are
evaluated as part of a methodical survey for their suitability for a specific role or pur-
pose. A screen utilises known analytical assays with relevant controls to yield a reliable
biological result but lacks the rigour used in the final method, e.g. screening data are
rarely produced in triplicate. Development of screening assays to a high-throughput
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Figure 4.1: The multi-method approach to find and verify compounds which robustly
modulate amyloid aggregation.
format has been implemented widely with debatable levels of success [445], from bio-
chemical research to use within the pharmaceutical industry. Generally high-throughput
(HTP) compound screening will have a hit rate of approximately 0.1 % but this can be
increased when used strategically in combination with methods such as rational design,
modelling, fragment screening, and prior biochemical knowledge about the system. Fo-
cused screening is an effective strategy for improving the hit rate of HTP screens to
approximately 10 %. It is achieved by biasing the starting library of compounds so it is
not fully randomised. Prior knowledge of compound relationships, molecular structure,
interactions, chemistry, and/or reactivity can be used to skew the library towards the
attribute which is being investigated.
Rapid Overlay of Chemical Structures (ROCS) analysis [446] was used to bias the screen.
ROCS analysis identifies compounds which occupy a similar 3D molecular space to
a query molecule e.g. a known inhibitor of amyloid aggregation. In this study, in
collaboration with Dr Richard Foster (University of Leeds), five query molecules (see
Section 4.2.1) were compared separately to all 50,000 members of the structurally diverse,
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in-house molecular library. This led to the production of a 67-member library of small
molecules which was screened biochemically for effects on Aβ40 aggregation.
4.2.1 Selection of Known Modulators of Aβ40 Aggregation as a Basis
for Library Production
To use ROCS, a known structure (or ‘query compound’) was required for steric compar-
ison to other compounds in the in-house library. As selection of the query compound
ultimately dictated the region of compound space which was explored, it was essential
to choose a compound - or set of compounds - carefully.
There is a plethora of compounds which have been noted in the field for inhibitory effects
on Aβ40 aggregation (reviewed in [381, 447–449]). Some of the more commonly cited
compounds, such as EGCG, resveratrol, and curcumin, have been thoroughly investi-
gated [381, 448, 450] and could have been used as seed molecules for the creation of a
compound library. However, in light of recent publication by Habchi et al. [444], the
following compounds were chosen to seed a new library of compounds which could be
screened for amyloid modulatory effects. Choosing the less well-characterised molecules
gave rise to the potential of exploring an exciting new area of amyloid biochemistry,
with great potential which justified this more risky strategy.
Bexarotene first appeared in the literature in 1995 [451] as a potent retinoid X receptor
ligand which induced apoptosis in Leukemia cells. Since then it has become an FDA-
approved drug for the treatment of cutaneous T-cell lymphoma. In 2012, Crammer
et al. [452], published that oral administration of bexarotene to an AD model mouse
could stimulate physiological Aβ clearance mechanisms resulting in the rapid reversal
of cognitive, social and olfactory deficits leading to improved neural circuit function.
This effect was hypothesised to be due to an increased level of ApoE expression caused
by retinoid X receptor (RXR) stimulation. Since then there has been interest in re-
purposing the compound as a potential treatment for Alzheimer’s Disease [453, 454].
This led to research into the mechanism of how bexarotene can restore cognitive func-
tions in AD models. There is evidence for bexarotene to act in a range of mechanisms
including inhibiting cholesterol binding to β-amyloid peptides and the prevention of
Ca2+-permeable amyloid pore formation[455, 456], and direct interaction of bexarotene
with Aβ42 and Aβ25-35 [455], as well as the amyloid precursor protein transmembrane
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domain causing alterations in its helical conformation[457]. Recently the interaction of
bexarotene with Aβ42 was studied and it was shown that bexarotene could suppress the
primary nucleation reaction of amyloid fibril formation[443]. This is supported by other
researchers using ThT and AFM methods[458]. Docking studies revealed that the basic
residues His13 and Lys16 of Aβ are important for interaction with bexarotene [459].
As bexarotene had originally been developed primarily to interact with the RXR, it is
possible that the structure of bexarotene could be optimised for interaction with Aβ.
Since the primary species with which bexarotene interacts are transient [443], it was
not possible to use traditional structure-based drug development strategies (such as
molecular docking, substrate-based or structure-based design [460]) to develop similar
compounds. Quasi-structure-based drug discovery (QSBDD) was implemented [444]
which assumes there are some shared structural features among the binding targets of
bexarotene, i.e. there are areas of similarity between Aβ primary nuclei and RXRs. From
this, it can be hypothesised that other RXR ligands (both agonists and antagonists) may
be able to interact with Aβ primary nuclei.
Physiologically, RXRs form DNA-binding heterodimers with retinoid A receptors (RARs)
which are ligand-controlled transcription factors[461]. Ligands which bind to RARs can
affect the dimerisation of RXR and RAR, reviewed in [462], by well characterised inter-
actions [462, 463]. Due to this relationship, ligands which interact with RARs have also
been considered. From work by Habchi et al. [444] a total of four, structurally-diverse
compounds were chosen including an agonist and antagonist for RXRs (bexarotene and
UVI3003) and RARs (adapalene and MM11253), respectively. UVI3003 is a selective
antagonist of RXRs and was suggested as a valuable tool to study RXR function [464].
Adapalene is an FDA-approved drug for treating mild to moderate acne but has also
been shown to have retinoid activity (reviewed in [465]). Finally MM11253 is a selective
antagonist of retinoic acid receptor (RAR) leading to the inhibition of the growth of oral
squamous carcinoma cells [466]. The structures of the molecules are shown in Figure
4.2.
The final molecule selected for use as a starting compound was 1,2-naphthoquinone.
Early work on rifampicin [318] suggested that the naphthoquinone group may be re-
sponsible for the ability of rifampicin to inhibit Aβ40 aggregation. In 2007, Necula et
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Figure 4.2: Structures of the five query compounds used as a root for the screening
library.
Rifampicin is included as 1,2-naphthoquinone was based on part of this structure (red
outline).
al. [467] published that 1,2-naphthoquinone could inhibit Aβ42 oligomer formation ag-
gregation using immuno-dot blot assays. However, in the same paper they used ThT
fluorescence, light scattering and TEM to show that although 1,2-naphthoquinone could
prevent oligomer formation, fibrillation still occurred. This suggested that the compound
may be causing amyloid to form by a different mechanism compared with the apo protein
which forms amyloid via immuno-binding oligomers. Work conducted by Nikki Green
and Dr K. Stewart at the University of Leeds indicated that 1,2-naphthoquinone could
also delay Aβ40 oligomerisation during the amyloid aggregation process. The ability
of a compound to alter the amyloid pathway could stabilise an alternative monomeric
conformation or oligomeric structure that may reveal specific features of the Aβ40-Aβ40
interaction.
Selection of five query compounds (bexarotene, adapalene, MM11253, UVI3003, and 1,2-
naphthoquinone) broadens the diversity of compound steric space which can be accessed
and assessed in this study. In collaboration with Dr Richard Foster (University of
Leeds), each query compound was used to search for compounds with similar spatial
arrangements within the 50,000 member in-house library in silico to create a smaller
library that was suitable for biochemical analysis.
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4.2.2 Compound Library Creation using ROCS
Through the use of ROCS (Figure 4.3) a selection of 67 compounds was chosen based
on the query compounds chosen in the previous section (Tables 4.1 to 4.4). All the
compounds were selected from the in-house library to be used in biochemical screening.
Compounds were supplied as 10 mM stocks in 100 % DMSO and stored in air-tight
Eppendorfs at -20 oC. Compound selection was based on the ‘ROCS Combiscore’ (the
default comparator of the ROCS programme) with a sensitivity to maintaining structural
and chemical diversity within the 67-member screening library. The ROCS Combiscore
measures the similarity of the compound shapes as well as the pharmacophoric features
[421].
Figure 4.3: Examples of structural comparision using ROCS.
Query compounds (blue) adapalene (left), bexarotene (middle) and
1,2-naphthoquinone (right) overlaid with library compounds (green) during ROCS.
Adapted from images taken by Dr C. H. Revill.
Molecules with similar steric forms as the query molecules were then checked for PAINS
(Pan-assay interference compound) motifs. PAINS molecules are defined by their activ-
ity across a range of assay platforms and against a multitude of proteins such as metal
chelation, chemical aggregation, redox, compound fluorescence, cystine oxidation, and
promiscuous binding. All PAINS molecules found in the ROCS analysis were excluded
to increase the likelihood that any observed effects on amyloid aggregation were a result
of direct interaction between the small molecule and Aβ40. A notable exception to this
is the query molecule 1,2-naphthoquinone.
The final library of compounds for screening for Aβ40 amyloid aggregation modulatory
activity are shown in Tables 4.1 to 4.4. Many thanks are owed to Dr C. H. Revill and Dr
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R. J. Foster (University of Leeds) for conducting the ROCS and selecting the 67-member
library.
The selected compounds:
Table 4.1: Selected compounds based on the structure of adapalene.
Compounds based on adapalene structure
ID Structure MW (Da) LogP
Adapalene 413 6.25
A1 351 3.21
A2 359 2.57
A3 377 0.93
A4 431 1.85
A5 388 3.02
A6 345 2.78
A7 376 3.98
A8 362 2.15
A9 409 4.63
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Continuation of Table 4.1
ID Structure MW LogP
A10 421 3.78
A11 361 4.02
A12 407 1.72
A13 366 3.99
A14 337 3.60
A15 344 3.28
A16 382 1.00
A17 355 3.99
A18 355 2.20
A19 369 2.76
A20 269 5.01
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Continuation of Table 4.1
ID Structure MW LogP
A21 375 4.30
A22 385 1.23
Table 4.2: Selected compounds based on the structure of bexarotene.
Compounds based on bexarotene structure
ID Structure MW (Da) LogP
Bexarotene 348 6.38
B1 326 3.12
B2 314 3.34
B3 287 2.51
B4 371 4.22
B5 325 0.94
B6 306 3.26
B7 323 3.55
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Continuation of Table 4.2
ID Structure MW LogP
B8 370 3.25
B9 306 2.96
B10 298 1.21
B11 382 2.62
B12 278 2.51
B13 331 3.80
B14 310 3.62
Table 4.3: Selected compounds based on the structure of 1,2-naphthoquinone.
Compounds based on 1,2-naphthoquinone structure
ID Structure MW (Da) LogP
1,2-NQ 158 1.50
Q1 288 2.71
Q2 263 2.47
Q3 236 1.23
Q4 248 1.03
Q5 217 1.44
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Continuation of Table 4.3
ID Structure MW LogP
Q6 287 3.22
Q7 305 2.29
Q8 221 0.87
Q9 152 1.67
Q10 251 0.77
Q11 265 1.15
Q12 277 1.44
Q13 218 2.00
Q14 204 1.64
Q15 219 2.98
Q16 238 2.57
Q17 191 1.57
Q18 209 -0.09
Q19 203 0.39
Q20 273 0.04
Q21 207 2.01
Q22 187 3.14
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Continuation of Table 4.3
ID Structure MW LogP
Q23 190 0.05
Q24 218 1.06
Q25 204 0.53
Q26 311 1.45
Q27 205 3.13
Q28 195 2.21
Table 4.4: Selected compounds based on the structure of MM11253 and UVI3003.
Compounds based on MM11253 or UVI3003 structures
ID Structure MW (Da) LogP
MM11253 -
M01 430 3.56
M02 384 3.44
UVI3003 -
U01 253 02.88
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The partition coefficients, logP, have been included and provide a measure of the hy-
drophobicity of each compound. LogP values are a component of Lipinski’s Rule of 5
and represent the lipophilicity of a drug which is important for its solubility, absorption,
membrane penetration, and distribution. For an oral drug, the logP should be less than
five, however, a drug targeting the central nervous system should ideally be less lipophilic
and have a logP of less than two. Such levels of lipophilicity make it more likely for the
drug to move across lipid membranes rather than solubilising and remaining in the lipid
phase.
The 67 compounds listed formed the library which was subjected to biochemical analysis
for effects on Aβ40 aggregation. The following sections detail the initial biochemical
screening of these compounds for their ability to perturb Aβ40 aggregation (using the
Thioflavin-T fluormetric assay), followed by aggregation assessments from orthogonal
perspectives to probe the compound mechanism of effect on the amyloid mechanism.
4.3 Screening for Compounds which Modulate Aβ40 Ag-
gregation using Thioflavin-T Fluorescence
4.3.1 Initial screening of 67 compounds for Aβ40 modulatory behaviour
The compound screening method in the toolbox (devised in Chapter 3) was a ThT
fluorescence-based assay (described in Section 1.4.1 and justified in Section 3.5.1). This
assay reported on the aggregation kinetics of Aβ40 aggregation by fluorescence emission
at 480 nm. As described previously (Section 1.4.1), the assay was compatible with the
use of compounds solubilised in DMSO (Section 3.5.1).
To screen the 67-member library for effects on Aβ40 aggregation, a series of 96-well plates
were prepared. On each plate nine compounds were tested alongside a compound-free,
Aβ40 sample positive control (Figure 4.4). Each sample was prepared as 20 µM Aβ40
(from a 4.7 M stock in 100 % (v/v) DMSO), in 50 µM ammonium acetate, pH 6.8,
with 10 µM ThT (from a 1.2 M stock in H2O), and 100 µM compound (from a 10 mM
stock in 100 % (v/v) DMSO). The final DMSO percentage was adjusted to 2 % (v/v)
DMSO. Each compound sample was aliquotted into four wells in one column of a 96-well
plate (Figure 4.4) and an Aβ40-free negative control was applied to the two wells below.
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Plates were incubated quiescently at 37 oC and fluorescence was measured every 300 s
for 21 h using a FLUOstar OPTIMA plate reader.
Figure 4.4: The 96-well plate layout used in the ThT screen.
The wells in the red box contain Aβ40 only in buffer as a positive aggregation control.
Wells in the blue box contain no Aβ40 to ensure the compounds do not interact with
ThT causing it to fluoresce, and wells in the green box contain no small molecule and
no Aβ40 as a negative control. The wells around the edge of the plate were filled with
100 µl of 50 mM ammonium acetate, pH 6.8 buffer only to ensure consistency in
environmental conditions for peripheral sample wells.
Initially, the assay was conducted to probe Aβ40 aggregation behaviour in the presence of
the parent compounds adapalene, bexarotene, and 1,2-naphthoquinone (MM11253 and
UVI3003 were unobtained), Figure 4.5. Data were plotted on an absolute fluorescence
intensity scale as well as on relative axes. This is because the absolute intensity val-
ues can vary between experimental runs and thus without normalisation, plate-to-plate
comparison would not be possible.
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Figure 4.5: Compound screening by ThT fluorescence.
Each graph shows the aggregation kinetics for 20 µM Aβ40 (black) and 20 µM Aβ40
with 100 µM of each query compound 1,2-NQ (purple), adapalene (light blue), and
bexarotene (dark blue). There are four examples in each trace taken from within a
single experiment on the same plate. The left-hand column shows the normalised data
and the right-hand column shows the absolute absorbance values. All samples are in 50
mM ammonium acetate, pH 6.8, 2 % (v/v) DMSO, 37 oC, under quiescent conditions.
Adapalene - which was chosen as a query compound based on its interaction with
retinoid receptors like bexarotene - showed no effect on Aβ40 kinetics (by ThT fluores-
cence) but bexarotene and 1,2-naphthoquinone both affected the fluorescence measured.
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Bexarotene has been shown to have an inhibitory effect on Aβ40 aggregation, observable
as an extension of the lag time observed by ThT fluorometry [458], however, the converse
is observed here. For Aβ40 - under the specified conditions - the lag time shortens by
approximately 2 h. This difference may be explained by the different mechanisms which
dominate Aβ40 and Aβ42 amyloid aggregation: primary or secondary nucleation respec-
tively. The aim of work in this Chapter was to find small molecule modulators of the
mechanism of Aβ40 aggregation, which is evident here. Eventual structural investigation
of bexarotene-induced monomer conformations may highlight important folds or chem-
ical interactions which are important in the amyloid mechanism. 1,2-naphthoquinone
did not affect the lag time observed but it did dramatically reduce the maximum level
of fluorescence measured (by approximately 97 %). This behaviour was akin to that of
EGCG (Section 3.5.1) and was subsequently probed using other methods in the tool-
box. The dramatic effect of 1,2-naphthoquinone was encouraging for finding new small
molecule inhibitors of Aβ40 aggregation through the ROCS-generated library based on
this compound.
The kinetic aggregation profiles of Aβ40 in the presence and absence of the 67 compounds
in the screening library are shown in Figures 4.6 to 4.11. ThT plots in this chapter are
presented as normalised fluorescence levels to aid flow and clarity of the work (abslute
intensity plots are found in Appendix A.1). During investigation and data processing,
absolute values were quantified and have been included when conveying a notable effect
such as for Aβ40 in the presence of 5x 1,2-naphthoquinone.
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Figure 4.6: Screening by ThT fluorescence of compounds A01-A15.
Each graph shows four replicates of the aggregation kinetics for 20 µM Aβ40 in 50 mM
ammonium acetate, pH 6.8, 2 % (v/v) DMSO (black), 10 µM ThT (black) and 100 µM
of each adapalene-based compound (colours). There are four examples of each trace.
Traces where a clear (double tick) or moderate (single tick) qualitative effect on
aggregation is observed are indicated.
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Figure 4.7: Further screening by ThT fluorescence of compounds A16-A22.
As described in Figure 4.6.
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Figure 4.8: Screening by ThT fluorescence of compounds B01-B14.
As described in Figure 4.6 except the colours represent bexarotene-based compounds.
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Figure 4.9: Screening by ThT fluorescence of compounds Q01-Q15.
As described in Figure 4.6 except the colours represent 1,2-naphthoquinone-based
compounds.
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Figure 4.10: Further screening by ThT fluorescence of compounds Q16-Q28.
As described in Figure 4.9.
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Figure 4.11: Screening by ThT fluorescence of compounds M01, M02, and U01.
As described in Figure 4.6 except the colours represent compounds based either
MM11253 (M01, M02) or UVI3003 (U01).
Each graph shows the kinetic profile of Aβ40 aggregation in the presence of a test com-
pound compared with the Aβ40 apo aggregation profile measured on the same 96-well
plate. The differences in the kinetics of the Aβ40 apo and Aβ40 with compound ag-
gregation profiles can be interpreted by visual inspection of the fibril growth curves
[64].
As expected for a screen, the majority (75 %) of the compounds did not exhibit an effect
on Aβ40 kinetics by ThT fluorescence. However, eight compounds clearly perturbed
aggregation (A09, A13, A14, A21, B08, Q06, Q22, and Q23), and a further 11 showed
possible effects (A10, A11, A12, A18, A20, A22, B04, B05, B09, and Q03).
For example, compound A14 had an effect where the exponential increase in ThT fluo-
rescence was delayed due to an increased lag time. According to Knowles et al., [64], this
indicated that compound A14 was acting at the primary nucleation stage of aggregation
making it less likely that Aβ40 monomers will come together and form oligomers which
would seed fibril growth. This effect was also observed for A09, A10, A11, A12 and B08,
and to some extent for A18, B09, Q03. Conversely, compounds A21, Q06, Q22, and Q23
(and possibly A20, B04, and B05) reduced the lag time observed by ThT fluorescence,
indicating that the interaction of Aβ40 with these molecules promoted amyloid aggrega-
tion. This could be achieved through influencing Aβ40 conformation, and encouraging
the adoption of amyloid-prone conformers leading to the self-association of Aβ40.
Another type of perturbation was observed for compound A13 (and possibly A10). Here
the shape of the Aβ40 aggregation profile is altered from the typical sigmoidal curve
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associated with amyloid aggregation. The gradient of the fluorescence increase was
shallower indicating a reduced rate of elongation and/or secondary nucleation had been
caused by the addition of A13 [64].
Based on the qualitative data collected there were a range of compounds which could
have been taken forward for further investigation of their affects on Aβ40 aggregation.
To aid decision making, more objective, quantitative parameters were measured - based
on the ThT screening data presented here - to enable justified compound selection.
4.3.2 Quantitative Analysis of Compound Effects on Aβ40 Aggregation
Profiles
Qualitative assessment of curve shape has typically been used to identify modulators of
amyloid formation. In this thesis quantitative limits were also implemented for molecule
selection based on the Aβ40 aggregation profiles - monitored by ThT fluorescence-. The
following section discusses how eight compounds were chosen for further biochemical
study based on qualitative and quantitative analysis of the initial ThT screening data.
As described in the preceding chapter (section 3.5.2), three quantitative measures were
considered. Firstly, the effect of the compound on the lag time was monitored as an
indication of whether the compounds can interfere with the primary nucleation phase
of amyloid aggregation. Secondly, the time taken to reach 50 % of the maximum fluo-
rescence level, T50, was used as an indication of the compound effects on elongation or
secondary nucleation processes. Lastly, the maximum fluorescence level was measured
to indicate aggregate yield or perturbed fibril morphology. To enable inter-plate com-
parison, all measures calculated relatively by division of the parameter value by that of
the Aβ40 apo sample from the same 96-well plate.
To measure the lag time a tangential line was extended from the steepest point on the
curve (maximum first differential) to intersect with the x-axis. This was calculated using
a script written by Emma Cawood (University of Leeds) and refinement of this script is
noted in Section 3.5.2. The point of intersection was used as the ‘lag time’ and in the
majority of cases this value gave a sensible approximation of the end of the lag time when
compared qualitatively with the curve shape. Clear outliers and erroneous measures
- caused by noise in the acquired data - were removed from analysis and such data
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points were remeasured using linear fitting to the steepest part of the sigmoidal curve in
OriginPro version 2018b. Use of linear fitting was less accurate than using the tangent
to the maximum first differential as the linear portions of curves were variable and in
some cases accounted for only around 10 % of the measured data. Figure 4.12 presents
the relative changes to the lag time and statistically different data are highlighted based
on a t-test (P<0.05). Data are plotted according to their parent compound rather than
in the randomised order they were screened.
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Figure 4.12: A plot of the relative lag times for Aβ40 aggregation in the presence of each
compound.
The mean of the relative effects that each compound had on the lag time observed for
Aβ40 aggregation are plotted (black) in numerical compound order (i.e. A01–A22, in
the bottom graph the compound order is M01, U01, M02) compared to the Aβ40 apo
control (red) on the same 96-well plate. Error bars which show the standard deviation
and compounds which affect the lag time significantly according to the student t-test
(P<0.05) are labelled (blue).
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Compounds which show no effect on the lag time of Aβ40 aggregation are located close
to the y = 1 line on the plots in Figure 4.12. Compounds which have had a significant
impact on the Aβ40 aggregation lag time are labelled in blue. For example, compounds
A09, B08, and Q27 increased the length of the lag phase relative to Aβ40 alone. This
implied these compounds were able to delay the formation of amyloid-prone species.
Conversely, compounds A21, Q22, and U01 had the opposite effect and decreased the
relative lag time of Aβ40 aggregation, possibly through promotion of formation or desta-
bilisation of amyloid precursor conformations.
The effects of each compound on the T50 (Figure 4.13) were also quantified. The T50
value (time taken to reach 50 % of the maximum fluorescence level) can be influenced by
perturbations in curve gradient and the start time of the exponential increase in fluores-
cence which are caused by elongation or secondary nucleation and primary nucleation
of amyloid aggregation respectively. The contributions from these can be deconvoluted
by additionally measuring the relative change in lag time as described to separate the
primary nucleation contribution to T50 measures.
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Figure 4.13: A plot of the relative T50 for Aβ40 aggregation in the presence of each
compound.
The mean of the relative effects that each compound had on the T50 observed for Aβ40
aggregation are plotted (black) in numerical compound order (i.e. A01–A22, in the
bottom graph the compound order is M01, U01, M02) compared to the Aβ40 apo
control (red) on the same 96-well plate. Error bars which show the standard deviation
and compounds which affect the lag time significantly according to the student t-test
(P<0.05) are labelled (blue).
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Compounds which had an effect on the T50 values (P<0.05) of Aβ40 aggregation are
labelled in blue. Interestingly, the majority of compounds based on 1,2-naphthoquinone
which have an effect on aggregation decrease the T50 value, which implied these com-
pounds, such as Q06, Q14, and Q23, increase the propensity of Aβ40 to aggregate, which
is contrary to the effects of 1,2-naphthoquinone (Figure 4.5). Four of the six compounds
based on bexarotene which showed a significant effect on relative T50 - of Aβ40 aggre-
gation - increased the T50 time and thus were indicative of inhibitory effects, which is
the converse to the effect bexarotene (Figure 4.5).
Lastly, the effects of each compound on maximum fluorescence intensity were probed
(Figure 4.14). There is a multitude of contributing and hard to control factors which af-
fect the level of ThT fluorescence such as heterogeneity of fibrils and aggregates formed,
their affinity to bind ThT, or synergistic or antagonistic contributions to the fluores-
cence emitted. However, for published inhibitors of Aβ40 aggregation, the absolute
fluorescence level is an indication of aggregation inhibition; this was demonstrated for
1,2-naphthoquinone in Figure 4.5. Maximum fluorescence levels can be used tentatively
to imply the extent of aggregation which could be tested more reliably using the SDS-
PAGE-based fibril yield assay in the toolbox (Section 3.5.3) or may be more affected by
a compound-induced change in fibril morphology (which could be tested more reliably
using TEM (Section 3.5.4).
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Figure 4.14: A plot of the relative final fluorescence intensities for Aβ40 aggregation in
the presence of each compound.
The mean of the relative effects that each compound had on the final fluorescence
intensities observed for Aβ40 aggregation are plotted (black) in numerical compound
order (i.e. A01–A22, in the bottom graph the compound order is M01, U01, M02)
compared to the Aβ40 apo control (red) on the same 96-well plate. Error bars which
show the standard deviation and compounds which affect the lag time significantly
according to the student t-test (P<0.05) are labelled (blue).
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Many of the compounds which had a significant effect on the maximum fluorescence
intensity (P < 0.05, highlighted in blue) showed a negative impact. This could indi-
cate that fewer β-sheet containing aggregates have been formed. Alternatively, these
molecules may interfere with ThT fluorescence when in the presence of β-folds. This
can be examined in more detail on application of toolbox methods. Some compounds
(such as Q10–14 and Q25) showed the opposite; an increase in maximum fluorescence
intensity was observed compared with Aβ40 alone. From conducting fibril yield exper-
iments (Section 3.5.3) it is known that the yield of Aβ40 into fibrils is greater than 90
%, therefore there must be a contribution from variation in fibril morphology leading to
greater ThT fluorescence.
Figure 4.15 collates and represents the qualitative and quantitative data obtained for
each compound. Actual quantitative measures are included in Appendix A.2. Using
multiple measures (ThT signal shape, lag time, T50, and maximum ThT signal) as
an indication of compound effect on Aβ40 aggregation increased the probability that
compounds which were selected for further analysis would have genuine effects on ag-
gregation.
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Figure 4.15: A heat map to represent extent of evidence of aggregation for each com-
pound to perturb Aβ40 aggregation.
Each compound is represented by its screening name (i.e. A01). The number of
statistically significant quantitative measures of aggregation perturbation are
represented as shade of blue: one measure (light blue), two measures (mid-blue), or all
three measures (dark blue). The extent of the qualitative indication of perturbation is
represented: possible perturbation (dashed outline), or clear perturbation (solid
outline). Compounds which were chosen for further analysis are shown in red text.
From this summary, eight compounds (highlighted in red) were selected for more detailed
investigation of their effects on Aβ40 aggregation; A12, A13, A14, A18, A21, B08, Q06,
Q14. The ThT curves for each of these compounds are reproduced in Figure 4.16 (copied
from Figures 4.6 to 4.11) for clarity. Figure 4.16 also introduces the compound colour
identity which will be used throughout the rest of the chapter as a visual aid. The
subsequent figure (Figure 4.17) shows enlarged structures of the compounds.
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Figure 4.16: Summary of the eight compounds selected for further investigation.
Reproduction of the screening results for eight compounds which are likely to be
modulators of Aβ40 aggregation and will be studied further.
Screening for Novel Modulators of Amyloid-β40 Aggregation 176
Figure 4.17: The chemical structures of each of the eight compounds selected for further
investigation.
These compounds were taken forward for more detailed investigation to discover whether
the effects on aggregation which were observed by ThT were reproducible, and whether
other methods revealed additional insight into the mechanism of how these compounds
modulated Aβ40 aggregation.
4.3.2.1 Confirmation of Compound Identity by Mass Spectrometry
When working with molecules from compound libraries it is good practice to check the
mass of the compounds which are provided to the laboratory from the library. This is
because many compounds can be unstable after prolonged storage even under optimal
library management. Storage of powdered compounds tends to be problematic in large
scale libraries [468] due to varying powder properties (i.e. density, hygroscopicity). The
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most common solution for the disparity in solid compound properties is to create stan-
dardised samples in uniform, automation-friendly vials. Typically compounds are stored
at a high concentration and solubilised in DMSO [469]. DMSO is highly hygroscopic
thus samples should be stored under humidity-controlled conditions to limit the poten-
tial oxidation of the stored compound. Based on the length of time spent in DMSO at
a storage facility, some compounds may degrade or be chemically modified by the time
they are required for biochemical screening.
Mass spectrometry was used to detect whether there were any impurities, degradation,
or chemically-modified species present in the stock solution. The eight compounds were
diluted from the 100 % DMSO stocks provided by the library to 2 % DMSO solutions in
50 mM ammonium acetate, pH 6.8. These solutions underwent liquid chromotography
mass spectrometry (LC-MS) examination (using a 10–90 % (v/v) acetonitrile gradient
in 0.1 % (v/v) TFA) conducted and processed by Dr Yong Xu (University of Leeds).
The results of the analyses are presented in the top panels of Figures 4.18 to 4.24.
There were multiple mass discrepancies evident and low purity of stock compounds. To
eliminate the possibility of modification and contamination during the LC-MS process,
commercially-available, powdered versions of the compounds were purchased from the
original library suppliers and 10 mM aliquots in 100 % (v/v) DMSO were created. These
were stored at -20 oC in air-tight Eppendorf tubes before application to the same LC-MS
analysis conducted and processed by Dr Yong Xu (University of Leeds), presented in
the bottom panels of Figures 4.18 to 4.24. The new samples are denoted with an ‘a’
following the compound number to distinguish them from the library samples. It was
not possible to purchase compounds A18a, B08a, or Q14a.
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Figure 4.18: LC chromatogram and MS spectra of library compound A12 and commer-
cial compound A12a.
LC chromatogram and MS of each peak present on the LC chromatogram for A12
(top) and A12a (bottom).
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Figure 4.19: LC chromatogram and MS spectra of library compound A13 and commer-
cial compound A13a.
LC chromatogram and MS of each peak present on the LC chromatogram for A13
(top) and A13a (bottom).
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Figure 4.20: LC chromatogram and MS spectra of library compound A14 and commer-
cial compound A14a.
LC chromatogram and MS of each peak present on the LC chromatogram for A14
(top) and A14a (bottom).
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Figure 4.21: LC chromatogram and MS spectra of library compound A18 and commer-
cial compound A18a.
LC chromatogram and MS of each peak present on the LC chromatogram for A18
(top) and A18a (bottom).
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Figure 4.22: LC chromatogram and MS spectra of library compound A21 and commer-
cial compound A21a.
LC chromatogram and MS of each peak present on the LC chromatogram for A21
(top) and A21a (bottom).
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Figure 4.23: LC chromatogram and MS spectra of library compound Q06 and commer-
cial compound Q06a.
LC chromatogram and MS of each peak present on the LC chromatogram for Q06
(top) and Q06a (bottom).
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Figure 4.24: LC chromatogram and MS spectra of library compound B08 and commercial
compound B08a.
LC chromatogram and MS of each peak present on the LC chromatogram for B08
(top) and B08a (bottom).
These data are summarised in Table 4.5.
Table 4.5: Mass spectrometry analysis of compound molecular weight.
Compound
(expected
MW)
Structure Library MW Commercial
MW
A12 (407) 407, 425, 607 407
A13 (366) 384, 366 366
A14 (337) 337, 445 337, 445
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Continuation of Table 4.5
Compound
(expected
MW)
Structure Library MW Commercial
MW
A18 (355) 371, 389, 353,
341
N/A
A21 (376) 375 375
Q06 (287) 471, 499, 223,
more peaks
223, 309
B08 (370) 370 N/A
Q14 (205) None present N/A
The LC chromatogram for compound A12 (expected mass 407 Da) showed a doublet
peak indicating sample impurity (Figure 4.18). A 407 Da species was present in low
abundance in the second of the two peaks. However, this peak was dominated by
major species with a MW of 607 Da which, based on the relative peak intensity, is
approximately 10x more present than A12. The preceding peak was caused by a 425 Da
product which is hypothesised to be an oxidised form of compound A12 (as the mass
increase of 18 Da could correspond to H2O). For A12a, a single species was present with
the expected mass of 407 Da, and a dimeric form is observed in low abundance. The
minor peak in the A12a corresponds to a dimeric form of the compound.
Similarly, the LC chromatogram for compound A13 (expected mass 366 Da) also showed
two peaks (Figure 4.19). A13 was present in the second peak, whereas, the preceding
peak (∼ 3x the intensity of the compound-containing peak) corresponded to a 384 Da
compound which is presumably an oxidised form of A13. The A13a LC chromatogram
also showed a single peak corresponding to the expected (protonated) mass of 367 Da.
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The A13a spectrum shows a minor population with a mass of 754 Da which is probably
a dimeric form of A13a with a sodium adduct.
Unlike the previous two compounds, the LC chromatogram for A14 (expected mass 337
Da) revealed that the desired compound was the major species in the sample (Figure
4.20, top, peak 1). Despite this, there was evidence of impurities present and a second
peak was evident on the LC chromatogram corresponding to a 445 Da contaminant.
The major species present for A14a was the correct mass, 337 Da, however there is an
additional species at 445 Da. This species was also present in the library compound A14
at a similar level. This could indicate that this compound was prone to reaction with
the air or in DMSO to form this higher MW species, or that during LC-MS some of the
337 Da is modified.
Multiple masses were detected for compound A18 (expected mass 355 Da). A18 was
present in the second major peak (peak 3, Figure 4.21). However, within this peak
there were contaminant species making up approximately 40 % of the total population.
Furthermore, the additional peaks in the LC chromatogram corresponded to other con-
taminant species. Only one of the identified masses was less than the expected mass of
A18 indicating degradation was not a major cause of sample contamination. A18 was
not commercially available.
Compound A21 (expected mass 375 Da) was present in a pure form as was evident from
the single peak observed on the LC chromatogram (Figure 4.22). The peak at 750 Da
corresponds to a dimer form of A21. Similarly, commercial A21a appeared to contain
only the expected compound and its dimeric form.
Analysis of compound Q06 (expected mass 287 Da) showed species of various masses
but none which corresponded to Q06 (Figure 4.23). LC-MS for the purchased compound
Q06a revealed the presence of multiple masses. Although fewer species were evident then
in the library Q06 sample some of the species detected are of the same MW, e.g. 223 Da
and 309 Da. There was no evidence of a 287 Da species which would have corresponded
to the expected compound.
The LC chromatogram for compound B08 (expected mass 370 Da) presented three over-
lapping peaks which implied there were multiple species present in the sample (Figure
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4.24). However, the mass analysis reproducibly showed that peaks 1, 2 and 3 all cor-
responded to the same mass, 370 Da, with a different retention time. The compound
may be able to form different rotamer or isomer states which have different affinities for
the hydrophobic surface of the LC column. A minor population of a 762 Da species was
present which was hypothesised to be a B08 dimer with a sodium ion adduct. B08 was
not available commercially.
Compound Q14 was analysed but no mass signals were detected above the noise level
by LC-MS, additionally, Q14 was no available commercially.
From comparison of the LC-MS traces of library compounds and purchased compounds,
it was apparent that many of the library compounds had encountered some modification
or contamination during the long storage period in DMSO in the compound library e.g
compounds A12, A13, A18, Q06, and Q14. As these library compounds were not the
same as the commercial compounds, the commercial compounds were subjected to the
ThT fluorometry screening assay (Figure 4.25) to screen the commercial compounds for
effects on Aβ40 aggregation. A14a and A21a - which are equivalent to A14 and A21
respectively - were also screened.
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Figure 4.25: ThT fluorometry screen of the new commercial compounds.
Each graph shows the aggregation kinetics for 20 µM Aβ40 apo (black) and 20 µM
Aβ40 with 100 µM of each purchased compound; A12a (red), A13a (blue), A14a
(green), A21a (yellow), and Q06a (purple) in 50 mM ammonium acetate, pH 6.8, 2 %
(v/v) DMSO with 10 µM ThT. There are four replicates of each.
From Figure 4.25 there was evidence of amyloid perturbation by compounds A14a, A21a
and Q06a. A12a and A13a showed no effect on Aβ40 aggregation by ThT fluorometry.
A12a does not exhibit the increased lag time observed for A12. This could be because
the 608 MW species in A12 was the active compound rather than the 407 Da compound
which is pure in A12a. The additional 384 Da species in A13 may have affected the
elongation rate of Aβ40 (observed in Figure 4.16) in a way which A13a (366 Da) cannot,
or the 384 and 366 Da species may have interacted together in order to influence Aβ40
aggregation kinetics.
Comparison of A14a and A21a to A14 and A21 in Figure 4.16 show the same behaviour
whereby A14 and A14a delay Aβ40 aggregation by ∼2 h and A21 and A21a promote
Aβ40 aggregation by ∼2 h. This was expected as the LC-MS analysis showed that the
commercial compounds were the same as the library compounds (Figures 4.20 and 4.22).
Q06a showed a strikingly different effect on Aβ40 aggregation by increasing the lag time
(by 3–5 h) compared with Q06 which showed a decreased lag time (by 2–3 h). This
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discrepancy was understandable as Q06 was very impure and Q06a contained different
molecular weight species.
All five of the commercial compounds were taken forward for application of further
toolbox methods to demonstrate the ability of the toolbox to differentiate small molecule
modulators of aggregation by a stringent and robust approach. Investigation of the
original library compounds was not continued due to the uncertain nature of the active
species in the compound samples; determination of which was beyond the scope of this
project. Moreover, limited supply of library compounds meant that further application
in the toolbox would have been limited.
4.4 Verification of Compound-mediated effects on Amy-
loid Aggregation using a Multi-method Approach
In this section, toolbox methods are used to verify the effects of the selected compounds
(A12a, A13a, A4a, A21a, and Q06a) on Aβ40 aggregation. Firstly, reproducibility of
effects was explored using a titration of compound:peptide ratios in the ThT fluormetry
assay. Next, an SDS-PAGE-based assay was used to detect aggregate species and to
quantify the amount of insoluble material produced at the end of the aggregation reac-
tion. Finally, TEM is used to investigate aggregate morphology of Aβ40 formed in the
presence of each compound.
4.4.1 Assessment of the Reproducability of Compound-Induced Mod-
ulation of Aβ40 Aggregation using Titration Effects
Validation of compound effects - for the compounds A12a, A13a, A14a, A21a, and Q06a
- on Aβ40 was achieved through ligand titration ThT fluorometry assays. This technique
reported on the reproducibility of effects each compound had on Aβ40 aggregation ki-
netics, as well as determining whether there was a dose-dependent relationship between
compound concentration and effect on Aβ40 aggregation.
A deviation on the screening assay was used where the ratio of compound:Aβ40 was
varied to 5:1, 1:1 and 1:5. The Aβ40 concentration was kept constant at 20 µM across
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all of the experiments and the amount of compound was varied to achieve the aforemen-
tioned ratios. The experimental procedure was the same as in the initial screen whereby
a 96-well plate format was used, ThT fluorescence was monitored every 300 s, and the
experimental conditions (37 oC, quiescent) and buffer conditions (50 µM ammonium
acetate, pH 6.8, 2 % (v/v) DMSO, 10 µM ThT) were the same. Plates were also set up
similarly to those in the screen with four wells of each compound concentration mixed
with Aβ40, and four wells of the Aβ40 apo control.
The titration experiments were initially conducted in triplicate for one of the query
compounds, 1,2-naphthoquinone, Figure 4.26 to demonstrate the method.
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Figure 4.26: Titration analysis of 1,2-naphthoquinone on Aβ40 aggregation.
Absolute (left) and relative (right) plots of triplicate repeats of ThT fluorometry to
monitor effect of a 5:1 (red), 1:1 (orange) and 1:5 (yellow) molar ratios of
1,2-naphthoquinone to Aβ40 (black) on aggregation. Buffer and reaction conditions
were the same as in the screen, and described in Section 2.2.5.1.
Plots of absolute ThT fluorescence revealed a clear titratable effect in the maximum fluo-
rescence level attained when the 1,2-naphthoquinone:Aβ40 was varied. Increased levels of
1,2-naphthoquinone showed a more drastic suppression of the fluorescence level attained.
This could be due to a lower fibril yield or a greater change in fibril morphology which
binds poorly to ThT. The relative plots revealed sigmoidal curves suggesting β-sheet
formation occurs and reached a plateau which may be indicative of amyloid formation.
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Moreover the relative plots revealed the dose-dependent effect 1,2-naphthoquinone had
on the lag time more clearly. In all replicates, a 1x molar ratio of 1,2-naphthoquinone
appeared to delay aggregation but the extent of this effect varied between experiments.
In the second and third replicate the 5x molar excess of 1,2-naphthoquinone exacerbated
this effect. The general trend observed was that spread in lag time increased as the lag
time extended, consistent with stoichastic nucleation [470].
Subsequent to the 1,2-naphthoquinone titration experiment, the ratios of compound:peptide
were adjusted (from 5:1,1:1, 1:5 to 1:1, 1:5, 1:10 compound:Aβ40 while the v/v DMSO
percentage remained constant at 2 %) for the compound investigation. The hypothesis
to justify this was based on the expectation that adding a large excess of compound
would augment the effects observed on Aβ40 aggregation kinetics reported on by ThT
fluorescence, Figure 4.27.
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Figure 4.27: Titration analysis of the commercial compounds on Aβ40 aggregation.
Relative plots of triplicate repeats of ThT fluorometry to monitor effect of a 10:1
(brown), 5:1 (red) and 1:1 (orange) molar ratios of compound to Aβ40 (black) on
aggregation; A12a (red box), A13a (blue box), A14a (green box), A21a (yellow box),
and Q06a (purple box). Buffer and reaction conditions were the same as in the screen,
and described in Section 2.2.5.1.
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From Figure 4.27, few large, reproducible trends were observed on the effect of the
compounds on ThT fluorescence. The qualitative analysis of the curve shape revealed the
effects observed in the screening assay to be very small and higher compound:Aβ40 ratios
may have been necessary to cause more reproducible effects on Aβ40 aggregation. From
these data it was unlikely that the selected compounds would be promising modulators
of Aβ40 aggregation.
4.4.2 Quantification of the Extent of Aggregation of Aβ40 in the Pres-
ence of Each Compound
Thus far, only a single technique (based on ThT fluorescence) had been used to probe
compound interference in Aβ40 aggregation. Use of alternative methods in conjunc-
tion with the ThT fluorometric assay enabled different aspects of the compound-Aβ40
interaction to be investigated.
The maximum fluorescence level reported in the ThT assay can be misleading due to
the multitude of contributing factors (discussed in Section 1.4.1. To measure the extent
of aggregation of Aβ40, the SDS-PAGE-based fibril assay was used (described in Section
2.2.5.3 and demonstrated in Section 3.5.3).
At the end of the ThT reaction (20 µM Aβ40 in 50 mM ammonium acetate, pH 6.8,
2 % (v/v) DMSO, 10 µM ThT, 21 h quiescent incubation at 37 oC), samples were
removed from the 96-well plate and transferred into Eppendorf tubes. Samples were
taken from the solution before and after centrifugation for 20 minutes at 14,000 rpm
in a benchtop microfuge. This centrifugation caused large species, such as aggregates
and insoluble oligomers, to form a pellet at the base of the tube whilst soluble species
remained in the supernatant. Samples from the insoluble and soluble fractions were run
on an SDS-PAGE gel alongside a non-centrifuged sample which represented the protein
in the whole sample, Figure 4.28a. Measurement of band intensity by densitrometry
(using Fiji software, Section 2.2.5.3) was used to quantify how much protein aggregated
in the presence of each compound as a relative percentage of the ‘whole’ sample. The
assay was first applied to three of the query molecules - adapalene, bexarotene, and 1,2-
naphthoquinone - (Figure 4.28b) which the screen (Section 4.3.1) was based upon. This
suggested that after 21 h under the conditions described, Aβ40 existed predominantly as
insoluble - presumably aggregate - forms in the presence of each parent molecule. The
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fibril yield assay was then applied to compounds A12a, A13a, A14a, A21a and Q06a
(Figure 4.28c).
Figure 4.28: Application of the SDS-PAGE fibril yield assay.
a) SDS-PAGE gel for Whole (W), soluble (S), and pelleted (P) protein samples of 20
µM Aβ40 in the absence of compound (black), and in the presence of A12a (red), A13a
(blue), A14a (green), A21a (yellow), and Q06a (purple) after 21 h incubation at 37 oC,
in 50 mM ammonium acetate, pH 6.8, 2 % (v/v) DMSO and 10 µM ThT. b and c)
Relative amounts of Aβ40 in the Whole (W), soluble (S), and pelleted (P) protein
samples of the query molecules (b) based on densitrometry and the commercial
compound leads (c). Error bars represent standard deviation.
Figure 4.28 showed that the majority of Aβ40 was present in the insoluble pellet (P)
fractions rather than in soluble (S) states irrespective of whether any compound was
present. Each bar is plotted relative to the band intensity for the whole (W) sample prior
to centrifugation. There were no significant differences (P < 0.05) in the proportion of
Aβ40 in the soluble and pellet fractions with each of the compounds compared to the apo
state - using a 5x molar excess of compound tested here-. Thus none of the compounds
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investigated can prevent 20 µM Aβ40 forming insoluble aggregates in 50 mM ammonium
acetate, pH 6.8, with 2 % (v/v) DMSO and 10 µM ThT over 21 h at 37 oC.
4.4.3 Aβ40 forms Fibrillar Aggregates in the Presence and Absence of
Compounds
To assess qualitatively whether the aggregate species of Aβ40 were influenced by the
addition of 5x molar excess of compounds A12a, A13a, A14a, A21a and Q06a, TEM
was used. Samples were taken directly from the 96-well plates used in the ThT fluo-
rometry experiments after 21 h of quiescent incubation at 37 oC (20 µM Aβ40 in 50
mM ammonium acetate, pH 6.8, 2 % (v/v) DMSO. with 10 µM ThT). These samples
were fixed onto carbon-coated grids and negatively stained using uranyl acetate. As
the samples were all taken after 21 h of incubation at 37 oC the aggregation reaction
had reached completion and presence of aggregates were implied by fibril yield results
(Section 4.4.2). Moreover, ThT fluorometry (Figure 4.16) implied these aggregates were
β-sheet rich. Samples were imaged to show whether amyloid-like fibrils were present or
whether the compound had caused the Aβ40 to aggregate in a colloidal manner.
Figures 4.29 and 4.30 show images - at 1500x magnification and 10,000x magnification -
of representative aggregate morphology observed for Aβ40 apo, and with each compound
under investigation including 1,2-naphthoquinone.
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Figure 4.29: Transmission electron micrographs of Aβ40 aggregates in the absence or
presence of compounds.
Samples were taken directly from ThT assay samples (Section 2.2.5.2) and fixed onto
carbon-coated EM grids which were negatively stained using 2 % uranyl acetate.
Images were taken at 1500x magnification (left) and 10,000x magnification (right).
Aβ40 aggregates formed in the absence of compounds (black box) is shown and in the
presence of 5x molar excess of 1,2-naphthoquinone (grey box), A12a (red bx), A13a
(blue box). Imaged according to Section 2.2.5.2.
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Figure 4.30: Transmission electron micrographs of Aβ40 aggregates in the absence or
presence of compounds (continued).
As for Figure 4.29 but the compounds present were A14a (green box), A21a (yellow
box), and Q06a (purple box).
As expected there was evidence of fibrillar species of Aβ40 in the apo sample, which
was typical of amyloid formation. Such species were also observed for aggregates formed
in the presence of 5x molar excesses of A12a, A13a, A14a, A21a and Q06a. The fibril
morphology appeared largely consistent with fibrils with widths of 1-20 nm observed.
When 5x 1,2-naphthoquinone was present no fibrillar aggregates were observed. Instead,
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amorphous masses were detected and the grid was predominantly covered with circular
colourations (Figure 4.31) which may be off pathway aggregates.
Figure 4.31: Observation by TEM of circular species formed by Aβ40 in the presence of
1,2-naphthoquinone.
TEM image of aggregate or oligomer morphology noted when Aβ40 was incubated
quiescently at 37 oC in the presence of a 5x molar excess of 1,2-naphthoquinone in 50
mM ammonium acetate, pH 6.8, 2 % (v/v) DMSO, and 10 µM ThT. Black arrows
indicate circular species close to the amorphous aggregate, and red arrows highlight
circular species which were noted across the grid.
Combination of the TEM data with the ThT, and fibril yield results presented in the
previous two sections indicated that none of the novel compounds affected Aβ40 aggrega-
tion under the conditions used, but 1,2-naphthoquinone pushed Aβ40 off of the amyloid
pathway.
4.5 Probing the Interaction between Small Molecules and
Aβ40 Species
4.5.1 Probing the Molecular Interaction between Compounds and Aβ40
by ESI-IMS-MS to Indicate Binding Mode
Subsequent to the verification that aggregation occurred in the presence of all the in-
vestigated compounds, the focus was then directed on whether the compounds bound
to Aβ40 monomers. This was investigated using electrospray ionisation-ion mobility
spectrometry-mass spectrometry (ESI-IMS-MS). This method also probed the com-
pound binding mode; specific, non-specific, or colloidal interaction with the peptide [421].
Screening for Novel Modulators of Amyloid-β40 Aggregation 200
Compounds (solubilised in 100 % DMSO) were mixed with aqueous Aβ40 monomer in 50
mM ammonium acetate, pH 6.8, at a 5:1 (compound:Aβ40) molar ratio and then anal-
ysed immediately by Dr P. Knight and Dr Y. Xu (University of Leeds). Fast analysis
ensured that monomeric species were observed which was desirable as the binding mode
of the compounds with monomeric (and low oligomeric forms of) Aβ40 was of interest in
this study. ESI-IMS-MS investigation was conducted on the query compounds adapa-
lene, bexarotene and 1,2-naphthoquinone (Figure 4.32) and on the five novel compounds
(Figure 4.33) which were identified in the screen (Section 4.3.1).
Figure 4.32: Mass spectra of Aβ40 in the presence of query compounds.
ESI-MS was conducted by Dr P. Knight and Dr Y. Xu, University of Leeds. 20 µM
Aβ40 in 50 mM ammonium acetate, pH 6.8 in the absence (bottom) or presence of 100
µM compound were analysed. The coloured lines show Aβ40 species.
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Figure 4.33: ESI-Mass spectra of Aβ40 in the presence of lead compounds.
ESI-MS was conducted by Dr P. Knight and Dr Y. Xu, University of Leeds. 20 µM
Aβ40 in 50 mM ammonium acetate, pH 6.8 in the absence (bottom) or presence of 100
µM compound were analysed. The coloured lines show Aβ40 species. Compound (or
ligand) binding is labelled ‘L’.
Figure 4.33 shows that in the apo state Aβ40 was present as monomeric, and dimeric
forms. On some repeats trimeric species were also observed (data not shown). The dimer
was present when each compound is added. In the presence of 5x molar excess of query
compounds adapalene, bexarotene, or 1,2-naphthoquinone, no binding was observed.
Additionally, no Aβ40-compound interaction was observed on the addition of 5x molar
excess of A14a, A21a or Q06a.
In the presence of 5x molar excess of A12a, the abundance of the Aβ40 dimer was
lower than in other samples which implied that compound A12a may interfere with
the self-association of the peptide. However, this was inconsistent with the observed
ThT kinetics in Figure 4.25 where no effect on lag time was observed (an increased
lag time would have been indicative of an ability to interrupt monomer association).
This observation can be justified hypothetically due to the time scale of each of the
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experiments; for ESI-IMS-MS the effect of A12a could be short-lived and thus over the
course of the ThT reaction have little impact on the measured lag time.
The addition of compound A12a to Aβ40 showed multiple copies (one two or three)
of the compound bound to the 3+ and 4+ charge states of monomeric Aβ40 but not
to the 2+ state. This was suggestive of a non-specific interaction between A12a and
Aβ40, with the more highly charged species. To test this hypothesis the experiment was
repeated using a 1:1 molar ratio of Aβ40:compound. The abundance of observed bound
compound was reduced with a maximum of only two ligands bound to Aβ40 monomer
(Figure 4.34). This supported a non-specific interaction between A12a and Aβ40 at the
higher molar ratios used.
Figure 4.34: ESI-Mass spectra of Aβ40 in the presence of different compounds.
ESI-MS was conducted by Dr P. Knight and Dr Y. Xu, University of Leeds. 20 µM
Aβ40 in 50 mM ammonium acetate, pH 6.8 in the absence (bottom) or presence of 20
µM A13a (top) or A14a (middle) were analysed. The coloured lines show Aβ40 species.
Compound (or ligand) binding is labelled ‘L’.
Addition of a 5x molar excess of A13a showed a low level of 1:1 complex with the Aβ40
monomer suggestive of (possibly weak) binding but no effect on aggregation was observed
by ThT, TEM, fibril yield, nor when a lower (1x) molar ratio of compound:Aβ40 was
analysed by ESI-MS.
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4.6 Probing for Potential Molecular Interactions between
Compounds and Aβ40 by NMR
A robust method for detecting an interaction between a small molecule and a peptide
is to use NMR [363, 471]. As discussed previously, Aβ40 is well suited to study by
NMR due to its small and flexible nature. Measurement of chemical shift perturbations
(CSP) of the backbone amide resonances in the Aβ40
1H15N-HSQC spectrum - caused
on compound addition - can reveal residue-specific information, for example, CSP may
reveal compound binding sites. The Aβ40
1H15N-HSQC spectrum has previously been
assigned and published [364, 372]. Furthermore, effects of some small molecules on the
spectrum have also been studied, for example EGCG [428] (Figure 4.35).
Figure 4.35: Effect of EGCG on 1H15N-HSQC spectra of Aβ40.
1H15N-HSQC of 50 µM Aβ40 in 50 mM phosphate buffer, pH 7.4 at 5
oC apo (red) or
with a 3x molar excess of EGCG (blue). Reproduced from [428].
To aid interpretation of 1H15N-HSQC spectra collected, the assigned Aβ40 apo spectrum
is shown (Figure 4.36). Chapter 5 describes extensive condition optimisation of NMR
buffers - hence the buffer change from ammonium acetate to sodium phosphate in this
section - and the assignment process used.
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Figure 4.36: Assigned HSQC spectrum for Aβ40.
1H15N-HSQC spectra recorded using a 750 MHz Bruker spectrometer. 50 µM Aβ40
was solubilised in 20 mM sodium phosphate buffer, pH 7.4, containing 10 % D2O, 0.02
% (v/v) NaN3, 0.5 mM EDTA, and 2 % (v/v) DMSO at 5
oC. Peaks were assigned as
described in Section 5.1.4.
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1H15N-HSQC spectra were then collected for Aβ40 in the presence of a 3:1 compound
to peptide ratio (similarly to [428]) of each of the available query compounds (Figure
4.37). A 3:1 ratio of compound:peptide was used based on work by Fusco et al., [428], to
minimise compound self-association at the higher concentration. Given that the peptide
concentration had increased from 20 µM to 50 µM, the compound concentration would be
very high to maintain a 5:1 ratio (250 µM). If a compound bound to or near a backbone
amide, it would have caused an alteration in the magnetic environment around the nuclei
and this would have been evident as a CSP for the corresponding resonance.
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Figure 4.37: HSQC to detect chemical shift perturbations of Aβ40 in the presence of
A12a.
HSQC spectra recorded using a 750 MHz Bruker spectrometer. 50 µM Aβ40 was
solubilised in 20 mM sodium phosphate buffer, pH 7.4, containing 10 % D2O, 0.02 %
(v/v) NaN3, and 0.5 mM EDTA at 5
oC. 150 µM of each compound was added to the
Aβ40 sample as labelled and the spectrum (red) was overlaid with the apo (black)
spectrum to detect chemical shift perturbations.
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No chemical shift perturbations were observed on the addition of adapalene or bexarotene,
and only Gly9 and Glu11 shift (Figure 4.37, blue arrows) when 1,2-naphthoquinone is
added. Previously in the literature it has been shown that bexarotene does not interact
with the Aβ40 monomer in order to affect aggregation [472]. The results collected here
concur.
To explore whether any of the lead compounds interacted with Aβ40 under the conditions
used (20 mM sodium phosphate buffer, pH 7.4, containing 10 % D2O, 0.02 % (v/v)
NaN3, and 0.5 mM EDTA at 5
oC), 1H15N-HSQC spectra were recorded for Aβ40 in the
presence of 150 µM A12a, A13a, A14a, A21a, or Q06a (Figures 4.38 and 4.39).
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Figure 4.38: 1H15N-HSQC to detect chemical shift perturbations of Aβ40 in the presence
of A13a.
a) 1H15N-HSQC spectra were recorded as for Figure 4.37. 150 µM A12a was added to
the Aβ40 sample and the spectrum (red) was overlaid with the apo (black) spectrum to
detect chemical shift perturbations. . b) Zoomed in region of (a) with chemical shift
changes (blue arrows) and new resonance appearances (green arrows) to the Aβ40
spectrum on addition of a 3x molar excess of A12a.
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Figure 4.39: 1H15N-HSQC to detect chemical shift perturbations of Aβ40 in the presence
of other lead compounds.
1H15N-HSQC spectra were recorded as for Figure 4.37. 150 µM A13a, A14a, a21a or
Q06a was added to the Aβ40 sample and the spectrum (red) was overlaid with the apo
(black) spectrum to detect chemical shift perturbations. Chemical shift changes are
highlighted (blue arrows).
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The 1H15N-HSQC spectra of Aβ40 in the presence or absence of compound A12a are
distinct. There is evidence of peak shifts as well as evidence of some peak splitting which
is indicative of multiple conformations being populated and exchanging slowly with each
other. Compounds A13a, A14a and A21a show no perturbation in the chemical shifts of
the Aβ40
1H15N-HSQC spectrum which provides further evidence that these compounds
do not bind to Aβ40.
Q06a showed peak shifts for seven residues - Gly9, Glu11, Val12, Gln15, Lys16, Leu17
and Phe19- (Figure 4.39, blue arrows). This could indicate a region of Aβ40 which
interacted with Q06a. However, this region surrounded two histidines (His13 and His14)
which are very sensitive to mild pH changes, thus care must be taken to verify that the
effect seen is not due to pH.
In spite of the chemical shift perturbations observed for Q06a, other methods in the
toolbox showed there was no reproducible effect on Aβ40 aggregation, and that Q06a
did not interact with Aβ40 (under ESI-MS conditions). Moreover, the expected mass
(287 Da) was not present on ESI-MS of the compound alone (Figure 4.23) and extensive
investigation to identify the active molecule would have been necessary; this was beyond
the scope of this project. On the other hand, A12a showed a more pronounced influence
on the Aβ40
1H15N-HSQC spectrum and there was evidence of compound binding from
ESI-MS (Section 4.5.1). Due to this, A12a was chosen as the most promising lead
compound.
4.6.1 Analysis of Promising Compound A12a in Modulating Aβ40 Ag-
gregation and Discovery of Compound Stability
Since the chemical shift changes caused by compound A12a were most drastic it was
decided that further residue-specific investigation of this compound with Aβ40 was jus-
tified in order to locate specific residues which may interact with the compound. The
initial stage of this was to assign the Aβ40 + A12a spectrum. Upon remaking the NMR
sample, however, the chemical shift differences were no longer observed. To investigate
whether compound instability could be a cause of this finding, an aliquot of 10 mM A12a
in 100 % DMSO was exposed to air at room temperature over a period of two weeks. At
multiple time points the sample was subject to mass spectrometry (conducted by Owen
Cornwell, University of Leeds). The results of this are shown in Figure 4.40.
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Figure 4.40: ESI-mass spectra of the hydrolysis of A12a.
ESI-mass spectra of A12a initially (bottom), after 4 (middle), and after 8 (top) days of
exposure to air. The red arrows highlight the expected 407 Da mass of the compound
and the blue arrows highlight the increase in 425 Da oxidised product over time.
From this analysis it is evident that the 407 Da compound A12a is prone to modification
on contact with the air. On the initial day of exposure to air the compound exists as
a majority in the expected from. However by day four a modified, 425 Da product is
already the dominant species and by eight days the original compound is barely present.
The 425 species is 18 Da larger than the expected mass of A12a and is likely to be a
hydrolysed product (Figure 4.41). The 444 Da species present after four days of air-
exposure is un determined. Due to the hygroscopicity of DMSO it was possible that
when stock aliquots of A12a in DMSO are thawed, opened, and re-frozen there was
opportunity for water to enter the solution and hydrolyse the compound (Figure 4.41).
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Figure 4.41: Predicted hydrolysed product of A12a.
To explore whether the hydrolysed A12a product affected Aβ40
1H15N-HSQC CSPs
- and thus explain the irreproducibility of the CSPs observed (Figure 4.38) - 1H15N-
HSQC were collected for Aβ40 in solution with 3x molar excess of A12a which had been
exposed to the air for zero, four, or eight days (Figure 4.42). To complement this, ThT
fluorometry was also used to probe discrepancy in how A12a and the oxidised A12a
compound impacted Aβ40 aggregation kinetics.
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Figure 4.42: 1H15N-HSQC and ThT fluorescence investigation of the effect of compound
A12a on Aβ40 aggregation as it undergoes hydrolysis.
a) The 1H15N-HSQC spectra presented were recorded using a 750 MHz Bruker
spectrometer. 50 µM Aβ40 was solubilised in 20 mM sodium phosphate buffer, pH 7.4,
containing 10 % D2O, 0.02 % (v/v) NaN3, and 0.5 mM EDTA at 5
oC. To each sample
of Aβ40 150 µM A12a was added after either 0 (red), 4(purple), or 8 (blue) days. b)
ThT fluorescence analysis of the effect of zero, four, or eight days old A12a on Aβ40
aggregation. Analysis was conducted at 37 oC, quiescently with 20 µM Aβ40 in the
ammonium acetate buffer used previously for ThT analysis, MS, and TEM (50 mM
ammonium acetate, pH 6.8, with 2 % (v/v) DMSO and 10 µM ThT) and the sodium
phosphate buffer used for NMR in (b).
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The HSQC spectra showed no perturbation in chemical shifts for any of the A12a sam-
ples, thus, hydrolysed A12a was not responsible for the irreproducibility of the CSP
observed. In contrast, the Aβ40 aggregation profiles reported on by ThT fluorescence
show a dose-dependent effect on the extent of A12a hydrolysis in ammonium acetate
buffer, whereby more hydrolysis leads to an increased lag time and reduced maximum
fluorescence. In sodium phosphate, the converse is observed whereby only the unmodi-
fied A12a can increase the lag time of Aβ40.
Although this investigation did not reveal the cause of the irrepressible effects on Aβ40
1H15N-HSQC spectra, it did highlight an additional criterion which could be added to
the toolbox. It is well known that amyloid aggregation is sensitive to buffer conditions.
Testing whether compounds are able to modulate Aβ40 aggregation under a range of
buffer conditions would add a new level of stringency to the toolbox.
4.7 Discussion
The purpose of this chapter was to demonstrate the applicability of the method tool-
box developed in Chapter 3. Work was geared to identify a novel compound, or set
of compounds, which could modulate Aβ40 aggregation and then to probe how this
modulation was achieved. Although unsuccessful in identifying a new modulator of
Aβ40 aggregation, the testing of the toolbox conducted demonstrated the suitability of
method chosen and even highlighted an addition criteria for compounds which could
improve of the toolbox stringency (Figure 4.43).
The journey from library choice to being able to make an informed decision on compound
impact on Aβ40 aggregation has been documented in this chapter. The initial library
of compounds was chosen based on a focused screen using ROCS analysis. This was
followed by a ThT fluorometry screen to choose a subset of molecules for more detailed
investigation. Based on this screen, mass analysis was conducted on compounds of
interest to check the integrity of the library samples and commercial versions of the
compounds were purchased where possible. During this stage of the investigation there
were indications of compound instability as many of the library compound contained
unexpected masses, often in addition to the expected mass, but in the case of compound
Q06 the expected mass was not observed. As Q06 was still absent from the purchased
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Figure 4.43: The improved toolbox strategy for finding robust modulators of amyloid
aggregation.
The new step to ensure effectiveness of compounds in different buffers is highlighted in
blue.
form of this compound it is a clear indication that either Q06 was highly unstable
or that it was not amenable to ESI-MS analysis on the acetonitrile gradient. Despite
mass discrepancies it was interesting to investigate how the compounds could affect Aβ40
aggregation. The variation in compound structures was now broader than had originally
been planned as many of the library compound structures were clearly divergent from
the original query molecules.
The reproducibility of effects observed by compounds on Aβ40 aggregation was poor
when studied by ThT fluorometry. This projected some uncertainty onto whether the
ThT screen was an optimal method to use as the first step in finding potential inhibitors
of Aβ40. Nevertheless, the use of ThT fluorometry was justified due to its high false
positive rate as it would have been problematic to use a more stringent assay in the first
instance of compound testing due to the risk of obtaining false negative results. These
could have resulted in the exclusion of promising aggregation modulators from further
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investigation. False positive results are easily identified from the additional experiments
in the toolbox as discussed in Chapter 3. The alterations in the aβ40 aggregation kinetics
observed by ThT fluorometry were minor in comparison to the effects of query compound
1,2-naphthoquinone - the published inhibitor of amyloid aggregation. It was possible
therefore that the effects compounds had on the ThT profiles in the initial screen were
too small despite the significance indicated by the student t-test. Although a significant
inhibition or promotion affect on aggregation would have been interesting to study - and
to probe how a compound could cause such a large effect - the small changes detected
on Aβ40 kinetics may have indicated more subtle alterations in the Aβ40 monomer
conformation which would be identified using NMR. Based on the work conducted in
this chapter it may be worthwhile to derive threshold levels of perturbations observed by
ThT fluorometry. However, a balance must be struck in order to not exclude compounds
which can cause reproducible small changes in amyloid aggregation. This could be
achieved by requiring compounds to enter the screen multiple times.
As the ThT assay was only a single approach to detecting effects on Aβ40 aggregation,
the investigation was continued using the selection of structural methods proposed in the
previous chapter (and outlined in Figure 4.43) which provided insight into Aβ40 aggre-
gation from orthogonal perspectives. Use of TEM showed that none of the compounds
prevented Aβ40 forming fibrillar aggregates by the end point of the reactions and the
SDS-PAGE fibril yield assay showed that aggregates were formed reproducibly.
The ESI-MS was a useful indication of interaction between the compounds and Aβ40.
After the ESI-MS, compound A12a was most interesting as an intereaction between
A12a an dAβ40 was observed. Ideally, a compound hit would have exhibited specific
binding to Aβ40 and its site of interaction could then have been probed in subsequent
NMR experiments. Had this been the case, 1H15N-HSQC experiments would have been
carried out using a titration of compound concentrations in order to measure a binding
affinity. If the binding affinity was too high to be observed by NMR, then alternative
methods, such as surface plasmon resonance could have been considered, optimised and
used.
The observation of A12a effects on the Aβ40 spectrum by NMR was exciting. Although
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compound stability issues prevented further investigation into the A12a-Aβ40 interac-
tion and how Aβ40 conformation was affected, it demonstrated that the use of
1H15N-
HSQC spectra was a useful tool to use as an indication of compound-Aβ40 interaction.
The instability of the compounds investigated, namely A12a, explains some of the irre-
producibility of results and some of the discrepancies in compound effects, e.g. when
compounds could promote aggregation in one instance and then delay aggregation in
another repeat of the experiment. This is possibly due to different compound species and
population distributions being present in the compound stocks. The difficulty in work-
ing with these compounds makes them non-ideal candidates for future study into the
mechanism of Aβ40 aggregation. Closer investigation as to why Q06a affected the Aβ40
1H15N-HSQC spectrum could have been interesting but work was needed to identify the
compound identity.
Through the investigation into A12a stability, the contrasts in compound effects on
Aβ40 in different buffers were highlighted. Some of the methods in the toolbox were
more suited to different buffers, for example, ESI-IMS requires a volatile, low-ionic buffer
such as ammonium acetate. However, for NMR, the volatile nature of ammonium acetate
caused concerns over sample ‘bubbling’ on application of magnetic pulses. For NMR,
sodium phosphate is ideal as it can be pH-ed using mono- and di-basic forms rather
than typical use of NaOH/HCl which increases salt content. Due to this, an additional
step in the toolbox was suggested whereby compounds were tested for effects on Aβ40
aggregation in different buffers to monitor the stringency of compound robustness.
At this stage, compound profiles were assessed to decided whether any of the lead com-
pounds were reliable modulators of Aβ40 aggregation. For the compound investigated,
it was decided that none of the compounds were robust modulators of amyloid aggrega-
tion and thus did not warrant further investigation to assess in vivo effects - using the
β-lactamase assay - or for residue-specific profiling by NMR investigation.
Despite not identifying a novel modulator of amyloid aggregation, the testing of the
toolbox has been worthwhile as it has led to the improvement of the toolbox strategy
which can be applied in the future to other sets of compounds.

Chapter 5
Residue Specific Investigation
into the Intrinsically Disordered
Aβ40 Peptide
The methods toolbox which was brought together in Chapter 3, and applied in Chapter
4, focused on a combination of complementary techniques to identify small molecules
which could modulate Aβ40 aggregation. This chapter set out to prepare the framework
for study into how these small molecules caused their effects on Aβ40 aggregation at
a residue-specific level using NMR techniques. Hence this chapter brings together an
NMR-based strategy which can probe the influence of small molecules on amyloidogenic
IDPs. To demonstrate the techniques, and to create a set of data for future comparative
analysis, the structural and dynamic properties of Aβ40 (without small molecules) are
measured under optimised conditions which are suitable for small molecule addition
later.
As discussed in the introduction, IDPs do not exist solely as a random coil, but instead
are an ensemble of transiently inter-converting states. Characterisation of the Aβ40
monomer ensemble has been conducted previously using a combinatorial approach in-
cluding multiple structural methods, e.g. CD and NMR, to generate parameters which
have been used in molecular modelling. Conformational ensembles are excellent re-
sources for understanding the behaviour of IDPs such as Aβ40 monomer. However, the
219
Residue Specific Investigation into the Intrinsically Disordered Aβ40 Peptide 220
nature of the modelled, landscape inherently means that measured parameters are aver-
aged and precise data are moulded into an overall, snapshot of structural probabilities.
The purpose of this work is to be able to characterise the precise difference in ensem-
ble properties on addition of small molecules - which can perturb amyloid formation.
As the Aβ40 monomer exists as a heterogeneous, dynamic ensemble, a variety of NMR
techniques must be implemented to probe different attributes of the peptide - such as
structural features, structural preferences and dynamic regions-. Assimilating a set of
experimental data which are highly sensitive to even subtle structural or dynamic per-
turbations in Aβ40 - which occur on small molecule addition - will yield insight into key
features of the amyloid formation pathway of the peptide.
All NMR measures are an ensemble average of all the Aβ40 molecules in solution. In a
calculated energy landscape, small changes in conformation stability may be overlooked
or subsumed into the general error of the predictions. However, directly comparing
parameter measures ensures small changes can be noted and not overlooked. This is
the power of such a sensitive technique. This work will act as a reference to future
work in the amyloid field, especially related to small molecule perturbations in Aβ40
conformation in the early stages of aggregation.
One of the major benefits of using NMR to probe the Aβ40 conformation ensemble is that
residue specific information can be obtained and different thermodynamic and kinetic
properties can be monitored. Firstly different buffer conditions were tested to ensure
Aβ40 could be monitored along the entire length of the peptide distinguishing features
of the N-, C-terminal regions and central regions of the peptide chain. Section 5.1
depicts the effects of two buffer compositions, pH, temperature, and DMSO. A DMSO
titration was conducted in order to ensure compatibility of the Aβ40 apo methods and
measurements with future Aβ40 investigations with small molecules.
Narrow dispersion in the 1H dimension of the NMR 1H15N-HSQC spectrum can indicate
intrinsic disorder in a peptide because the flexible chain yields little variation in backbone
amide environments (i.e. most interact only with their neighbouring residues and have
a similar level of exposure to the solvent, and consequently to hydrogen exchange with
the solvent).
To probe conformational features and the structural propensity of the Aβ40 backbone
and to reveal deviations from random coil conformations, three methods were used:
Residue Specific Investigation into the Intrinsically Disordered Aβ40 Peptide 221
δCα chemical shifts (Section 5.2.1), which constitute an empirically based method to
predict regions of secondary structure; temperature coefficients of backbone 1H amide
shifts (Section 5.2.2), which reveals probability of participation in hydrogen bonding;
and residual dipolar couplings (RDCs) (Section 5.2.3) which are very sensitive probes
of secondary structures propensity.
To monitor the fast (ps-ns) and slow (µs-ms) dynamic movements of the Aβ40 pep-
tide, R2 measurements (or T2 measurements, as R2=1/T2) (Section 5.3.1)and heteronu-
clear NOEs (hetNOEs) (Section 5.3.2) were collected, as described in Section 2.2.5.5.
Examples of motions which occur on fast dynamic timescale include bond rotations
and vibrations, whereas slower motions include binding, folding and unfolding events
[367, 379, 473]).
These methods were chosen as they can inform on multiple, complementary, aspects of
Aβ40 behaviour. Together the methodological approach is sensitive to small effects on
Aβ40 structural propensity and dynamics [474–476]. The approach has the potential
to reveal major and even very subtle perturbations in the Aβ40 ensemble caused by
small molecule addition. Future application of this work has the potential to reveal key
structural transitions for specific regions of the peptide which may be vital in the amyloid
aggregation mechanism. Ultimately, it is a potential tool to direct small molecule design
for either therapeutic or further investigatory studies.
5.1 Prerequisities to the study of Aβ40 by NMR
5.1.1 Optimisation of Sample Conditions for NMR Investigation
In order to maximise the information gained from NMR investigation, it was important
to select conditions which would provide well-resolved peaks for the majority of the back-
bone amides of Aβ40. It is well known in the literature that both amyloid formation and
IDP behaviour are greatly affected by buffer conditions such as salt concentration, ionic
strength, pH, temperature, as well as peptide concentration. In this project, buffer salts,
temperature, and pH were varied to find optimal conditions for NMR data collection as
described in this section.
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5.1.1.1 Comparing Ammonium Acetate and Sodium Phosphate as Buffers
for NMR Samples
To ascertain whether Aβ40 could yield clear NMR signals,
15N-labelled Aβ40 was recom-
binantly expressed and purified (see Sections 2.2.2.1 and 2.2.2.3). To aid comparison
with previous work in this thesis, the peptide was solubilised in the same buffer used
in the ThT, MS and TEM studies described in Chapters 3 and 4; 50 mM ammonium
acetate, pH 6.8. Figure 5.1a shows the 1H15N-HSQC spectrum for 50 µM Aβ40, at 37
oC. This spectrum showed 30 resolved peaks corresponding to 30 backbone amides out
of a potential 40. Even at this initial, pre-optimised stage, it was promising that Aβ40
would be amenable to NMR investigation.
With an aim to increase the appearance of more amide resonances an alternative buffer
was tested: 20 mM sodium phosphate buffer (Figure 5.1b). The sodium phosphate buffer
was chosen based on work by Newby et al., [372] which presents Aβ40 apo
1H15N-HSQC
spectra with 38 peaks evident (26 well-resolved peaks, 8 partially-overlapped peaks, and
4 substantially-overlapped peaks).
Overall, both spectra were very similar indicating that the peptide adopts conformations
which are similar in both buffers. Notably each of the spectra presented in Figure
5.1 show good dispersion in the 15N dimension, but are only narrowly dispersed in
the 1H dimension which is indicative of an intrinsically disordered peptide. As there
was precedent in the literature using Aβ40 in a sodium phosphate buffer [372], 20 mM
sodium phosphate was taken forward as the buffer to optimise for residue specific NMR
investigation of Aβ40. The reason for this precedent is because phosphate is a non-
protonated buffer and therefore does not obscure protein signals.
5.1.1.2 Effect of Temperature on the 1H15N-HSQC Aβ40 Spectrum
Next, the effect of temperature on signal intensity was tested. It was important to
acquire data under conditions which gave rise to intense peaks to minimise acquisition
time which is particularly important for an aggregation prone system such as that of
Aβ40. Figure 5.2 shows the change in
1H15N-HSQC spectra when acquired at 5 oC and
37 oC.
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Figure 5.1: Preliminary 1H15N-HSQC spectra of Aβ40 in different salt solutions
a) 50 mM Aβ40 in 50 mM ammonium acetate, pH 6.8, 37
oC, with 10 % D2O. b)
Figure a (black) overlaid with the HSQC spectrum of 50 mM Aβ40 in 20 mM sodium
phosphate, 0.5 mM EDTA, 0.02 % (w/v) NaN3, pH 6.8, 37
oC (red). All spectra were
acquired using a 750 MHz spectrometer with a TCI-cryoprobe; 1H-optimised triple
resonance NMR inverse probe and Bruker Avance III HD console.
In globular proteins, increased temperatures usually lead to greater signal intensity be-
cause of faster tumbling, and therefore faster R2 relaxation rates leading to sharper
peaks with narrower linewidths. In contrast, the opposite is typical for IDPs as signif-
icant line broadening occurs at higher temperatures. Line broadening is observed as a
result of the fast exchange of 1HN protons with water. As expected, a decrease in peak
intensity was observed for Aβ40 as the temperature was increased to 37
oC. Thus, the
best spectrum quality was observed when data were acquired at 5 oC. In conclusion from
this experiment, further NMR investigation was conducted at 5 oC.
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Figure 5.2: Comparision of 1H15N-HSQC spectra of Aβ40 at high and low temperatures.
1H15N-HSQC spectrum of 50 mM Aβ40 in 20 mM sodium phosphate, 0.5 mM EDTA,
0.02 % (w/v) NaN3, pH 6.8, with 10 % D2O acquired at either 37
oC (left panel, red)
or the same sample acquired at 5 oC (right panel, black). Both spectra were acquired
using a 750 MHz spectrometer with a TCI-cryoprobe; 1H-optimised triple resonance
NMR inverse probe and Bruker Avance III HD console.
5.1.1.3 Effect of pH on the 1H15N-HSQC Aβ40 Spectrum
Next, a pH titration between 6.8 and 7.4 was conducted (Figure 5.3) using the conditions
previously optimised: 20 mM sodium phosphate buffer, at 5 oC. Altering the pH may
enable separation of some overlapping peaks, for example, His residues are very sensitive
to pH as they can experience different protonation states close to physiological pH and
thus a change in the nuclei magnetic environment is experienced. This is represented on
the 1H15N-HSQC spectrum as a chemical shift change.
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Figure 5.3: Aβ40
1H15N-HSQC spectra dependence on pH.
1H-15N-HSQC spectrum of 50 mM Aβ40 in 20 mM sodium phosphate, 0.5 mM EDTA,
0.02 % (w/v) NaN3, 5
oC, with 10 % D2O across a pH gradient: pH 6.8 (light blue),
pH 7.0 (mid-blue), pH 7.2 (dark blue), pH 7.4 (black). Red arrows and peak labels
highlight resonances which are affected by pH and the zoom in region (black box)
shown in the top right clarifies the movement of some of the overlapping amide signals.
Samples were made as described in 2.2.5.5 and the pH adjusted using 10 mM NaOH
and HCl. All spectra were acquired using a 750 MHz spectrometer with a
TCI-cryoprobe; 1H-optimised triple resonance NMR inverse probe and Bruker Avance
III HD console.
As expected, there are large shifts observed for Histidine residues (His6, His 13, and
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His14) and the sequential amino acids (Arg5, Asp7, Ser8, Gly9, Tyr10, and Gln15,
Lys16, Leu17) likely to be caused by the change in Histidine protonation.
The lower limit of this pH titration was chosen for consistency with ThT, ESI-IMS-
MS, and TEM data in the previous chapter, and the upper limit was chosen based on
conditions used in a published investigation of Aβ40 by Newby et al., [372]. Newby
et al., published the pKH values of His6, His13, and His14 in Aβ40 (without the N-
terminal methionine) as 6.85, 6.81, and 6.79 respectively. In fact, the paper [372] goes
onto quantify the extent of protonation for each Histidine at pH 6.8, ∼ 50 % chance of
protonation, and pH 7.4, ∼ 20-25 % chance of protonation. This is consistent with the
chemical shift changes observed in this study.
It was decided to conduct further NMR experiments at pH 7.4 as most peaks were well
resolved with strong peak intensity. Moreover, aligning pH with previous work in the
field enabled comparison of results.
5.1.2 Ensuring Stability of the Aβ40 Peptide for the Time Period Re-
quired for NMR Data Acquisition
For some NMR experiments, including 3D experiments and relaxation measurements,
long acquisition times are needed to obtain the necessary resolution and sensitivity.
This is especially true when measuring IDP parameters which are likely to exhibit very
small changes. To investigate whether Aβ40 would be suitable for long experimentation
the peak intensity of the Aβ40 sample was monitored over 16 hours, Figure 5.4, using
1H15N-HSQC spectra.
In contrast to the ThT assays presented in Chapter 4, Section 4.6.1, Figure 5.4 suggests
that Aβ40 is stable in 20 mM sodium Phosphate, pH 7.4, 5
oC as the peak intensity
only decreases by a maximum of ∼ 20 %. There are no chemical shift perturbations or
new resonances detected suggesting the absense of conformational changes over this time
period. This finding suggests that monomeric Aβ40 is the most populated species over 16
h under the NMR conditions. Based on this experiment, these buffer conditions would be
suitable for the study of Aβ40 using long NMR procedures, including 3D experiments for
spectral assignment in Section 5.1.4, R2, and hetNOE relaxation measurements (Section
5.3.1 and Section 5.3.2).
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Figure 5.4: Stability of Aβ40 in optimised buffer conditions.
Change in peak intensity of the 1H-15N-HSQC spectrum of 50 mM Aβ40 in 20 mM
sodium phosphate, 0.5 mM EDTA, 0.02 % (w/v) NaN3, pH 7.4, 5
oC, with 10 % D2O
over 16 h (red) compared to the initial spectrum at 0 h (black). All spectra were
acquired using a 750 MHz spectrometer with a TCI-cryoprobe; 1H-optimised triple
resonance NMR inverse probe and Bruker Avance III HD console.
5.1.3 The Effect of DMSO on Aβ40 Conformation
A requirement of the methodological approach devised in this chapter is its compatibility
with small molecule presence in samples of Aβ40. DMSO (a weakly acidic, polar, and
aprotic compound) is a largely universal solvent. Due to this, DMSO is commonly used
to solubilise small molecules in high-throughput compound screening [477], as has been
implemented in this thesis in Chapter 4 which used small compounds stock solutions in
DMSO. Thus, to compare measured parameters between Aβ40 and Aβ40 in the presence
of small molecules, a small amount (< 10 % (v/v) of the sample volume) of DMSO must
be included in the buffer composition.
To measure the extent of spectral perturbation caused by DMSO, a titration of DMSO
percentages was conducted. Figure 5.5, shows a titratable effect is observed for chemical
shift position on increasing the DMSO percentage of the sample from 0 % to 6 %
(v/v). Only small perturbations were observed upon DMSO titration suggesting that
the presence of up to 6 % (v/v) DMSO does not significantly change Aβ40 conformation.
As all of the compounds listed in Chapter 4 were solubilised in 100 % DMSO before
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incorporation into Aβ40 samples, DMSO was present in all of the samples. In Chapter 4
the majority of samples contained 2 % (v/v) DMSO, thus 2 % (v/v) DMSO was selected
for Aβ40 analysis for consistency.
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Figure 5.5: Monitoring the effect of DMSO percentage on the 1H15N-HSQC spectrum
of Aβ40.
1H-15N-HSQC spectra of 50 mM Aβ40 in 20 mM sodium phosphate, 0.5 mM EDTA,
0.02 % (w/v) NaN3, pH 7.4, 5
oC, with 10 % D2O across a gradient of DMSO: 0 %
(dark red), 2 % (v/v) (red), 4 % (v/v) (pink), and 6 % (v/V) (light pink). Black arrows
and resonance labels highlight changes in chemical shifts of some residues. All spectra
were acquired using a 750 MHz spectrometer with a TCI-cryoprobe; 1H-optimised
triple resonance NMR ‘inverse’ probe and Bruker Avance III HD console.
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As a result of the preceding work to optimise buffer conditions for NMR data collection
the following composition was used for sample preparation: 50 µM Aβ40, 20 mM sodium
phosphate buffer including 0.02 % (w/v) NaN3, 0.5 mM EDTA, 10 % D2O, 2 % DMSO
(v/v), at pH 7.4.
5.1.4 Backbone Amide Assignment of Aβ40
NMR spectral assignment for globular proteins and IDPs is well established with multiple
methods which can be used [478, 479]. These methods tend to rely on coherence transfer
steps between backbone 13C and 15N nuclei as well as associated 1H nuclei. For Aβ40,
good assignment was achieved from standard 3D assignment methods, due to its small
size.
The backbone assignment of Aβ40 was previously published under varying conditions
[367, 372, 480–482], including those similar to the optimised sample conditions used
in this work [372]. Due to the nature of IDPs and their great sensitivity to small
environmental changes, validation of previous assignment of the recombinantly expressed
Aβ40 was performed (Figure 5.6 and Table 5.1) using a 3D Best Trosy HNCA experiment
described in Section 2.2.5.5. Comparison to published spectra, and pH dependence
behaviour observed previously was used to validate the assignments.
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Figure 5.6: Assigned 1H15N-HSQC spectrum of Aβ40.
Left: Vertical sequence of Aβ40 showing extent of assigned amides (red), overlapping
amides (blue) and unassigned amides (black). Right: Assigned 1H-15N-HSQC
spectrum of 50 mM Aβ40 in 20 mM sodium phosphate, 0.5 mM EDTA, 0.02 % (w/v)
NaN3, pH 7.4, 5
oC, 2 % (v/v) DMSO with 10 % D2O. Acquired using a 950 MHz
Bruker Ascend Aeon, Next-generation ultra-high field NMR magnet with a
TXO-cryoprobe or a TCI-cryoprobe; 1H-optimised triple resonance NMR inverse probe
and Bruker Avance III HD console.
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Table 5.1: Table of 1H, 15N, and 13C values for each residue in Aβ40. Resonances are
given in ppm and those preceded by a ‘t’ indicate that these assignments are tentative.
Residue 1HN 15N 13Cα
Met0 - - t51.530
Asp1 t8.517 t125.273 t49.807
Ala2 - - -
Glu3 8.360 120.638 53.670
Phe4 8.196 121.953 54.796
Arg5 8.060 124.074 52.591
His6 8.406 122.236 53.350
Asp7 8.349 122.275 51.047
Ser8 8.417 117.240 56.112
Gly9 8.525 111.323 42.381
Tyr10 7.932 120.639 55.278
Glu11 8.369 123.075 53.576
Val12 8.074 121.766 59.819
His13 8.271 123.016 53.143
His14 8.210 121.662 53.329
Gln15 8.405 122.055 52.914
Lys16 8.398 123.754 53.390
Leu17 8.264 124.512 52.123
Val18 7.995 122.153 58.953
Phe19 8.269 125.062 54.452
Phe20 8.227 123.621 54.346
Ala21 8.244 126.797 49.364
Glu22 8.378 120.221 53.614
Asp23 8.424 122.441 51.105
Val24 8.164 121.335 59.796
Gly25 8.550 112.362 42.489
Ser26 8.140 116.104 55.553
Asn27 8.480 121.154 50.249
Lys28 8.351 122.325 53.733
Gly29 8.418 110.140 42.156
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Continuation of Table 5.1
Residue 1HN 15N 13Cα
Ala30 8.021 124.129 49.432
Ile31 8.188 121.386 58.067
Ile32 8.294 126.969 58.168
Gly33 8.476 113.720 42.148
Leu34 8.056 122.254 52.116
Met35 8.451 122.623 52.223
Val36 8.253 123.078 59.567
Gly37 8.610 113.819 42.204
Gly38 8.255 109.277 42.072
Val39 8.080 120.484 59.478
Val40 7.818 128.990 60.782
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Figure 5.7: Examples of how Aβ40 spectral assignment was conducted.
Two examples of how backbone assignments were performed using a HNCA
experiment of 50 mM Aβ40 in 20 mM sodium phosphate, 0.5 mM EDTA, 0.02 % (w/v)
NaN3, pH 7.4, 5
oC, 2 % (v/v) DMSO with 10 % D2O. Acquired using a 950 MHz
Bruker Ascend Aeon, Next-generation ultra-high field NMR magnet with a
TXO-cryoprobe or a TCI-cryoprobe; 1H-optimised triple resonance NMR inverse probe
and Bruker Avance III HD console. The most intense peak in each strip corresponds to
the ‘i’ and the weaker peak is the ‘i-1’ residue which enables matching up of strips to
permit assignment. For Met35 the i and i-1 peaks overlap which is confirmed by the
alignemnt of Leu34i peak and Val26i-1 peaks.
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The unassigned resonance has been tentatively assigned to Asp1 though may represent
Met0 (as the Aβ40 used in this study has an N-terminal Methionine). However, as an i-1
peak is detected (Figure 5.8) it is more likely to represent Asp1 than Met0 as generally
the N-terminal amide experiences too great line broadening from hydrogen exchange
with the solvent to give a detectable resonance. Macao et al., [391] published 2D amide
spectra for Aβ40 and Met-Aβ40. For the peptide with the N-terminal methionine a peak
is observed in a similar location to the unassigned peak whereas the Aβ40 spectrum
shows no resonance here. Whether this resonance represents Met0 or Asp1 is non-vital
for this investigation as it can be use to represent a marker for the far N-terminal region
of the peptide (in further analyses this resonance will be referred to as tentative Asp1
(tAsp1).
Figure 5.8: Evidence for the tentative assignment of Asp1.
Due to the lack of correlation between the the i-1 peak observed for Glu3 and the
peaks for the unassigned resonance, Ala2 can be ruled out, leaving only Met0 or Asp1.
Sample and data collection as in Figure 5.7.
38 out of the 41 residues were assigned using the HNCA data (Figure 5.6) from detection
of i and i-1 peaks in the HNCA spectra, Figure 5.7. Ala2 was not observed and there
was one unassignable resonance remaining. Of these 38 residues, six are overlapping
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so will be excluded from NMR analysis: His6 and Gln15, Asp7 and Lys28, His13 and
Val36. Thus for further NMR analysis there is an expected 80 % sequence coverage.
In summary, there is almost complete assignment of the Aβ40 peptide and a significant
amount of well resolved peaks making this an appropriate system to profile how well a
complementary set of NMR methods can be used to investigate IDP conformers. The
subsequent sections in this chapter show how, using a combination of NMR techniques,
a precise and detailed comparative set of parameters of an IDP can be ascertained.
On identification of small molecules which can influence amyloid aggregation, these
parameters can be compared to ligand-bound states of Aβ40 to reveal specific regions of
the peptide which experience either a change in structural propensity or flexibility.
5.2 Characterisation of residue-specific structural propen-
sity in IDPs
This work strives to collate a method strategy for the investigation of important con-
former or structural motifs. To this end, structural investigation of Aβ40 by NMR
techniques was conducted as described in this section.
5.2.1 Predicting Secondary Structure using δ13Cα Chemical Shifts
Chemical shifts can be good reporters of backbone conformation and there has been
focus to develop approaches to exploit this to probe local structural propensities of IDPs
(reviewed in [483]). Such approaches use deviations from empirically defined random
coil values to imply local geometries and to quantify secondary structure propensities
[484–486]. As previously mentioned, the 1H dispersion observed for Aβ40 is narrow
which is indicative of an IDP. δ13Cα chemical shifts can provide further insight into
secondary structure. Using the HNCA data used for spectral assignment (Figure 5.1.4),
the ∆δ13Cα chemical shifts can be calculated using the following equation:
∆δCα = δCαi − δCαrandom coil (5.1)
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Where δ Cαi is the δ Cα position obtained from the experimental data, and δ Cαrandom coil
is the δ Cα position predicted if that Cα atom was part of a random coil. For this anal-
ysis, ∆δ13Cα chemical shifts were calculated within CCPNAnalysis which bases random
coil chemical shifts prediction on [392, 393].
Figure 5.9: Backbone conformation indication from 13Cα chemical shifts.
δ13Cα values for each residue in Aβ40 calculated in CCPNAnalysis whereby the
13Cα
chemical shifts are subtracted from the predicted values had the peptide existed as an
entirely random coil.
Residues involved in α-helices have δ13Cα chemical shifts of greater than 2 ppm [376]
whereas residues within β-sheets exhibit negative values less than -2 ppm [376]. Figure
5.9 shows the majority of the δ13Cα chemical shifts are within 2 ppm of zero showing
strong evidence for intrinsic disorder across the length of the peptide.
NMR 13Cα chemical shift analysis will be a fast way to extract initial indications of
α-helical perturbations on addition of small molecules using previously acquired data.
Notwithstanding, this is only a predictive mechanism based on empirical evidence and
thus structural propensity needs to be measured specifically using other methods as
described in the subsequent sections.
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5.2.2 Hydrogen-bonding and Secondary Structure Indications from
Temperature Coefficients
The probability of elements of secondary structure forming can be predicted for each
residue. Measurement of the extent to which the 1H-chemical shift of amide protons is
perturbed across a temperature gradient can indicate residues which are more likely to
be involved in intramolecular, backbone hydrogen bonding oposed to those involved in
solvent hydrogen bonding [378, 487–490]. These parameters are known as 1HN-chemical
shift temperature coefficients (1HN-CSTC) and can be used to distinguish intrinsically
disordered regions from structured regions of a peptide. 1HN-CSTCs are able to shed
light on hydrogen bonding due to the thermal expansions in bond length which occur
as temperature increases [378]. Larger expansions are more likely between backbone
amides and surrounding water molecules than between backbone amide-amide hydrogen
bonds due to the less restricted movement of the solvent.
1H15N-HSQC spectra were collected across a temperature gradient (5 oC, 15 oC, 20
oC, 25 oC, and 37 oC) and are presented in Figure 5.10a. The spectra are referenced
as described in Section 2.2.5.5 and resonances show the expected upfield shift which is
typically observed on temperature increase for IDP spectra.
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Figure 5.10: Amide temperature coefficients in Aβ40.
(Figure legend continued on the following page)
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Figure 5.10: a) 1H-15N-HSQC spectra of 50 mM Aβ40 in 20 mM sodium phosphate, 0.5
mM EDTA, 0.02 % (w/v) NaN3, pH 7.4, 2 % (v/v) DMSO, with 10 % D2O across a
temperature gradient: 5 oC (cyan), 15 oC (blue), 20 oC (green), 25 oC (orange), and
37 oC (red). All spectra were referenced using the water peak position and the 1H
temperature factor -0.0119 ppm/o [376] acquired using a 750 MHz spectrometer with a
TCI-cryoprobe; 1H-optimised triple resonance NMR inverse probe and Bruker Avance
III HD console. b) Exemplar plots of the linear correlation between 1H chemical shift
position and temperature increase for each resonance (the complete set are in Appendix
B.1). The gradient of the linear fit is the temperature correlation coefficient plotted
in (c). -3.6 is an empirical cut off value to imply disorder [378]. Predicted regions of
structural propensity (think lines) are shown in the purple schematic.
From Figure 5.10a, the temperature titration enables clear peak monitoring for most of
the resonances observed in the original 5 oC despite the change in chemical shift position.
Monitoring the change in peak position in the 1H dimension shows a linear dependence
on temperature for each residue, a selection of examples are presented in Figure 5.10b.
The intensity of some peaks become too low for detection at higher temperatures due
to increased exchange with water but there are enough data points for most residues to
plot a reliable linear fit which can be used to calculate the 1HN-CSTC values (Figure
5.10c).
The more negative the 1HN-CSTC is, the less likely the amide is involved in a hydrogen
bond. The purpose of using 1HN-CSTCs in this study is as a predictor of regions which
may be more prone to forming secondary structure. However, as the distinction between
structured and unstructured regions is not fully equivalent to hydrogen bonded or non-
hydrogen bonded states, an empirically derived threshold value of - 3.6 ppb/K was
used in Figure 5.10, to distinguish intrinsically disordered regions [378]. From the data
presented, no regions of secondary structure are evident, indeed the 1HN-CSTCs for all
residues are well into the disordered segment of the graph.
To summarise, based on 1HN-CSTC analysis, the entirety of Aβ40 is intrinsically disor-
dered with no regions indicating propensity to form Hydrogen-bonded secondary struc-
ture elements. The conformational flexibility and dynamics can be inferred from the lack
of secondary structure elements as loops and random coils are more likely to exhibit fast
flexible movement than rigid α-helices or β-sheets.
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5.2.3 Characterisation of Residual Secondary Structure Elements in
Aβ40 using RDCs
Use of RDCs as an indicator of structural propensity for regions of an IDP has many
advantages over other methods including ∆δCα predictions and 1HN-CSTCs. For many
IDPs, measurement of RDCs can be used as a highly sensitive tool to obtain residue-
specific structural propensities and are commonly used for structural ensemble calcula-
tions and MD simulations of IDPs [415] as they can yield insight into conformer inter-
change on up to a ms timescale and are sensitive to transient long-range interactions
[362, 374, 375]. A current trend is to use RDCs to study unfolded proteins [491–494],
akin to an IDP, for example, efforts have been made to monitor the conformational
space of urea-denatured ubiquitin [491, 495]. Measured RDC values are averages of the
whole ensemble of dipolar interactions within a protein, including all protein conformers
interconverting at time scales faster than the inverse of RDC values (1/RDC s) [495].
RDCs were used in this work to contribute to the backbone investigation of Aβ40 by
mapping regions of structural propensity. Future studies can analyse how the pattern
of structural propensity is altered by the addition of compounds which perturb amyloid
aggregation.
The method exploits the dependence of dipolar coupling of an NH backbone amide on
its vector orientation with respect to the magnetic field vector [362, 375]. RDCs in IDPs
are very sensitive to local structure propensities. RDCs provide valuable information
about the conformational properties of proteins, including IDPs, and reports on both
local and long range structure [363]. RDCs are a measure of the through-space dipolar
interaction between two nuclei, given by Equation 5.2.
Dij = −γiγjhµ0
4pi2r3
(
3cos2θ − 1
2
)
(5.2)
where γi, γj are the gyromagnetic ratios of each nucleus, h, Plank’s constant, µ0 the
permeability of a vacuum, r, the distance between nuclei i and j, and θ the orientation
of the nuclear vector within the external magnetic field. RDCs contain information on
long range angular information of internuclear vectors. In isotropic solutions proteins
are free to tumble randomly, thus θ can take all possible values and hence the dipolar
coupling, Dij, in Equation 5.2 averages to zero. RDCs arise when the tumbling of proteins
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is restricted, reducing the range of values θ can take, and thus giving rise to a non-
zero dipolar coupling. Restriction of tumbling can be achieved by adding an alignment
medium to a protein sample, for example a filamentous bacteriophage, polyacrylamide
gel, or lipid bicelles [496], Figure 5.11a.
Figure 5.11: Representation of how RDCs are measured from protein samples.
a) Addition of an alignment medium (grey cylinders) to a protein solution (blue
protein, PDB: 1AM2, [497]) restricts the protein tumbling. b) Interactions between the
alignment medium and folded proteins biases protein orientation. Interaction of the
medium with disordered proteins still permits peptide chain flexibility. c) For folded
proteins, the angle θ is non-zero due to the biased orientation of the protein in the
magnetic field. d) An undecoupled HSQC spectrum in isotropic and aligned solutions.
RDCs are calculated by the different in splitting of the aligned and isotropic peaks.
In this study, protein tumbling was restricted using filamentous bacteriophage Pf1 (Sec-
tion 2.2.5.5), a commonly used alignment medium [496]. When in solution, proteins will
associate with the Pf1 meaning their orientation will be biased in a specific way. The
angle, θ which a heteronuclear bond vector takes whilst in this orientation, is measured
relative to the external magnetic field, B0 (Figure 5.11c). For folded proteins a large
percentage of the population will adopt the same orientation (Figure 5.11b) so θ is heav-
ily biased providing a large RDC. For an IDP - or for an unfolded protein [498]- the
Residue Specific Investigation into the Intrinsically Disordered Aβ40 Peptide 243
flexibility and lack of defined structure still permits great variation in vector orientation
with respect to B0 even though they interact with the Pf1 matrix (Figure 5.11b). Thus
for IDPs, the angles θ can adopt are only slightly biased and the RDC is close to zero.
The RDC for each vector is calculated from the probability of alignment. RDCs are
typically measured using inphase-antiphase (IPAP) sequences which separate the up -
and downfield components of the J-coupled doublet, (Figure 5.11d) [363, 499].
Due to the flexibility of IDPs, they generally align parallel to the external magnetic
field in an extended conformation. This gives rise to negative RDCs for the majority of
the peptide. The termini usually have RDCs very close to zero due to their dynamic
freedom, thus a shallow, bowl-shaped curve is expected [363, 498, 500, 501].
Due to the sensitivity of IDPs to buffer conditions, care must be taken to ensure the
IDP conformational ensemble is not majorly perturbed by the addition of the align-
ment medium. Pf1 filamentous bacteriophage was used previously in work by Newby
et al., [372] which probed the relationship between alignment medium and Aβ40, which
concluded that Pf1 did not majorly perturb the Aβ40 peptide [372].
Figure 5.12 shows the dipolar splitting of the unaligned (Figure 5.12a) and aligned (Fig-
ure 5.12b) samples of Aβ40 (prepared as optimised in Section 5.1 and described in Sec-
tion 2.2.5.5) which were collected using standard interleaved Bruker IPAP experiments.
The spectra show the decoupled ‘up and down’ peaks which are usually combined in a
HSQC spectrum. The magnitude of the dipolar coupling depends on the angle between
the internuclei vector (HN) and the external magnetic field as well as the internuclei
distance. As the dipolar interaction is between two covalently bonded nuclei, the inter-
nuclear distance is mostly fixed and mainly the orientation dependence influences the
RDC [495].
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Figure 5.12: RDC probes of Aβ40 structural propensity.
(Figure legend continued on the following page) .
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Figure 5.12: a) Overlaid ‘up (grey) and down (black)’ spectra of Aβ40 in the optimised
sample buffer: 50 mM Aβ40 in 20 mM sodium phosphate, 0.5 mM EDTA, 0.02 % (w/v)
NaN3, pH 7.4, 5
oC, 2 % (v/v) DMSO with 10 % D2O. b) Overlaid ‘up (light blue) and
down (blue)’ spectra of Aβ40 in the optimised sample buffer as in (a) with 26 mg/ml
Pf1 alignment medium. c) RDC values: Differences in splitting between peaks in (a)
and (b) converted from ppm to Hz. Predicted regions of structural propensity (thick
lines) are shown in the purple schematic. RDC data were collected using a 750 MHz
spectrometer with a TCI-cryoprobe; 1H-optimised triple resonance NMR inverse probe
and Bruker Avance III HD console.
Figure 5.12c shows the RDCs for each backbone amide in Aβ40, A region of increased
structural propensity is observed between Tyr10-Ala21 which correlated well with the
structure prediction (purple boxes). Additionally there is a region of posible structural
propensity nearer the C terminus, Ile31-Gly38, which also corresponds well to predic-
tions. Furthermore, the RDCs measured here show good agreement of published RDCs
by Newby (et al., [372], (Figure 5.13).
Figure 5.13: Correlation of experimental and published RDCs.
Comparison of measured RDC values from experimental data and those published by
Newby et al., [372]. Sample conditions in the published work differed only in the
absence of 2 % (v/v) DMSO. Excellent correlation was observed, R2 = 0.912 (3 s.f.).
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Of the methods used to probe Aβ40 structural propensity, RDCs are the most sensitive,
noting regions which were not highlighted by CSTCs or ∆δCα methods.
5.3 Characterisation of residue-specific dynamics in IDPs
One of the key characteristics of IDPs is their innate flexibility. Along the peptide chain
different regions will have different degrees of motion which can be modulated for IDP
functions, e.g. to tune the affinity for target recognition or the formation of dynamic
complexes in different environments [502, 503]. When investigating an amyloidogenic
IDP it is therefore of interest to be able to extract measurable parameters on the dynam-
ics of protein flexibility as well as conformer inter-conversion behaviour [362]. Figure
5.14 shows a selection of NMR methods which can provide information on differing types
of peptide flexibility.
Figure 5.14: Diverse NMR methods to collect data on different dynamic timescales.
These can highlight how flexible specific regions in the Aβ40 sequence are and can be used
to compare with the same measurements in the presence of small molecules which perturb
amyloid formation. Such comparators may reveal necessary flexible regions for amyloid
formation. Here, transverse relaxation rates and heteronuclear NOEs are described as
these measures were collected to probe motions on ps-ns and µs-ms timescales.
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5.3.1 T2 Measurements to probe ps-ns and and µs-ms Conformational
Dynamics of Aβ40
Characterisation of an IDP would not be complete without considering the dynamic
flexibility of the system. Fast (ps-ns) timescale motions of the local polypeptide chain can
be monitored by 15N spin relaxation experiments: 15N-R1,R2 and
15N-1HN NOEs. 15N-
R2 times are also sensitive to rotational correlation time and chemical exchange caused
by larger peptide motions on the µs-ms e.g. conformational exchange [379]. Due to this
R2 values were collected to reveal information on bond rotations and vibrations (ps-ns
movements) and folding and eventually ligand binding interactions (µs-ms motions).
Nucleus spin relaxation is caused by fluctuations in the local magnetic field arising from
molecular reorientation. Thus relaxation depends on overall rotation of the peptide
within the magnetic field, B0, and internal fluctuations of individual bonds. The T2
is the lifetime of coherent transverse (x-y) magnetisation and T2 measurements are
generally used to investigate protein dynamics. To measure T2, a set of HSQC spectra
are recorded with different delay times, t (Figure 5.15).
Figure 5.15: Schematic of transverse relaxation which gives rise to R2 rates.
Step 1: A 90o pulse being applied to the equilibrium sample along the positive z-axis.
This puts the signal onto the x-y plane where it can be detected. Step2: After the
pulse is applied, the sample is left for a period of time, t, during which the sample
disperses as it relaxes back towards its equilibrium position along the positive z-axis.
Step 3: A 180o pulse is applied to mirror the spins around the x-axis. Step 4: After
time, t, again all the spins should return to the coherent alignment along the positive
x-axis. Step 5: Comparison of the intensity of the signal on the x-axis after step 1 and
step 5 can indicate the extent to which contributing signals spread out during time, t,
and thus indicate flexibility.
For this experiments, the time delay, t, after the initial 90o pulse was varied to 7.5, 14.9,
29.8, 44.7, 59.9, 74.5, 89.4, and 104.3 ms. R2 values were calculated, Figure 5.16a by
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fitting the amide proton peak intensities to monoexponential decay functions (Figure
5.16b) for each resonance. Standardised errors of 2 % were used based on common
protocols in NMR and their agreement with errors calculated from the difference of
duplicate peak intensities using relaxation delays of 14.9 and 74.5 ms. The overall trend
observed in the R2 values shows there is more flexibility in the terminal regions than in
the central region which is typical for an IDP (Figure 5.16a). The R2 profile of Aβ40
(Figure 5.16a) shows typical IDP behaviour which is comparable to published data [372].
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Figure 5.16: R2 rates for backbone amides in Aβ40 to indicate ps-ns dynamics.
(Figure legend continued on the following page)
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Figure 5.16: a) Transverse relaxation rates for each backbone amide bond in Aβ40 with a
qualitative trend line (red) to which echos the same trend as from published data (black)
[these are not a quantitative fits, instead they show overall shape]. b) Experimental fit to
a relaxation decay for several representative residues (teh complete seat are in Appendix
B.2). Data were collected using a standard Bruker experiment protocol whereby multiple
HSQC spectra are acquired using various delay times (7.5, 14.9, 29.8, 44.7, 59.9, 74.5,
89.4, and 104.3 ms). The sample consisted of 50 mM Aβ40 in the optimised sample
buffer: 20 mM sodium phosphate, 0.5 mM EDTA, 0.02 % (w/v) NaN3, pH 7.4, 5
oC, 2
% (v/v) DMSO with 10 % D2O.
5.3.2 Heteronuclear NOEs to probe ps-ns Dynamics
To obtain information on the motion of individual backbone amides, 15N-1H-heteronuclear
Nuclear Overhauser Effects (15N-1H-hetNOEs) were measured. Backbone 15N-1H-hetNOEs
provide information on the motion of individual N-H bond vectors [415], specifically, on
a ps-ns timescale. Amides which undergo motion that is faster than the overall rotation
correlation time of the peptide in solution (i.e. ps-ns motions such as vibrations and
side chain rotations) show a decreased 15N-1H-hetNOE intensity relative to those col-
lected for other, more restrained backbone regions. For example, decreased values are
often found at the N- and C-terminals of an IDP. Conversely, increased 15N-1H-hetNOEs
indicate areas which are less dynamic [415, 504].
15N-1H-hetNOEs are a measure of the change in the steady state population of the 15N
spin when the attached proton is saturated.
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Figure 5.17: Heteronuclear NOEs for Aβ40.
a) Heteronuclear NOE values for each backbone amide of Aβ40 (calculated by:
Intensitysaturated/Intensityequilibrium). Data were collected for 50 mM Aβ40 in the
optimised sample buffer: 20 mM sodium phosphate, 0.5 mM EDTA, 0.02 % (w/v)
NaN3, pH 7.4, 5
oC, 2 % (v/v) DMSO with 10 % D2O and acquired using a 750 MHz
spectrometer with a TCI-cryoprobe; 1H-optimised triple resonance NMR inverse probe
and Bruker Avance III HD console. b) Overlay of experimental data with published
hetNOEs for Aβ40, adapted from [415].
The low (∼ 0.5) 1H-15N heteronuclear NOE values shown in Figure 5.17a, suggest that
the Aβ40 backbone is incredibly dynamic on the ps-ns timescale. The experimental
hetNOEs collected are superimposed on data originally collected by Yan et al., [505]
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and presented alongside simulated values by Ball et al., [415] in Figure 5.17b. This
shows that the data collected correlates well with the experimental data by Yan et al..
However, both lack evidence of flexibility at the N terminus which was expected for the
peptide chain, and predicted in MD simulations [415]. Interestingly, hetNOEs collected
by Rezaei-Ghaleh et al., [367] detected negative values for Arg3, as predicted, under very
similar conditions to those used in this study. Excluding the N terminus, the hetNOE
values are similar in each set of work, including the work by Resaei-Ghalei and coworkers.
In this work, the hetNOEs measured indicated that teh N-terminus is similarly dynamic
to the central part of the peptide chain. The small values measured (less than 1) indicate
dynamics on the ps-ns timescale [367]. The C-terminus shows negative hetNOE values
indicating an area with a high likelihood of ps-ns, rotational and vibrational motions.
The large hetNOEs measured for Asp7 and His13 are most likely to be an artefact
from exchange or data processing. This is because these residues are overlapped with
other peaks which are more dominant (Lys28 and Val36 respectively) and thus there are
multiple resonances contributing to the intensity measured.
5.4 Discussion
In this chapter, an NMR-based strategy for investigating the structural and dynamic
properties of small IDPs has been assembled. The purpose of this strategy was for use
in future studies of IDP-small molecule interactions. It was designed to follow on from
the methods toolbox developed in Chapter 3 to probe how a small molecule modulator
of IDP aggregation was able to influence - structurally and dynamically - the monomeric
peptide. This was based on the hypothesis that a small molecule, which reproducibly and
robustly affects IDP amyloid aggregation, may perturb aggregation through an ability
to bias the conformational population distribution of the monomer (Figure 5.18).
Figure 5.18 clarifies the chapter aims. On addition of a small molecule to an IDP en-
semble, the molecule may interact and skew the peptide distribution as it may favour
a specific state or be more inclined to adopt a partial fold (thick lines). Some of these
states which are more populated may be prone to amyloid formation (e.g. the con-
formation induced by the red molecule). In this case, the methods strategy in this
chapter can be applied to the ensemble to extract specific parameters to reveal which
regions of the peptide are acting differently to when they are in an apo population. This
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Figure 5.18: Schematic of investigation into how small molecules may influence confor-
mation distribution of Aβ40.
The methods used in the toolbox contribute information to help build up a structural
and dynamic understanding to gain insight into peptide behaviour are Small molecules
are represented by the coloureds shapes. Line thickness indicates population size. [506]
analysis could reveal important structural transitions on the IDP-to-oligomer-competent
monomer journey. In contrast, if a small molecule acts to inhibit amyloid formation (e.g.
the green molecule), application of the methods strategy will probe structural and dy-
namic changes of a conformation which is not amyloidogenic. This can yield insight to
structural features which could prevent amyloid formation. For all future comparative
studies, a parameter base for the IDP without any small molecules present would be
necessary. This has been provided in this chapter for future studies of Aβ40.
Work presented here sets up the foundation for future studies which will monitor struc-
tural and dynamic features of Aβ40 - the exemplar amyloidogenic IDP used in this work
- in the presence of small molecules. This can be achieved using the set of NMR meth-
ods compiled herein to collect comprehensive data that can be used to monitor peptide
behaviour.
To probe structural properties, δ13Cα predictions were used in combination with 1HN-
CSTCs and RDCs. Of these RDCs has the greatest sensitivity for structural propensities
- as evidenced in Section 5.2.3) - but cannot differentiate different types of secondary
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structure. δ13Cα predictions complement the RDC data as they can provide a possible
distinction between β-sheet and α-helical forms. It will be interesting to monitor whether
small molecules which perturb aggregation are able to alter the Aβ40 conformer enough
to make these predictions δ13Cα. 1HN-CSTCs were included as an indication of how
probable it is for each backbone amide to participate in peptide secondary structure.
For dynamic investigation, transverse relaxation rates (R2) and hetNOEs were included
in the strategy. Both of these methods are able to shed light on ps-ns movements and
thus data can be validated. R2 rates are also sensitive to µs-ms motions thus a broad
range of dynamic timescales can be probed using this strategy.
To complete the toolbox, a method to collect and analyses RDCs collected in different
alignment media should be included. This would permit the determination of the ns-ms
timescale dynamics and filled the gap between very fast (ns-ps dynamics inferred from R2
values) and slower motions (ms-s dynamics inferred from chemical shift perturbations)
of Aβ40 [507]. Moreover, observing how concentration affects Aβ40 parameters could be
a good way to probe structural changes. In the case of R2 rates, higher concentrations
of Aβ40 are more likely to yield information on important areas of the peptide for
oligomerisation and protein-protein interactions. To further structural investigation,
deeper analysis and experimentation into 1HN-CSTC data could have been conducted
to deconvolute the contribution from the rate of tumbling (rotational correlation time)
and the rate of exchange using TROSY and antiTROSY spectra.
The data collected have been similar to previous work on Aβ40 [367, 372] showing that
the optimised conditions -which are suitable for small molecule addition - do not perturb
Aβ40 dramatically despite the known sensitivity of IDPs to environmental conditions.
Often such studies compile measured parameter data to construct ensemble models or
conformational landscapes, however, in this study parameters were purposely analysed in
isolation to avoid loss of the finer nuances of the peptide. With this, precise, quantiative
comparisons can be made in future studies involving small molecules. The assignment of
90 % of the Aβ40 peptide has led to near-complete data set collection for each parameter
monitored.
The value of this work will be realised upon its application to small molecule:Aβ40
investigations and small molecule studies on other amyloidogenic IDPs. The strategy
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may also be applied to broader investigative strategies, such as the investigation of
substituted and mutant IDPs, truncated peptides, and peptide mimetics. For example,
the strategy could be used to probe the structural and dynamic properties of different
lengths of Aβ, or to reveal the importance of certain aromatic or charged residues in an
IDP sequence.
The methods presented here were used together to create structural and dynamic conclu-
sions about the Aβ40 backbone. Although their true value will be revealed on comparison
of parameters with small molecule containing systems. In subsequent studies the tech-
niques implemented here can be used to directly compare localised (within the peptide
chain) effects of the compound on specific aspects of Aβ40.

Chapter 6
Concluding Remarks
6.1 Summary of Findings
Amyloid diseases are some of the most common afflictions in society causing huge burden
to sufferers, healthcare providers, and families [81]. Despite the prevalence of Alzheimer’s
disease, the major neurodegenerative disorder in dementia [81], the understanding the
first steps in the aggregation mechanism which is linked to the disease, are still re-
mains elusive. An explanation for this is due to the substantial challenges in studying
the heterogeneous, transient populations of low-order amyloid intermediates (monomers
and oligomers) involved in amyloid formation which is compounded by the dynamic
conformational heterogeneity of IDPs.
Considering IDP populations as a landscape of conformational probabilities is perhaps
the clearest way to realise the extent of the intricacies within the system. Definition
of every conformation in the landscape can be predicted using ensemble calculations
molecular modelling methods [508, 509]. However, due to the delicate sensitivity of IDP
behaviour and structural propensity to minor changes in buffer conditions, transferable
value of such landscapes is limited between studies. The work described in this the-
sis aimed to set up a methods toolbox to probe for small molecule modulators of the
aggregation of IDPs - using hIAPP and Aβ40 as exemplar peptides - followed by an
NMR-based methods strategy to explore how these small molecules could cause such ef-
fects. The eventual hope of this work is that it will be implemented to reveal important
structural transitions required for IDP entry into the amyloid pathway.
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Small molecules can bias the conformer probability distribution of IDP populations,
potentially increasing or decreasing the predominance of species with certain structural
traits (e.g. by stabilising a short α-helical segment in a terminal region of an IDP) which
are important for either promoting or preventing amyloid progression. Such structures
can be identified using the methods presented in this work and can reveal important
structural transitions in amyloid progression.
The value of this project lies in the decision of creating a balanced toolbox of methods
from the extensive range of methods which could have been applied to the IDP system.
The toolboxes of methods which have been brought together in this thesis (in Chapter 3
for small molecule selection and initial structural implication, applied in Chapter 4, and
Chapter 5 for precise structural assessment at a residue-level resolution) can be used to
build up a comprehensive impression of IDP behaviour from multiple, complementary
perspectives.
Initially, methods which could identify perturbations in the rates of amyloid formation
had to be selected and their compatibility with small molecule addition was tested
(Chapter 3). Use of methods which indicated amyloid formation of Aβ40, such as the
ThT assay, TEM, and fibril yield measures, were combined with ESI-MS and 1H15N-
HSQC NMR experiments to yield monomer and oligomer level indications of compound-
peptide interactions. Each method examined how the addition of a small molecule can
influence aggregation from a differing perspective; ThT can reveal information on the
kinetics of the reaction and whether the small molecule is interfering within the lag
phase, possibly interacting with monomers and small oligomers, or whether the small
molecule perturbs amyloid formation at the secondary nucleation stage; TEM reveals
aggregate morphology; and fibril yield quantifies the extent of aggregation. ESI-MS
showed the stoichiometry of the peptide-compound interaction, and 1H15N-HSQC NMR
had the potential to reveal interaction sites and binding affinity.
Use of the toolbox of methods was demonstrated using Aβ40 as presented in Chapters 3
and 4. To enable this, work was conducted to optimise the expression and purification
procedures for this peptide. Optimisation improved peptide yields from 2-4 mg/L to
4-6 mg/L of pure Aβ40. Within the last year a new approach to the purification of
Aβ40 has been published. This method uses HPLC and can achieve a yield of up to 9
mg/L [397]. At the outset, a second amyloidogenic IDP, hIAPP, was also going to be
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used to demonstrate the versatility of the method toolbox, however, issues with hIAPP
purification prevented this.
To increase the possible impact of the work conducted here, small molecule selection
was considered. To demonstrate the use of the method toolbox, any of the wealth of
known small molecule inhibitors of amyloid aggregation could have been used as a test
system. Indeed, Chapter 3 demonstrates how the methods were optimised for use with
Aβ40 in the presence of small molecules which have already received a large amount of
research attention: EGCG (as a known amyloid inhibitor) [328, 510, 511] and aspirin
(as a negative control) [429]. Chapter 4 had the potential to discover a novel small
molecule which could perturb Aβ40 amyloid aggregation. Although this did not occur
on this application of the methods toolbox, the screening and testing approach is ready
for application to other compound libraries and different known modulators of amyloid
aggregation can be used to direct screening.
The selected compound library used in Chapter 4 for in silico screening was an extensive
in house library at the University of Leeds, Department of Chemistry, and compounds
were selected from it for in vitro screening based on structural similarity to known mod-
ulators of amyloid aggregation and their derivatives; 1,2-naphthoquinone, bexarotene,
MM3003, and UV11532 [444]. The ThT assay was used for screening due to its rela-
tively high-throughput, and information rich nature. Lead compounds identified were
then tested for amyloid-modulatory effects using the toolbox of methods from Chapter
3. This was vital to validate the effects seen in the screening assays. Overall, Chapter 4
clearly showed how the toolbox can be applied to a new, small molecule discovery and
testing investigation.
Finally, a selection of NMR methods were compiled to form a strategic investigation
approach in how small molecules may alter monomer conformation dynamics. Similarly
to the methods toolbox used to identify small molecule modulators of amyloid formation,
the NMR approach assembled in Chapter 5 is a multi-method plan which can evaluate
how small molecules effect IDPs from complementary perspectives. The NMR approach
was applied to Aβ40 apo state to obtain a set of parameters which can be compared
to those measured when the approach is applied to a small molecule-containing system.
Had a new small molecule modulator of amyloid aggregation been identified, the method
approach that was compiled in Chapter 5 could have been used to glean sequence-specific
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impressions of how the small molecule was perturbing the IDP. This will reveal delicate
changes in the structural propensities of each region of the Aβ40 peptide induced by
small molecules which alter the amyloidogenic properties of the IDP.
6.2 Future Work
The power of the work conducted in this thesis comes from its future applicability, not
only to other small molecule libraries, but to other amyloidogenic IDP systems, for
example, Tau, α-synuclein, hIAPP, and length variants of Aβ.
The toolbox of methods in Chapter 3, could be applied to alternative compound li-
braries for screening and robust assessment of effect on aggregation. The small molecule
screening, and complementary validation methods, can be applied to further carefully
selected compound libraries with a view to identify compounds which can alter the pro-
gression of amyloid formation. Furthermore, this could lead to the identification of novel
compounds, whose effects on amyloid have not previously been considered. More impor-
tantly, application of the methodological strategy in Chapter 5 to other small molecule
libraries (whether novel or known modulators of amyloid) has the potential to reveal
important conformers in the amyloid pathway and mechanistic insight. This may be of
particular interest for therapeutic development to find target structures for drug inter-
actions. In extension to this, investigation of the peptide-compound interaction would
also yield valuable direction for therapeutic development; a method toolbox for such
study by NMR has recently been published [512].
The ability to transfer the methods selected here for use on other IDP systems give this
work a wide breadth of impact. Not only would this give specific insight into various
disease pathogenesis, but it also would allow the comparison of monomer transitions
between amyloid disorders. Such comparative analysis may reveal key folding or inter-
action events which are essential for amyloid formation.
As new methods are developed, it will become important to include or substitute IDP-
optimised methods for those currently in the toolbox. Care must be taken as the tool-
boxes could be expanded with many methods and technical approaches. To prevent
devaluation of the work in this thesis, methods should only be added to the toolbox if
they can provide a new perspective on the monomer conformations to avoid collection of
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overlapping information. Despite this, one experiment which should ideally be included
in the toolbox in Chapter 5, is to test for regions involved in monomer-monomer inter-
action by monitoring the dependence of the Aβ40
1H15N-HSQC spectrum on peptide
concentration. This could also show the oligomeric state of Aβ40.
In summary, presented in this thesis are two methodological strategies; one to identify
and validate small molecule modulators of amyloid aggregation (which has been applied
to the study of Aβ40), and one for detailed, comparative analysis of the structural
and dynamic properties of amyloidogenic IDPs in conjunction with the identified small
molecules (which has been fully prepared for small molecule additions to the tested Aβ40
apo system). Use of these strategies will enable the discovery of important transient
monomer conformers of IDPs and low order oligomers which affect amyloid formation.
Such knowledge will help to piece together the puzzle of how and why IDPs such as
Aβ40 swap their highly-entropic and disordered conformations for rigid, ordered amyloid
fibrils.

Appendix A
Appendix A
A.1 Absolute ThT fluorescence measured for Aβ40 aggre-
gation in the presence of each compound screened
Absolute fluorescence intensity of ThT fluorescence to monitor Aβ40 aggregation in the
presence of each of the 67 compounds in the screening library.
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A.2 T-test values for quantitative analysis of the ThT screen
Table A.1: Table of t-test values
T-test values
Compound Lag time T50 Max. Fluorescence
Compounds based on adapalene
A01 0.420 0.283 0.014
A02 0.162 0.181 0.219
A03 0.575 0.183 0.448
A04 0.283 0.247 0.142
A05 0.119 0.309 0.164
A06 0.235 0.193 0.029
A07 0.388 0.319 0.042
A08 0.484 0.358 0.753
A09 0.013 0.274 0.632
A10 0.344 0.157 0.003
A11 0.062 0.091 0.855
A12 0.284 0.126 0.002
A13 0.324 0.000 0.376
A14 0.008 0.001 0.156
A15 0.010 0.249 0.069
A16 0.796 0.613 0.629
A17 0.660 0.807 0.860
A18 0.023 0.008 0.001
A19 0.891 0.409 0.321
A20 0.580 0.000 0.640
A21 0.001 0.000 0.804
A22 0.852 0.009 0.471
Compounds based on bexarotene
B01 0.806 0.193 0.271
B02 0.810 0.211 0.776
B03 0.118 0.124 0.002
B04 0.973 0.001 0.000
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Continuation of Table A.1
Compound Lag time T50 Max. Fluorescence
B05 0.253 0.049 0.889
B06 0.379 0.752 0.001
B07 0.035 0.455 0.138
B08 0.000 0.000 0.021
B09 0.028 0.015 0.211
B10 0.328 0.651 0.104
B11 0.011 0.007 0.236
B12 0.211 1.000 0.001
B13 0.700 0.837 0.210
B14 0.856 0.050 0.020
Compounds based on 1,2-naphthoquinone
Q01 0.494 0.945 0.012
Q02 0.672 0.699 0.127
Q03 0.631 0.817 0.084
Q04 0.166 0.479 0.040
Q05 0.051 0.260 0.019
Q06 0.002 0.000 0.694
Q07 0.158 0.525 0.002
Q08 0.011 0.043 0.075
Q09 0.046 0.115 0.169
Q10 0.120 0.140 0.001
Q11 0.410 0.570 0.234
Q12 0.031 0.081 0.031
Q13 0.219 0.486 0.001
Q14 0.014 0.015 0.003
Q15 0.003 0.026 0.086
Q16 0.594 0.867 0.746
Q17 0.916 0.933 0.291
Q18 0.072 0.129 0.262
Q19 0.454 0.158 0.474
Q20 0.411 0.115 0.710
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Continuation of Table A.1
Compound Lag time T50 Max. Fluorescence
Q21 0.048 0.044 0.499
Q22 0.000 0.040 0.817
Q23 0.000 0.026 0.251
Q24 0.410 0.505 0.080
Q25 0.582 0.227 0.003
Q26 0.403 0.233 0.188
Q27 0.003 0.012 0.119
Q28 0.275 0.098 0.259
Compounds based on UVI3003 or MM11253
M01 0.955 0.011 0.433
U01 0.016 0.114 0.089
M02 0.200 0.308 0.832

Appendix B
Appendix B: NMR parameters
B.1 Data for calculating temperature coefficients
Plots of peak intensity after different delay times for the calculation of R2 measures of
each backbone amide of Aβ40.
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B.2 Data for calculating R2s
Plots of 1H-chemical shift perturbations across a range of temperatures for the calcula-
tion of 1HN-CSTCs of Aβ40 backbone amides.
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